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InTROduCTIOn 
Degenerative aortic stenosis is the most common valvular heart disease in developed 
countries. The prevalence of severe aortic stenosis increases with age from 1% in people 
below 65 years of age to nearly 6% in people over the age of 85.1-2 Since the population 
life expectancy continues to expand, severe aortic stenosis represents a growing health 
problem: the global annual need for aortic valve replacement (AVR) is expected to triple to 
approximately 850,000 by the year 2050.3
According to the guidelines of the American College of Cardiology (ACC), the American 
Heart Association (AHA) and the European Society of Cardiology (ESC) for the manage-
ment of patients with valvular heart disease, symptomatic patients with severe aortic 
stenosis require AVR because prognosis is poor when treated conservatively:4-5 after onset 
of angina average life-expectancy is reported to be 4.5 years, after syncope 2.6 years and 
after heart failure less than one year.6 Besides this dismal prognosis, not much is known 
about the burden of disease of symptomatic patients during these final years of life. Surgi-
cal aortic valve replacement (AVR) with either a mechanical or biological prosthesis is the 
treatment of choice because it offers good long-term results even in elderly patients.7-10 
However, up to 60% of symptomatic patients are denied AVR because of advanced age or 
severe co-morbidity.11-14 Furthermore, the proportion of symptomatic patients is likely to 
be underestimated: up to 37% of the patients who claim to be asymptomatic, experience 
limiting symptoms when an exercise test is performed.15 
In truly asymptomatic patients AVR is not recommended since the risk of surgical in-
tervention may be higher than the risks of medical treatment.4 In contrast, recent reports 
document a dismal prognosis in asymptomatic severe aortic stenosis, suggesting that dia-
stolic dysfunction, interstitial fibrosis and secondary pulmonary hypertension already exist 
before symptoms occur, implying the threshold for performing AVR should be lowered to 
asymptomatic patients.5, 14, 16  Altogether it would be useful to have a better indicator of 
disease-severity, to be able to identify those who are at risk of rapid clinical deterioration 
and to determine the optimal threshold for AVR. Ideally this cut-off point would be just 
before irreversible left ventricular dysfunction occurs.
Implantation of a prosthetic aortic valve by transcatheter techniques has emerged in 
recent years. The Thoraxcentre of the Erasmus Medical Center pioneered these techniques. 
They were the first to perform a successful transcatheter aortic valve implantation (TAVI) in 
the Netherlands in 2005. This technique was designed to relieve the stenosis with minimal 
surgical trauma in order to improve postoperative outcome especially in patients with 
severe comorbidity and in the frail elderly. Now that even these patients with a relatively 
short life-expectancy can be offered treatment, new societal issues are being raised con-
cerning the increase of health care costs and the urgent need for its containment. In 
order to guide this political debate, several medical issues should be elucidated: we have 
Martijn BW6.indd   11 03-01-13   11:13
12
to gain more insight in the disease burden and life expectancy of the elderly patient with 
severe aortic stenosis when treated medically, in the choice of a surgical or transcatheter 
replacement, and in the expected benefit –both in terms of survival ánd quality of life- after 
either treatment option.
ThESIS ObjECTIvES 
The goal of this thesis is to explore the current treatment options, treatment utilization and 
prognosis of elderly patients with aortic valve stenosis. The following research questions 
were posed:
1.  What is the current knowledge of aortic stenosis, and how does the disease progress 
with time?
2.  What are the main therapeutic choices for patients with severe aortic stenosis, what are 
the options for replacement of the aortic valve in middle aged and elderly patients, and 
how can we compare patient outcome after implantation with several available devices?
3.  In contemporary clinical practice, how are patients with severe AS treated? What are 
reasons for non-referral to surgical treatment, what are the determinants of treatment 
selection and how do they affect prognosis in terms of survival and quality of life? 
OuTlInE
Chapter 2 is a review of the clinical presentation of a patient with aortic stenosis and of 
the causes and pathology of the diseased aortic valve. It also discusses current diagnostic 
tools and treatment options.
In chapter 3 a systematic review of literature was undertaken to estimate the rate of 
progression of aortic stenosis in adult patients.
The departments of Cardiothoracic Surgery and Public Health in the Erasmus Medi-
cal Center in Rotterdam (the Netherlands) in collaboration with the University of British 
Columbia, Vancouver (Canada) developed microsimulation models to simulate outcome 
of patients who underwent aortic valve replacement. Chapter 4 gives insight into the 
microsimulation methodology, its advantages and disadvantages, and how it can assist in 
counseling a patient when choosing between different types of valve prostheses. 
In chapter 5 the microsimulation model was used to study age- and gender-specific 
life expectancy, event-free life expectancy and reoperation-free life expectancy after aortic 
valve replacement with either a mechanical- or biologic valve prosthesis. 
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Chapter 6 presents how to use microsimulation to compare patient outcome after 
AVR with several valve substitutes: stented- and stentless bioprostheses, allografts and 
autografts. 
Chapter 7 describes the difference between the ACC/AHA and the ESC guidelines 
and what takes place in daily practice with regards to the management of symptomatic 
patients with severe aortic stenosis. We studied treatment decisions in 179 symptomatic 
patients and documented the reasons why so many patients did not receive the indicated 
surgical treatment. 
Based on the paper presented in Chapter 7, a letter to the editor was written with a 
short discussion on the role of statins in the treatment of patients with aortic stenosis.17 
Our reply constitutes Chapter 8. 
Chapter 9 elaborates on the Aortic vAlve RIjnmond study: a multi-center prospective 
observational cohort study among patients with severe aortic stenosis in the outpatient 
cardiology clinics of the Rotterdam Rijnmond region (The Netherlands). The primary goals 
were to study determinants of treatment selection and patient outcome. Patients were 
followed over a time-period of two years and subjected to several clinical assessments.
In Chapter 10 the SF-36v2 Health Survey was used to assess the quality of life of all 
symptomatic and asymptomatic patients in the AVARIJN cohort and this was compared to 
the general age-matched Dutch population. 
Chapter 11 sequels the previous chapter and describes the quality of life of the symp-
tomatic patients during follow-up: it compares the quality of life after AVR to the quality 
of life of conservatively treated patients. 
In Chapter 12 recent or ongoing multi-center randomized trials are discussed that 
explore the safety, benefits, (dis-) advantages and cost-aspects of the new TAVI technology 
compared to the conventional AVR in order to define the indication of either technique. 
Chapter 13 provides the general discussion with conclusions and recommendations 
following from this thesis. 
Martijn BW6.indd   13 03-01-13   11:13
14
REfEREnCES
 1. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: 
an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220-
5.
 2. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve 
disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630-4.
 3. Yacoub MH, Takkenberg JJ. Will heart valve tissue engineering change the world? Nat Clin 
Pract Cardiovasc Med 2005; 2: 60-1.
 4. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of 
patients with valvular heart disease: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 
Guidelines for the Management of Patients With Valvular Heart Disease): developed in col-
laboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for 
Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circula-
tion 2006; 114: e84-231.
 5. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural history of 453 nonsur-
gically managed patients with severe aortic stenosis. Ann Thorac Surg 2006; 82: 2111-5.
 6. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J 1988; 9 Suppl E: 
57-64.
 7. Gehlot A, Mullany CJ, Ilstrup D, et al. Aortic valve replacement in patients aged eighty years 
and older: early and long-term results. J Thorac Cardiovasc Surg 1996; 111: 1026-36.
 8. Gilbert T, Orr W, Banning AP. Surgery for aortic stenosis in severely symptomatic patients older 
than 80 years: experience in a single UK centre. Heart 1999; 82: 138-42.
 9. Melby SJ, Zierer A, Kaiser SP, et al. Aortic valve replacement in octogenarians: risk factors for 
early and late mortality. Ann Thorac Surg 2007; 83: 1651-6; discussion 6-7.
 10. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Survival in elderly patients with severe aortic 
stenosis is dramatically improved by aortic valve replacement: Results from a cohort of 277 
patients aged > or =80 years. Eur J Cardiothorac Surg 2006; 30: 722-7.
 11. Bouma BJ, van Den Brink RB, van Der Meulen JH, et al. To operate or not on elderly patients 
with aortic stenosis: the decision and its consequences. Heart 1999; 82: 143-8.
 12. Charlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe symptomatic 
aortic stenosis. J Heart Valve Dis 2006; 15: 312-21.
 13. Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic steno-
sis: why are so many denied surgery? Eur Heart J 2005; 26: 2714-20.
 14. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, he-
modynamically significant aortic stenosis during prolonged follow-up. Circulation 2005; 111: 
3290-5.
 15. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J 
2005; 26: 1309-13.
 16. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe 
aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg 2006; 82: 2116-22.
Martijn BW6.indd   14 03-01-13   11:13
C
hapter 1
G
eneral introduction 
15
 17. Paraskevas KI. Prescribing statins in aortic stenosis: little to lose, much to gain. Eur J Cardiotho-
rac Surg 2010; 37: 497; author reply 8.
Martijn BW6.indd   15 03-01-13   11:13
Martijn BW6.indd   16 03-01-13   11:13
AP Kappetein
MWA van Geldorp
JJM Takkenberg
JJC Bogers
Expert Rev Cardiovasc Ther 2008;6:491-501
ChApter 2 
Optimum management  
of elderly patients with 
calcified aortic stenosis
Martijn BW6.indd   17 03-01-13   11:13
18
AbSTRACT
Increased life expectancy has led to a growing elderly population frequently presenting 
with aortic stenosis. This review focuses on the pathogenesis of calcific aortic stenosis, 
diagnosis, and possible ways to halt progression to severe symptomatic aortic stenosis, 
methods of assessing symptoms and severity, and modalities and timing of aortic valve 
replacement. At present the treatment of aortic stenosis for the majority of patients is 
surgical, and any patient with symptomatic severe aortic stenosis should be considered for 
aortic valve replacement (AVR). This article also discusses the role of emerging techniques 
of closed heart valve implantation either transfemoral or transapical and which patients 
might be candidates for these new approaches to the treatment of aortic stenosis in the 
elderly population.
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InTROduCTIOn
The prevalence of aortic valve stenosis (AS) increases with age and as a result of the 
advancing age of the general population an increasing number of elderly patients are 
presenting with symptomatic valve disease.1 The prevalence of AS is 2.5% at the age of 
75 years and almost 8% at 85 years.1 Calcific aortic stenosis is due to an active chronic 
disease, starting with thickening and calcification of valve cusps, termed aortic sclerosis. In 
the beginning aortic sclerosis is without haemodynamic consequences but slowly it may 
progress towards heavily calcified stiff cusps, aortic valve stenosis, with restricted leaflet 
opening with obstruction to left ventricular outflow. 
Cause
A bicuspid aortic valve is the most common cause of aortic stenosis in patients under age 
65 while in patients over 65 years of age the most common cause is so called “senile 
calcific aortic stenosis.” Although bicuspid valves usually do not impede blood flow when 
the patients are young, they do not open as widely as normal valves with three cusps. 
Therefore, blood flow across the bicuspid valves is more turbulent, causing increased wear 
and tear on the valve leaflets. Over time, excessive wear and tear leads to calcification, 
scarring, and reduced mobility of the valve leaflet. Senile calcific aortic stenosis results from 
destruction of protein collagen of the valve leaflets and calcium is deposited on the leaflets. 
Turbulence across the valve increases causing scarring, thickening, and stenosis of the valve 
once valve leaflet mobility is reduced by calcification. 
Rheumatic fever is a condition resulting from untreated infection by group A streptococ-
cal bacteria. Damage to valve leaflets from rheumatic fever causes increased turbulence 
across the valve and more damage. The narrowing from rheumatic fever occurs from the 
fusion (melting together) of the edges (commissures) of the valve leaflets. 
Pathology
Histopathologically, sclerosis of the aortic valve is defined as fibrous thickening and cal-
cification of the valve cusps. In the past it was thought that aortic valve sclerosis was 
caused by passive calcium precipitation within the aortic valve leaflets. However, there is 
increasing evidence that the development and progression of calcific aortic stenosis may 
be triggered by underlying genetic and cardiovascular risk factors. These risk factors are 
frequent in the elderly and include smoking, hypertension, hyperlipidaemia, lipoprotein(a) 
levels, higher body mass index and diabetes.2 The accumulation of macrophages and 
lymphocytes observed in stenotic valves indicates that calcific aortic stenosis might be 
based on a chronic inflammatory process.3 The angiotensin-converting enzyme cascade 
also works locally within the aortic leaflet, causing fibroblasts within the fibrosa layer to dif-
ferentiate into myofibroblasts wherein the angiotensin I receptor is highly expressed. The 
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myofibroblast plays a central role in the process because it is believed to differentiate into 
an osteoblast-like cell phenotype, which in turn promotes deposition of calcified nodules 
and bone formation.4
The progression from aortic sclerosis, which can already easily be detected by echocar-
diography or computed tomography, to haemodynamically severe aortic stenosis is variable 
and may take many years. Although aortic sclerosis is clinically asymptomatic, its presence 
is associated with a 40% increase in the risk of myocardial infarction and a 50% increase 
in the risk of cardiovascular death in patients with no preexisting diagnosis of coronary 
artery disease.5
Clinical presentation
The three classical symptoms of aortic stenosis are dyspnoea, angina, and syncope. Chest 
pain is the first symptom in one–third of patients and eventually occurs in one–half of 
patients with aortic stenosis. Angina often occurs without any underlying narrowing of the 
coronary arteries. The thickened heart muscle must pump against high pressure to push 
blood through the narrowed aortic valve. This increases heart muscle oxygen demand 
in excess of the supply delivered in the blood, causing chest pain. Syncope related to 
aortic stenosis is usually associated with exertion or excitement. These conditions cause 
vasodilatation. In aortic stenosis, the heart is unable to increase output to compensate 
for the drop in blood pressure. Therefore, blood flow to the brain is decreased, causing 
fainting. The average life expectancy is less than three years after the onset of chest pain or 
syncope symptoms. Symptoms of pulmonary oedema and syncope are late manifestations 
of the disease process, and prompt treatment is necessary. It reflects the heart muscle’s 
failure to compensate for the extreme pressure load of aortic stenosis. Without treatment, 
the average life expectancy after the onset of heart failure due to aortic stenosis is between 
six to 24 months.6 
 Many patients will not report overt symptoms but might instead simply notice a de-
crease in exercise tolerance without a distinct limiting symptom. This exercise intolerance 
can often be misinterpreted as “due to aging” but is in fact symptomatic aortic stenosis. 
Patients become symptomatic when the degree of outflow obstruction prevents an ad-
equate increase in cardiac output with exertion. Some patients develop clear symptoms 
with obstruction that traditionally has not been considered important, while others remain 
asymptomatic with apparently severe obstruction. A difficult clinical problem is the patient 
who has symptoms compatible with aortic stenosis but has outflow obstruction that tradi-
tionally would be considered only moderate. In this situation it can be difficult to separate 
symptoms caused by outflow obstruction from symptoms caused by other comorbidity. 
Exercise testing can be helpful in providing an objective measure of exercise tolerance and 
in documenting the hemodynamic response to exercise in these patients.7 
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dIAGnOSIS
Echocardiography
Echocardiography is the clinical standard for evaluation of adults with suspected or known 
valvular aortic stenosis. Anatomic images show the aetiology of aortic stenosis, level of 
obstruction, valve calcification, leaflet motion, and aortic root anatomy. Obstruction at 
the aortic valve level increases left ventricular afterload, resulting in increased wall thick-
ness and early diastolic dysfunction. Echocardiography also evaluates the left ventricular 
function, wall thickness, and other hemodynamic consequences of aortic stenosis.8 Basic 
hemodynamic parameters include the velocity of blood flow through the narrowed aortic 
valve, the mean pressure gradient between the left ventricle and aorta, and the cross-
sectional area of valve opening. In humans, the normal aortic valve area (AVA) is 3.0 to 4.0 
cm2. As AS develops, little gradient is present until the orifice area becomes less than half of 
normal. The relationship of gradient to orifice area is best described by the Gorlin formula: 
gradient = CO2/AVA2 where CO = cardiac output and AVA = aortic valve area. AVA can be 
calculated from data obtained by cardiac catheterization and by Doppler echocardiogra-
phy. By cardiac catheterization the actual stroke volume is used in the calculation of AVA, 
thus, accounting for the variable of changes in flow affecting the gradient.9 Calculation of 
AVA by Doppler echocardiography can be obtained by dividing the flow measured  in the 
left ventricular outflow tract (LVOT) by transvalvular velocity. Difficulties in measuring LVOT 
diameter and velocity precisely at the same level as well as the simplifying assumption of 
a flat flow profile and circular shape for the LVOT may cause inaccuracies. This is known 
to result in an erroneously low calculated AVA in a significant percentage of patients.9-10 
Stress echocardiography
When stenosis is severe and cardiac output is normal, the mean transvalvular pressure 
gradient is generally greater than 40 mm Hg. However, when cardiac output is low, 
severe stenosis may be present with a lower transvalvular gradient and velocity. Stress 
echocardiography using low dose dobutamine may be helpful in patients with low-flow/
low-gradient aortic valve stenosis (AS) and left ventricular (LV) dysfunction to determine 
the transvalvular pressure gradient and to calculate valve area during a baseline state and 
Table 1. Criteria for grading the severity of Aortic Stenosis
Aortic Stenosis Jet velocity
(m per second)
Mean gradient
(mm Hg)
AVA (cm2) AVA index (cm2/m2)  
Mild < 3.0 <  25 > 1.5 >0.9
Moderate 3.0 – 4.0 25 - 40 > 1.0 to 1.5 >0.6 to 0.9
Severe > 4.0 > 40 ≤ 1.0 ≤ 0.6
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again during dobutamine stress, to distinguish whether stenosis is severe or only moder-
ate in severity. Patients who do not have true anatomically severe stenosis will exhibit an 
increase in the valve area and little change in gradient during an increase in stroke volume. 
Patients with severe AS will have a fixed valve area with an increase in stroke volume and 
an increase in gradient. These patients are likely to respond favourably to surgery. Patients 
failing to show an increase in stroke volume with dobutamine, referred to as “lack of con-
tractile reserve,” may have a superimposed and separate myocardial disease process such 
as cardiomyopathy, ischemia, or fibrosis in which myocardial function is abnormal. These 
patients have an increased operative risk, symptomatic status does not always improve, 
and ejection fraction remains depressed after valve replacement surgery.11-12
Coronary angiography 
Coronary angiography is routinely performed before aortic valve surgery because of the 
high prevalence of coronary disease in elderly patients so that bypass grafting can be 
performed at the time of valve replacement or percutaneous coronary intervention (PCI) 
before the surgical intervention takes place.
Multislice CT-scan 
The role of new imaging modalities as multislice Computed Tomography (MS-CT) at present 
is limited. At the present time quantification of calcification can be used in research studies 
of treatment that is hypothesized to interfere with the progression of AS. In clinical practice, 
however, echocardiography remains the preferred method for detection and quantification 
of AS. In patients with inadequate and inconclusive echocardiograms, MS-CT may serve as 
an alternative to obtain aortic valve area. However, the evaluation will remain incomplete 
as the method does not yield additional haemodynamic information such as transvalvular 
pressure gradients, presence of regurgitation and additional valve disease, and pulmonary 
artery pressure. Finally, MS-CT with a specific angiographic protocol, may gain a role for 
the pre-operative exclusion of coronary artery disease but so far only in patients with low 
likelihood of atherosclerosis.13
Brainnatriuretic peptide
Brainnatriuretic peptide (BNP) is a more objective marker in patients with unclear complaints 
and has a progressive association with the severity of AS and left ventricular dysfunction. 
Asymptomatic patients with more haemodynamically significant AS had higher serum BNP 
levels, which suggest that BNP may represent a marker of disease severity and may poten-
tially serve to discriminate between normal exercise tolerance and true early symptoms of 
heart failure. Postoperative survival also seems to be related with BNP.14-16 
Martijn BW6.indd   22 03-01-13   11:13
C
hapter 2 
O
ptim
um
 m
anagem
ent of elderly patients w
ith calcified aortic stenosis 
23
TREATMEnT
Medical therapy
Aortic stenosis is an actively regulated inflammatory process and given the clinical associa-
tion of calcific AS with hyperlipidaemia and coronary artery disease, hopes are high that 
the cause of calcific AS might be modifiable by medical therapy. Targeted drug therapy to 
prevent the progression of calcific aortic valve disease should be based on the knowledge 
of risk factors and the molecular pathogenesis of the disease.
Statins may lower lipid levels and reducing systemic inflammation and thereby influence 
the pathogenesis of calcification in patients with AS. Several retrospective studies have pro-
vided evidence that statins slow the hemodynamic progression of AS.17-20 The prospective, 
randomized clinical SALTIRE trial of 155 patients showed that, although atorvastatin 80 mg 
daily more than halved serum LDL cholesterol concentrations, it did not halt the progres-
sion or induce regression of the valve disease process as measured by  echocardiography or 
CT-scan.21  A possible explanation is that patients with aortic velocities below 2.5 m/s were 
excluded from the SALTIRE trial, and intervening at this earlier stage of the disease process 
may have been more beneficial. The results of the studies on statin therapy in patients with 
aortic sclerosis are eagerly awaited, and research on other drugs is likely to follow.22 
Recent findings raise the possibility that aortic valve calcium accumulation might slow 
by inhibiting angiotensin-converting enzyme (ACE) and mediate the fibrous thickening of 
the valve.23 However, ACE inhibition did not appear to slow the progression of AS in a 
clinical study, nevertheless this does not preclude the presence of ACE inhibiting effects 
at the valvular level, which may reduce aortic valve calcium accumulation. It might be that 
the initiation of ACE inhibition therapy at an earlier stage of disease and longer treatment 
intervals may have positive effects on disease progression.17 
Risk analysis and patients denied surgery
Although healthy elderly patients can be treated safely with good outcomes, additional risk 
factors may account for increased perioperative morbidity and mortality. Decision-making 
is particularly complex in older patients who represent a heterogeneous population, with 
more advanced and diffuse cardiovascular disease with higher co-morbidity resulting in a 
wide range of operative risk, as well as life expectancy. Elderly patients with symptoms due 
to severe AS, normal coronary arteries, and preserved left ventricular function can expect 
a better outcome than those with coronary artery disease or left ventricular dysfunction. 
Cardiac related factors that may further increase operative risk are pulmonary hyperten-
sion and previous cardiac surgery. Non-cardiac related factors that carry a greater risk of 
disabling complications and prolonged hospital stay are cerebrovascular and peripheral 
vascular disease, diabetes, respiratory dysfunction and renal failure. Advanced cancer and 
permanent neurological defects as a result of stroke or dementia make cardiac surgery 
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improper. Patients in a poor condition often do not return to an active existence because 
the presence of other comorbidities play an important role in their physical condition.
There is no perfect method for weighing all of the relevant factors and identifying 
specifically high- and low-risk elderly patients, but this risk can be estimated using various 
scoring systems e.g. the EuroSCORE or the STS risk calculator.24-25 A more specific risk 
score developed to predict outcome for cardiac valve surgery is the New York state score.26 
However, decision-making should rely not only on estimation of operative risk, but also on 
estimation of the risk–benefit ratio, requiring outcome after surgery to be compared with 
spontaneous evolution. Biological ageing is quite heterogeneous and precise algorithms 
should be replaced by integrative individualized management. Microsimulation allows 
modeling of complex outcome paths resulting from many simultaneous risks and might 
be a valuable tool to estimate patients’ individual outcome after valve replacement.27 The 
most difficult aspects of decision making are choosing the appropriate timing of surgery 
and the necessity of whether or not to perform combined valve and coronary procedures.9 
The statistical risk may be somewhat higher than the effective risk in experienced hands 
and individual and sometimes challenging decisions based on the surgeons’ skill and expe-
rience in the postoperative care of complex patients are required.
Many patients with severe AS do not undergo surgery because of excessive risk, ad-
vanced age, or preference. Recent studies have highlighted the underuse of AVR ranging 
from 30% - 60% of elderly patients with severe, symptomatic AS.6,28-30 Older age and left 
ventricular dysfunction are the most striking characteristics of patients who are denied 
surgery, whereas in some reports selection on basis of comorbidity played a less important 
role.28 Congestive heart failure and left ventricular dysfunction are strong predictors of 
poor outcome in non-operated patients with AS.6 Many physicians are unaware that 
elderly patients with AS and impaired left ventricular function are the most likely to benefit 
from relief of outflow obstruction.11 
Medical therapy for the inoperable patient
If a patient is deemed inoperable limited medical therapies are available to lessen symp-
toms. Patients with evidence of pulmonary congestion can benefit from cautious treatment 
with digitalis, diuretics, and ACE inhibitors. In patients with acute pulmonary oedema 
due to AS, nitroprusside infusion may be used to reduce congestion and improve left 
ventricular performance.31-32 Such therapy should be performed under the guidance of 
invasive hemodynamic monitoring. Excessive preload reduction can reduce cardiac output 
and lower systemic arterial pressure; patients with severe AS are especially subject to this 
untoward effect due to a small hypertrophied ventricle. Digitalis should be reserved for 
patients with depressed systolic function or atrial fibrillation.31-32 
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Balloon valvuloplasty
Percutaneous balloon aortic valvuloplasty is a procedure in which a balloon is placed 
across a stenotic valve and inflated to decrease the severity of AS. This procedure has been 
proposed as an alternative to operation in the treatment of high risk, elderly patients. It 
can also be used as a bridge to surgery in haemodynamically unstable patients. Hospital 
mortality ranges from 3% to 13% and hospital morbidity from 10% to 25%.33 Despite a 
relatively modest improvement in valve function, most often there is a degree of functional 
improvement of short duration however immediate restenosis (within 72 h) occurred in 
25% of patients and 66% had restenosis within 6 months. The acute aortic insufficiency 
that may occur after balloon valvuloplasty may also impair a hemodynamic improvement. 
Long-term survival after balloon aortic valvuloplasty is also poor with 1- and 3-year survival 
rates of 55% and 23%, respectively.34 Therefore, in adults with AS, balloon valvuloplasty is 
not a substitute for AVR. However, through improved knowledge and refined transcatheter 
device developments it might be that balloon valvuloplasty nowadays yields better outcome 
and perhaps the procedure is an alternative for the increasing numbers of high risk surgical 
candidates in the expanding very elderly population that mandate less invasive methods.35 
Aortic valve surgery
The natural prognosis of severe AS is poor with 90% of patients presenting with angina 
and syncope dying within 3 years.36  Symptomatic AS is therefore the definitive indication 
for surgery, in which valve replacement can both reduce symptoms and extend life.
Choice of prosthesis
There is no perfect heart valve substitute. Mechanical valves have the advantage of structural 
stability but all require long-term anticoagulation. Bioprostheses are less thrombogenic and 
do not require anticoagulation but have the disadvantage of being subject to structural 
valve deterioration over time. Both types of valves have suboptimal haemodynamics and 
present a risk to infection. There is no survival difference between mechanical and biologi-
cal valves and the choice between the two types of valves should primarily be determined 
by assessing the risk of anticoagulation related bleeding versus the risk of structural valve 
deterioration.37 
Besides structural valve deterioration the disadvantages of stented heterografts are 
imperfect hemodynamic performance, prosthetic valve endocarditis, and a low (0.7% per 
year) risk of thromboembolism. Bovine pericardial valves appear to have a low rate of 
structural valve deterioration with an 18-year actuarial freedom from reoperation of 76%, 
and freedom from valve failure of 85% among patients undergoing primary AVR at an 
age greater than 60 years.38 Structural deterioration of tissue valves is limited in the elderly 
population and the risk of a bleeding event due to anticoagulation in case of a mechanical 
valve is considerable and outweighs the risk of structural valve failure. Besides the differ-
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ences in prosthesis one should take into account that the life expectancy of a patient who 
survives an AVR is less than that of a matched person in the general population.39 Even 
the life expectancy of a hypothetical patient who is immune from valve-related events and 
from operative mortality is lower than that of the general population. This excess mortal-
ity is due to valve related mortality and an additional mortality. The additional mortality 
might be related to underlying valve pathology, left ventricular residual hypertrophy and 
functional abnormality and the valve replacement procedure itself. On the basis of these 
considerations, most patients over 60-65 years of age receive a bioprosthesis. Type of 
bioprosthesis does not seem to influence patient outcome.40 
Stentless valves are constructed from porcine aortic valves and do not have a prosthetic 
sewing ring, allowing for larger valves to be implanted with presumably better hemody-
namic performance than if a stented bioprosthesis is used. The disadvantage is that their 
implantation is more complex than that for stented valves. Retrospective data suggest 
excellent survival with this type of bioprosthesis but it is unclear whether this is due to the 
hemodynamic benefits of the valve or to patient selection.39 A stentless allograft might be a 
good choice for patients with small aortic root sizes at risk for patient-prosthesis mismatch.
PROGnOSIS
Hospital morbidity and mortality after surgery
Complication rates are higher in the elderly but not per se higher compared to the younger 
population. It seems that an operation is relatively safe and has little increased risk over 
younger age groups if the patient is operated upon in a stable condition and not in an 
urgent or emergent situation and the patient does not have major comorbidities.41 Identi-
fied risk factors for hospital mortality are previous coronary bypass operation, impaired 
renal function, age, left ventricular dysfunction, previous stroke and a history of myocardial 
infarction. NYHA classification was not an independent risk factor for operative mortality 
for patients aged 80 years and older.42-43 Postoperative complications in elderly patients 
occur frequently and involve renal failure (6-12%), arrhythmias (25-45%), permanent 
stroke (2-4%), respiratory complications resulting in prolonged ventilation (21-27%), or 
reoperation for bleeding (4-9%).42,44
In patients over the age of 70 years the operative mortality ranges from 2%-6%,6,45 
while 30-day mortality rates for octogenarians are approximately 8% to 20%, with lower 
mortality for isolated aortic valve surgery (6%) and higher mortality for multiple valve, and 
valve plus coronary artery bypass graft operations.42,44 Postoperative complications that 
account for hospital mortality are renal dysfunction and stroke.
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Late survival
Elderly patients have acceptable late outcome after AVR. Survival rates in octogenarians 
of 82-85% at 1 year, 70-81% at 3 years, and 55-73% at 5 years have been achieved at 
different centers.41,42,44 Preoperative risk factors for late mortality in octogenarians include 
female sex, congestive heart failure, recent myocardial infarction, cerebrovascular disease, 
peripheral vascular disease, respiratory disease, diabetes, and chronic renal impairment.46 
Postoperative complications as renal failure and permanent stroke are also strong pre-
dictors for poor long-term survival.42 Valve replacement for AS offers the best treatment 
option in elderly patients to ensure an acceptable late outcome. Comparing a surgically 
and medically treated group of patients over 70 years, survival during the first six months 
in both groups decreased to about 85%. However at three years the survival in the surgical 
group was 80% whereas the survival in the medical group continued in a steep decline to 
49%.6
Quality of life
Although valve surgery will be undertaken in select elderly patients for potential survival 
benefit, the main goal of cardiac valve surgery in this population is improvement in quality 
of life through reduction of symptoms and better physical function. This improvement 
comes at some cost, however. In addition to the risk of perioperative death, the morbidity 
rate is considerable and the hospital length of stay prolonged. Improvement in NYHA 
functional class however is substantial and similar to NYHA class among the general elderly 
population.47 In a series of operated octogenarians ninety percent of long-term survivors 
were in New York Heart Association class I or II.48 
Quality of life (QOL) as assessed with SF-36 scores in operated patients is equal to or 
better than that of the general elderly population.41 Intriguingly age alone is not a strong 
predictor of QOL improvement after surgery. The magnitude of improvement in mental 
health is similar in elderly and younger patients.49  At more than 2 years follow-up 68-85% 
of survivors are living at home and more than 90% of the long-term survivors believed in 
retrospect that having decided to have cardiac surgery after age 80 years had been a good 
choice.44,50 
Concomitant surgical procedures
There is convincing histopathologic and clinical data suggesting that calcific valve disease 
is an active disease process akin to atherosclerosis with lipoprotein deposition, chronic 
inflammation, and active leaflet calcification. The overlap in the clinical factors associated 
with calcific valve disease and atherosclerosis and the correlation between the severity of 
coronary artery and aortic valve calcification provide further support for a shared disease 
process. About 35 percent of octogenarians with AS have clinically significant luminal 
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narrowing on coronary angiography51 which must be considered in the evaluation of 
symptoms.
Previous investigators have found that the performance of concomitant surgical pro-
cedures exposes elderly patients to higher early mortality of up to 24%44 while others 
found that concomitant Coronary Artery Bypass grafting (CABG) improved operative and 
long-term survival in patients operated over 80 years of age.42 Myocardial revascularization 
however, should be performed at the time of AVR in all patients in whom a significant 
coronary stenosis coexist regardless of the presence or absence of angina.52  
Vice versa, patients presenting with coronary disease may also have aortic valve disease. 
If AS is severe, AVR should be performed in conjunction with CABG surgery. There is 
controversy, however, over the appropriate care of asymptomatic patients with mild or 
moderate stenosis. If no intervention is done at the time of CABG, AS symptoms may 
develop, necessitating a second open-heart procedure (AVR), with additional technical 
challenges and complications. Conversely, an initial CABG/AVR increases the initial opera-
tive risk and exposes patients to potential long-term valve-related complications of 2%-6% 
per year. Clinical factors as severity and rate of progression of AS, patient life expectancy, 
and probability of valve- or operative-related complications, must be considered in making 
this decision.53 Only about 12% of patients with mild AS will have developed severe AS 
in 10 years.54 For patients under age 70 years, an AVR for mild AS is preferred if the peak 
valve gradient is >25 to 30 mm Hg. For older patients, the threshold increases by 1 to 2 
mm Hg/year, so that an 85-year-old patient undergoing CABG should have AVR only if the 
gradient exceeds 50 mm Hg
Concomitant mitral regurgitation (MR) is found in as many as 78% of patients being 
evaluated for AVR.55 It has been suggested that MR occurs as a consequence of altered 
ventricular performance associated with AS and will improve after isolated AVR. However 
other reports have shown that MR improved only in 45% of the patients and in 55% 
it remained unchanged or deteriorated.55 It seems that patients who undergo AVR and 
have a preoperative mitral regurgitation ≥2+ have a higher risk of congestive heart failure 
which is an independent risk factor for late postoperative death.56 What remains to be 
determined however, is whether a more aggressive approach to mitral valve repair results 
in improved long-term outcome and outweighs the potential morbidity and mortality of an 
added procedure in high-risk patients.
Reoperation
An increasing number of patients have been followed with moderate AS after another 
heart operation. Many patients requiring AVR have had prior coronary artery bypass graft-
ing and return with severe AS. Especially in the setting of a patent internal mammary artery 
graft this poses a high risk because of potential damage to the internal mammary artery 
and poor myocardial protection in the LAD territory.57 Mortality rate ranges from 6-18%.58
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 Life expectancy of patients with heart valve replacement also increases and approxi-
mately 10% of patients who were between 60 and 70 years old at the time of their first 
operation will need replacement of their prosthetic valve in the ninth decade of their life. 
A cardiac redo procedure has a higher hospital mortality of approximately 5-15% but 
survival at 3 years is the same as octogenarians who had their first AVR.59-60 Increased risk 
of reoperation is due to sternal reentry complications, inconsistent myocardial protection, 
emboli originating from old grafts and aorta, comorbidities leading to diminished reserve 
of subsystems and tissue fragility.61 
This feasibility of an elective hybrid approach of combining minimally invasive AVR for 
aortic valve disease with PCI in combination of a drug-eluting stent for coronary artery 
stenosis produced satisfactory outcomes  and suggests an alternative treatment for high-
risk patients with AS and coronary artery disease.62 
Transcatheter valve implantation
Many patients with severe AS do not undergo surgery because of excessive risk, advanced 
age, or preference. Prognosis with medical management is poor and percutaneous alterna-
tives to surgery have been limited to balloon valvuloplasty with only transient modest 
improvement and is reserved for palliation only. The disappointing results of balloon valvu-
loplasty have led to investigation of the possibility of percutaneous placement of prosthetic 
aortic valves. The development of a technique for percutaneous valve implantation in the 
aortic position poses a challenge because of the high hemodynamic stresses and the prox-
imity of both the mitral valve and coronary artery orifices. The positioning of the implanted 
valve must be extremely precise, as malposition of the prosthesis in either direction could 
result in severe acute mitral dysfunction or acute myocardial ischemia.
Antegrade technique
The first percutaneous valve implantations were implanted using the antegrade approach.63 
This approach requires femoral venous access, a transseptal puncture, dilation of the atrial 
septum and passage of a flotation balloon through the mitral valve. The passage of large 
diameter catheters through the mitral valve produces temporary mitral insufficiency, and 
mitral injury may occur. Acute mitral insufficiency after injury of the mitral chordae carries 
a high mortality rate in this procedure. Hemodynamic instability has been characteristic of 
the antegrade technique, and acute procedural mortality is a concern.63
Retrograde technique
The technical complexity and associated risks of the antegrade approach enabled the de-
velopment of the percutaneous retrograde transfemoral implantation of aortic prosthetic 
valves.64-65 During this procedure first a valvuloplasty is performed and a large sheath is 
introduced to a position beyond the iliac arteries into the aorta. Next a steerable deflection 
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figure 1. The Edwards Sapien® Valve
figure 2. The stent of the Corevalve prosthesis 
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catheter is inserted which actively directs the prosthesis through the aorta. The prosthesis 
is then positioned coaxial with the calcified native valve leaflets and during rapid right 
ventricular pacing the stent-deployment balloon is rapidly inflated and then deflated. 
Vascular trauma accounted for 50% of the mortality in the initial series reported by Webb 
et al.64 This procedure can also be achieved in a true percutaneous way without a surgical 
exposure and closure of the femoral vessels.66 Currently two devices are under clinical 
investigation: the Edwards Sapien® heart valve (Figure 1) and the CoreValve® (Figure 2) 
self-expandable aortic implant. The Sapien® heart valve is fabricated from three equal 
sections of bovine pericardium affixed to a stainless steel expandable stent and comes in 
two sizes (23 mm and 26mm). The femoral introductory sheaths that are used have an 
internal diameter of 22F and 24F respectively. The CoreValve revalving system® contains 
a porcine bioprosthesis within a nitinol frame which is introduced through an 18F sheath. 
Both valves are also under investigation for transapical implantation (see below).
Transapical valve implantation
Another route for a closed heart valve procedure, which obviates vascular trauma, is the 
implantation of an aortic valve prosthesis through the apex of the left ventricle without 
sternotomy and the use of cardiopulmonary bypass.64 The apex of the left ventricle is in 
direct line with the aortic valve, and is crossed in an antegrade fashion in the direction of 
blood flow. This permits a shorter and stiffer delivery system that allows easier and more 
precise positioning and placement. After an anterolateral incision of the thoracic wall, 
the pericardium over the apex of the left ventricle is identified and opened. Temporary 
epicardial ventricular pacing wires are placed on the left ventricle. Sutures with pledgets 
are placed into the myocardium and after puncture of the apex a sheath is introduced 
into the left ventricle. A wire is placed through the sheath into the aorta. After balloon 
valvuloplasty (see Figure 3), the prosthesis, balloon for valve expansion, and steerable 
catheter are passed over the previously placed wire and introduced as a unit through the 
sheath. After positioning of the valve, rapid pacing is started and the balloon is inflated 
and the valve deployed. Subsequently wire and sheath are removed and the apex is closed. 
This transapical procedure might be better suited for patients with small femoral or iliac 
arteries, tortuosity of the vessels or atheroma. Technical difficulties may occur in case of 
fragile tissue of the apex, especially in elderly patients.64,67
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Valve-in-a-valve concept
Patients may suffer xenograft degeneration requiring reoperation. The risk of reopera-
tive surgery may be increased, because of advanced age, additional risk factors, and an 
increased technical difficulty caused by adhesions. A transcatheter implantation of a su-
tureless stent-fixed xenograft into a conventional bioprosthesis on the beating heart using 
a minimally invasive transapical approach has been demonstrated in a pig model. This new 
valve in a valve procedure may lead to a significantly decreased risk for reoperative valve 
replacement surgery.68 
Many critical questions towards percutaneous or transapical aortic valve implantation 
remain unanswered, including the durability of these devices and the potential adverse 
effects they may have on subsequent heart valve surgery. Risk for paravalvular leakage 
probably is the biggest issue at present but also the size of the catheters that are needed 
and the trauma to the femoral vessels and also valve embolization is a potential risk. 
Therefore, one cannot justify the use of these experimental technologies in patients for 
whom published guideline indications do not exist or in situations of prophylactic therapy 
until data on safety and effectiveness are gathered from well-designed clinical trials.
COnCluSIOn
Cardiac surgical therapy in the elderly is increasing and will increase even further in the 
coming years as healthcare in general improves and the numbers of elderly patients requir-
ing AVR increases. Symptom control is greatly improved following aortic valve surgery in 
seriously compromised patients compared with patients on continued medical treatment. 
figure 3. Transapical balloon valvuloplasty
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In the absence of severe comorbidities, octogenarian patients can undergo AVR with low 
morbidity and mortality, provided the elderly patient is operated upon in stable condition. 
A non-elective operation, a preoperative NYHA class III or preoperative intubation, and 
end-stage organ failure significantly increase the risks of surgery. Conventional surgery re-
mains the gold standard for the treatment of patients with significant aortic valve disease. 
Surgical consultation is recommended in nearly all patients with symptomatic severe AS. 
Some elderly patients will refuse surgery, even with a clear understanding of the risks and 
benefits. Other elderly patients have mental status alterations or physical limitations that 
markedly reduce the potential benefits of valve replacement. Clinical decision making in 
the elderly patient is based on assessment of the severity of AS, a complete medical history, 
evaluation of comorbid conditions, and a full discussion with the patient and family. The 
use of percutaneous valve replacement not requiring cardiopulmonary bypass is still being 
evaluated, but these procedures will be applied increasingly in the coming years.
Expert commentary
For patients with aortic valve disease there is no effective medical therapy and balloon 
valvotomy is not an acceptable alternative to surgery. Despite the fact that surgical valve 
replacement carries an important operative morbidity and mortality in elderly patients, AVR 
must therefore be considered in patients who have symptoms caused by aortic stenosis. 
There is increased operative risk with aortic valve replacement (AVR), but there also is 
reduced life expectancy without surgery and more important decreased quality of life. 
Unfortunately, there are no widely available alternatives to open surgery.
Percutaneous aortic valvuloplasty inhabits a small niche in stabilizing critically ill patients 
prior to surgery, but its offspring, percutaneously placed valves, have demonstrated short-
term benefits in patients deemed inoperable by multiple surgical teams. Their long-term 
benefits and results in the hands of others is still unknown. Surgically implanted prosthetic 
valves are the dominant therapy, with tissue valves traditionally reserved for patients over 
65 years of age.
Five year view
In light of the heavy calcification present at the time that many patients seek medical 
attention for AS, it seems very unlikely that drug therapy will play a role in established 
symptomatic AS. However, there is continued interest in statin and angiotensin-converting 
enzyme inhibitor therapy to slow the progression of mild and moderate AS. Aortic bal-
loon valvuloplasty is a generally unsatisfying procedure, and will continue to play a very 
limited role in treatment. For the next 5 years, percutaneously implanted aortic valves 
will be reserved for situations in patients too ill to survive technically successful surgery. 
Percutaneous valve ablation techniques and filters avoiding systemic embolization during 
percutaneous valve implantation will lower the risks of the procedure.
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Owing to its excellent long-term results with minimal mortality, AVR with a prosthetic 
valve using a median sternotomy will continue to be the mainstay of therapy for AS. 
At present there are no safe alternatives to warfarin, the active lifestyles of aging baby 
boomers and growing confidence in pericardial valves all favour the increasing use of tissue 
prostheses.
Key issues
• The numbers of elderly patients requiring AVR will increase further in the coming years.
•  Clinical decision making in the elderly patient is based on assessment of the severity 
of aortic stenosis, a complete medical history, evaluation of comorbidities, and a full 
discussion with the patient and family.
•  Improvement in the quality of life is the main goal in aortic valve replacement in the 
elderly.
•  The use of percutaneous aortic valve replacement in the elderly patients will increase in 
the coming years.
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AbSTRACT
Background and aim of the study 
Published reports on the progression of aortic valve stenosis (AS) over time are usually 
small, with widely varying AS progression rate estimates. Reliable estimates of AS progres-
sion are important for surveillance scheduling and optimal timing of surgical or interven-
tional treatment. This systematic review presents an overview of published evidence on AS 
progression over time in adult patients with AS.
Methods
A systematic review using PubMed and Embase was performed to assess AS progression 
over time in adult patients with AS measured by echocardiography. A total of 27 reports 
(15 prospective, 12 retrospective, total 4,921 patients, pooled age 69 years) was included 
in which the baseline and progression rates of the hemodynamic variables were pooled. 
Subgroup analyses were performed to investigate factors associated with AS progression 
and sources of heterogeneity.
Results
Pooled annual AS progression was 3.70 mmHg per year (SE = 0.10) for randomized clinical 
trials, and 6.03 mmHg per year (SE = 0.10) for observational studies. A large variability in 
observed AS progression was found between studies, as well as a wide variety of methods 
employed to measure AS.
Conclusion
The observed large individual variability in measuring AS progression among the selected 
studies calls for the implementation of a universal method of AS assessment. This will 
facilitate an insight into the determinants of AS progression and allow for an evidence-
based tailoring of treatment.
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bACkGROund And AIM Of ThE STudy
Aortic valve stenosis (AS) is a common disease among the elderly, with a prevalence of 
1-3% among American adults aged ≥65 years.1-5 In the same age group, the prevalence 
of aortic valve sclerosis is 25-29%, with 16% of cases deteriorating to AS within seven 
years.2,3,6 Mortality for patients with severe symptomatic AS is 56-83% within five to seven 
years after diagnosis.7
According to the present American College of Cardiology/American Heart Association 
(ACC/AHA) and European Society of Cardiology (ESC) guidelines, aortic valve replacement 
is indicated in symptomatic patients with severe AS, whereas the indication remains debat-
able in asymptomatic patients with severe AS.8,9 Asymptomatic patients with mild to severe 
AS are monitored over time.8,9 In the past, several small studies have been conducted to 
investigate AS progression and its potential determinants although, due to their small 
sample size, it is difficult to draw general conclusions. Thus, a systematic review and meta-
analysis of available echocardiographic information on AS progression would allow for an 
improved insight into AS progression and its potential determinants. This may ultimately 
provide important clues for treatment optimization.
The aim of the present systematic literature review was to provide an overview of the 
published evidence on the progression of AS in adult patients, as measured using echo-
cardiography.
MATERIAlS And METhOdS
Search strategy
A literature search using the PubMed and Embase databases, with the key words ‘aortic 
stenosis’ and ‘progression’, and their synonyms, was performed on July 20th, 2010. The 
search was limited to English-language publications, human adults aged ≥18 years, and 
published between January 1st, 1989 and July 20th, 2010. Any duplicates were filtered 
out. All titles and abstracts were screened for study design (prospective and retrospective 
observational studies or randomized clinical trials; RCTs) and study population (patients 
with AS with none or only mild aortic regurgitation, who were not initially selected for 
coronary artery bypass grafting; CABG). A second independent reviewer (M. van G.) as-
sessed whether the inclusions and exclusions had been performed correctly. In case of 
any disagreement, an agreement was negotiated. The references of selected reports were 
crosschecked for other relevant studies. Authors were contacted when a publication could 
not be obtained, or when not all required information could be retrieved from a publica-
tion.
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Data extraction
The selected reports were reviewed and the patient characteristics and outcome variables 
tabulated using MS Excel for Windows and Review manager (version 5.0; Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). The following patient 
characteristics were registered: gender (male), age (years), peak aortic gradient (PAG; 
mmHg), mean aortic gradient (MAG; mmHg), aortic jet velocity (Vmax, m/s), aortic valve 
area (AVA, cm2), left ventricular ejection fraction (%), aortic valve calcification, prevalence 
of coronary artery disease (CAD), current smoking, hypertension, hyperlipidemia, and dia-
betes. Typically, CAD was defined as prior percutaneous transluminal coronary angioplasty, 
CABG or (symptoms of) myocardial infarction, and obstruction of the coronary arteries 
(i.e. stenosis ≥70%). Hyperlipidemia was defined as (a history of) hypercholesterolemia or 
hyperlipidemia.
Hemodynamic echocardiographic variables were registered according to the ACC/AHA 
guidelines for the clinical application of echocardiography.10 Outcome variables included 
baseline AVA, PAG, Vmax, and MAG, annual decrease in AVA, and annual increase in PAG, 
Vmax, and MAG.
For studies that compared statin users with non-statin users, these two subgroups were 
considered as separate study populations because overall estimates of the total study 
population were unavailable.11-20
Statistical analysis
The initial AS, as measured by PAG, MAG, Vmax, and AVA, and AS progression rate were 
pooled using the inverse variance method. If only Vmax was reported, the simplified Ber-
noulli equation was used to calculate the PAG (see Appendix). The AS progression rates 
were assumed constant over time, and annual AS progression rates were calculated using 
the formula described in Appendix I. Studies were divided by study design, namely RCTs 
versus observational studies. Heterogeneity among the studies was explored by the Q and 
I2-statistic, and by funnel plots. A subgroup analysis was carried out among observational 
studies to study factors that were potentially associated with the progression rate of PAG, 
employing cut-off points for classical risk factors. In the subgroup analyses, the following 
subgroups were compared: studies with mean age ≥70 years versus <70 years, with a 
mean CAD prevalence of ≥50% versus <50%, with a mean hypertension prevalence of 
≥50% versus <50%, with a mean hyperlipidemia prevalence of ≥50% versus <50%, with 
a mean smoking prevalence of ≥25% versus <25%, with a mean diabetes prevalence of 
≥20% versus <20%, and with a mean PAG ≥40 mmHg versus <40 mmHg. Any missing 
values in the independent variables were excluded test-by-test. All statistical analyses were 
performed using Review manager 5.0 and SPPS 15.0 (SPSS, Chicago, IL, USA).
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RESulTS
Search results
The search identified a total of 1,332 publications (Fig. 1). In addition, 1,305 reports were 
excluded, including those in which no serial hemodynamic measurements were described 
(n = 364 studies), patients underwent (percutaneous) aortic valve replacement, (balloon) 
valvuloplasty or revascularization (elective or percutaneous cardiac intervention) during 
hemodynamic measurements (n = 232, 100, and 6, respectively), age <18 years (n = 142), 
specific patient subgroups (n = 93), case reports (n = 108), reviews, letters or editorials (n 
= 72), focus on biological features of AS (n = 46), patients with low-gradient AS, poor left 
ventricular function (left ventricular ejection fraction ≤30%) or congestive heart failure (n 
= 42), patients with concomitant valve pathology or root dissection (n = 61), supravalvular 
or subvalvular AS (n = 25), experimental studies (n = 8), or focus on aortic sclerosis (n = 
6). Finally, 27 Doppler echocardiography reports were used for the review.11-37 From these 
studies, eight study populations were obtained from four RCT reports,15,16,19,20 and 29 study 
populations from 23 observational study reports.11-14,17,18,21-37
figure 1: Flowchart of the search.
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Study characteristics
The eight study populations derived from the four RCTs (see Table I) included a total of 
2,344 patients with a mean age of 67 years at inclusion (range: 58 to 70 years), and 62% 
of these patients (age range: 54 to 72 years) were male. The mean follow up period was 
49 months; hence, the total follow up was 9,506 patient-years (pt-yr).
The 29 study populations derived from the 23 observational studies (see Table II) included 
a total of 2,577 patients with a mean age of 71 years at inclusion (range: 58 to 78 years), 
and 83% of these patients (age range: 33 to 99 years) were male. The mean follow up time 
was 30 months, and the total follow up 6,399 pt-yr. In total, there were 15 prospective and 
14 retrospective cohorts.
Study outcome
The echocardiographic hemodynamic variables of the RCTs and observational studies are 
shown in Tables I and II, respectively. Details of individual studies and pooled AS progres-
sion over time are shown in Figure 2a and b.
Heterogeneity, subgroup analyses, and publication bias
Heterogeneity and subgroup analyses
Significant heterogeneity was observed for all hemodynamic outcomes (see Tables I and II). 
Subgroup analyses of the observational studies showed that studies with a mean patient 
age ≥70 years had a slower AS progression rate compared to those with a mean patient 
age <70 years (p <0.00001). Studies with a higher smoking prevalence had a faster AS 
progression rate compared to those with a lower smoking prevalence (p <0.00001).
Studies with a higher CAD prevalence had a slower progression rate compared to those 
with a lower CAD prevalence (p <0.00001); the same effect was apparent for the variables 
hypertension and diabetes, in which the high prevalence groups had a slower progression 
rate (p <0.00001).
Studies with a higher mean baseline PAG showed a faster AS progression rate compared 
to those with a lower mean baseline PAG (p <0.00001).
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figure 2: a) Aortic valve stenosis (AS) progression in randomized clinical trials. b) AS progression in 
observational studies. PAGt: Peak aortic gradient at time t; SE: Standard error; t: Time. Dotted lines 
indicate individual study estimates; solid lines indicate pooled estimates.
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Publication bias
The funnel plot for baseline PAG was asymmetric. Smaller studies showed higher estimates 
of baseline PAG compared to larger studies (Fig. 3a), while the funnel plot for progression 
rate showed outliers in both small and large studies (Fig. 3b). Age, smoking, CAD, hyper-
lipidemia, hypertension, diabetes, and baseline PAG were each considered as potential 
determinants for the large variability of both funnel plots, though none was detected.
figure 3: a) Funnel plot of baseline peak aortic gradient (PAG, mmHg) in randomized clinical trials and 
observational studies. b) Funnel plot of AS progression in randomized clinical trials and observational 
studies. SE: Standard error. The funnel indicates 95% confidence intervals.
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dISCuSSIOn
This review is the first to compile, systematically and as a comprehensive overview, the 
available evidence published during the past two decades relating to AS progression in 
adults. Clearly, the main findings were the wide variability in observed AS progression 
between studies, and the wide variety of methods used to measure AS. Furthermore, the 
review findings have confirmed that AS progression is faster in those patients who have 
more severe AS at baseline.
Patient factors associated with AS progression
Although heterogeneity was considerable in this meta-analysis and may potentially lead to 
inaccurate results, a thorough examination of possible sources of heterogeneity was pur-
sued. Consequently, patient age, CAD, hypertension, diabetes, and smoking were found 
to be potentially associated with AS progression. Most of these patient factors are in some 
way inter-related, and it is beyond the scope of this review to attempt to disentangle their 
potential individual role in AS progression. However, these observations may form the basis 
for future studies that focus on dissecting the determinants of AS progression.
Older patient age, which is thought to be the most important risk factor for the preva-
lence of AS,3 was in the present subgroup analysis associated with a slower annual AS 
progression. Potential explanations for this may lie in age-dependent inflammatory and 
atherosclerotic pathways underlying AS pathogenesis,38,39 or the fact that the elderly pa-
tients - who typically have multiple comorbidities - are monitored more carefully or have a 
higher death rate, which may have influenced the serial AS measurements. Nevertheless, 
these are all highly speculative suggestions that are yet to be confirmed.
In the present review, smoking was found to be associated with a faster annual AS 
progression. A potential explanation for this may be found in the Cardiovascular Health 
Study, which showed that in elderly patients smoking was associated with a 35% higher 
risk for degenerative aortic valve disease.3 However, in another case-matched study of pa-
tients with severe AS, smoking was found to be significantly associated with the presence 
of CAD, but was not more prevalent among patients with severe AS when compared to 
a control population without AS.40 These conflicting results highlight the need for further 
exploration of the potential association between smoking and the progression of AS.
AS measurement methods
The present review confirmed the current use of several different classifications of AS se-
verity, with guidelines employing AVA, Vmax, and MAG for grading AS.
9 However, Minners 
and colleagues showed these criteria to be inconsistent, even in patients with a normal 
left ventricular systolic function.41 In the present review, PAG was used to measure AS 
progression because this was the method most often used in the studies. Nonetheless, a 
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universal classification of AS severity would greatly enhance the comparability of different 
reports and allow an enhanced estimation of AS progression.
In addition, a wide range of tests was employed to estimate aortic valve calcification, 
though without any reference test to quantify the extent of calcification. Although de-
termined in only a few of the studies reviewed, aortic valve calcification was identified 
on several occasions as a strong predictor for AS severity and outcome, and described a 
close association with AS severity.42-44 Unfortunately, pooling of the data from calcification 
studies was not possible because of the varying assessment methods employed.
Study design
The meta-analysis of RCTs demonstrated smaller AS progression estimates compared to 
the observational studies. This may be explained by differences in patient selection and 
monitoring methods over time.
Study limitations
The main limitation was that most of the included studies were retrospective, heterogenic, 
non-randomized and small, with a limited follow up duration and without registration 
of drug therapy. In addition, compared to RCTs, observational studies are more prone to 
publication bias.45
The primary aim of this systematic review was to provide an overview of AS progres-
sion, and for the subsequent subgroup analyses to provoke discussion. However, spurious 
results may emerge from the meta-analysis of observational data and must therefore be 
reproduced to be convincing. The included patients underwent serial measurements, 
which are most likely more frequently performed in more severe cases of AS. Attention 
was not focused on concomitant cardiac (valve) diseases, and this may have influenced the 
results. The reasons for patient referral (CAD or AS) were not retrievable, and may have 
hampered any analysis of the association between CAD and AS. Finally, disease severity 
at baseline potentially introduces bias. Most variables employed in this systematic review 
were continuous, for which different methods of analysis and cut-off points were used, 
leading to a potential bias of the results obtained.
COnCluSIOn
The present systematic review was the first to include all published echocardiography data 
on AS progression in adult patients with the condition. The results demonstrated a wide 
variability in observed AS progression which was, most likely, due to the heterogeneous 
nature of AS and the various methods used for its monitoring. Indeed, an optimal and 
uniform monitoring of AS severity is the key to a better understanding of AS progression 
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in adult patients, and these issues should be addressed in future clinical practice guidelines 
for the diagnosis and management of patients with this condition. This will eventually 
allow for a better assessment of the potential determinants of AS, the development of 
clinical decision tools that can predict disease progression, potential measures to reduce 
AS progression, and will ultimately also assist in an evidence-based tailoring of treatment 
for individual patients.
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APPEndIx
Statistical formula used for the different calculations
Simplified Bernoulli equation: 4 × Vmax
2
Progression rate peak aortic gradient (PAG): 
Progression ratei = (PAGfinal - PAGbaseline)/Follow upi
The 95% confidence intervals (CI) of the individual studies:
95% CI = pooled mean ± tα,df=n-1 × standard error, with α = 0.05 (if n < 30 patients).
95% CI = pooled mean ± 1.96 × standard error (if n ≥ 30 patients)
The 95% confidence intervals (CI) of the pooled outcomes:
Pooled standard error = 1/√(åweights).
95% CI = pooled mean ± 1.96*pooled standard error.
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AbSTRACT
Objective
Numerous reports have been published documenting the results of aortic valve replacement 
(AVR). It is often not easy to translate these valve outcomes into the actual consequences 
for the patient. We previously developed an alternative method to study outcome after 
AVR that allows direct estimation of patient outcome after AVR: microsimulation model-
ing. The goal of this article is to provide insight into microsimulation methodology and to 
give an overview of the advantages and disadvantages of simulation methods (in particular 
microsimulation) in comparison with standard methods of outcome analysis. 
Methods
Using a primary dataset containing 1847 patients and 14,429 patient-years, advantages 
and disadvantages of standard methods of outcome analysis are discussed, and the poten-
tial role of microsimulation is illustrated by means of a step-by-step explanation of building, 
testing and using such a model.
Results
Total life expectancy, event-free life expectancy, and reoperation-free life expectancy for a 
65-year-old male patient were 10.6 years, 9.2 years, and 9.8 years, respectively. Lifetime 
risk of reoperation due to structural valve deterioration was 13.3%.
Conclusions
Microsimulation is capable of providing accurate estimates of age-related life expectancy 
and lifetime risk of reoperation for patients who underwent aortic valve replacement with 
the Carpentier-Edwards supra-annular valve. It provides a useful tool to facilitate and 
optimize the choice for a specific heart valve prosthesis in a particular patient. 
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InTROduCTIOn
Numerous reports have been published documenting the results of aortic valve replace-
ment (AVR) with different types of valve prosthesis. In most reports emphasis is on the 
performance of the various prosthetic valves, as measured by the occurrence rates of valve-
related complications and their consequences, and time-to-event analyses. This is a valid 
approach but limited by several methodological issues,1 and it is often not easy to translate 
these valve outcomes into the actual consequences for the patient who requires AVR.
We have previously developed an alternative method to study outcome after AVR that 
allows direct estimation of patient outcome after AVR: microsimulation.2 This method 
solves most of the methodological limitations of standard outcomes analyses, but does 
have several limitations of its own. 
The goal of this article is to provide insight into microsimulation methodology and to 
give an overview of the advantages and disadvantages of microsimulation compared to 
standard methods of outcome analysis. This will be done using primary data on outcome 
after AVR with the Carpentier-Edwards supra-annular valve (CE-SAV) prosthesis from a 
large single center in Canada.3 The following issues will be addressed:
1.  Using the primary dataset on outcome after AVR with CE-SAV prosthesis we will 
discuss the advantages and disadvantages of standard methods of outcome analysis.
2.  The information from this primary dataset will then be used to estimate patient out-
come with a microsimulation model, illustrating step by step the construction and 
testing of a microsimulation model and its potential advantages and disadvantages.
MATERIAlS And METhOdS
Description dataset
For this study a primary dataset containing 1847 AVR procedures with the CE-SAV device 
was used to estimate the parameters of the Weibull distributions.3 These operations were 
conducted from February 1982 through December 1999 at the affiliated teaching hospitals 
of the University of British Columbia in Canada, namely, St. Paul’s Hospital, Vancouver 
General Hospital and the Royal Columbian Hospital. 
The characteristics of the complete dataset (n=1847) are summarized in Table 1. To 
calculate the input of the microsimulation model 85 aortic valve re-replacements were 
excluded, resulting in 1762 remaining primary AVR’s (see Table 1 for characteristics). Details 
of the occurrence of valve related events, and the associated mortality of these primary 
AVR’s are given in Table 2. Valve-related events were defined according to the Society of 
Thoracic Surgeons / American Association for Thoracic Surgery Guidelines for Reporting 
Morbidity and Mortality after Cardiac Valvular Operations4 with 2 modifications: transient 
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Table 1: Dataset summary
Total dataset Only primary AVR included
Number of procedures 1847 1762
Follow-up:
 Total follow-up (patientyears)
 Mean follow-up time (years)
 Range (years)
14,429
7.8
0-20.6
13,849
7.9
0-20.6
Male (%) 69.1 68.7
Mean age (years) 69.0 69.4
Operative mortality 5.3 5.0
Outcome: 
 Valve Related Morbidity #
 Valve Related Mortality
 Valve Related Reoperations
 Valve Related Events
311
158
161
469
292
154
148
446
# Valve Related Morbidity is defined as ‘non-fatal Valve Related Event’, thus including non-fatal reoperations
Table 2: Occurrence rates of valve related events and the associated reoperation and mortality rates for 
1762 primary AVR procedures with the CE-SAV.
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Hemorrhage 72 0.52 0 0 23 31.9 31.9
Non-Structural
Dysfunction
33 0.24 29 87.9 3 9.1 50.0
Prosthetic Valve
Endocarditis
46 0.33 17 37.0 19 41.3 62.1
Structural Valve 
Deterioration #. 
118 Weibull 98 83.1 26* 22.0 100.0
Thrombo-
Embolism
155 1.12 0 0 65 41.9 41.9
Valve Thrombosis 4 0.03 4 100.0 0 0 Not 
applicable
# Structural valve deterioration was confirmed at reoperation or autopsy
* 6 patients died at reoperation for SVD, 20 patients were not reoperated but died with SVD confirmed at autopsy
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ischemic attacks were not counted as neurologic events (in order to avoid recall bias), and 
structural valve deterioration (SVD) was only included if diagnosed either at reoperation 
or autopsy. 
Slight differences in reporting numbers of valve related events between this paper and 
the earlier report of essentially the same dataset3 can be explained by the use in the present 
study of a subset of 1762 patients, and by differences in definition of ‘SVD’. 
Standard methods of outcome analysis
The Kaplan-Meier (KM) and the actuarial method are commonly used time-to-event mod-
els to estimate the survival of patients after AVR. The distribution of the time-to-death for 
currently alive patients is assumed to follow the pattern of those who have already died. 
These methods have now been extended to summarize valve-related events such as SVD 
that are not necessarily fatal. In Figure 1 the cumulative (“actuarial”) risk of reoperation 
for SVD calculated by using the KM method (the complement of cumulative freedom from 
reoperation for SVD) is displayed for the CE-SAV dataset. For estimating the life-time risk 
of non-fatal events the KM and actuarial methods assume non-informative censoring: they 
assume the risk of dying and the risk of developing SVD are independent, which in fact 
is not true (patients with high risk of death have lower risk of SVD, and patients with low 
risk of death have a higher risk of having SVD at some time in their lives). The KM and 
actuarial methods therefore estimate the freedom from SVD by also censoring patients 
who have not yet experienced the event, including those who have died and will therefore 
never have the event. In doing so they describe the risk of SVD for the patient based on 
figure 1: Cumulative incidence of reoperation and cumulative risk (equivalent of ‘1 minus freedom 
from reoperation’) of all cause reoperation and reoperation due to SVD for patients in the CE-SAV 
dataset
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the assumption of immortality, resulting in a higher probability of SVD than the patient in 
reality has. This effect is magnified with advancing age of valve implantation and could 
serve to underestimate the benefits of biological valve implantation. So, although the 
KM and actuarial methods are perfectly capable of analyzing fatal events, for describing 
competing events their value is dubious because in clinical medicine the assumption of 
non-informative censoring can often not be guaranteed. 
One of the alternate methods of summarizing complications that are not necessarily 
fatal such as SVD is the cumulative incidence or “actual” analysis.5,6 This method takes into 
consideration the competing risk of death, it excludes future events attributed to already 
deceased patients, and therefore calculates the percentage of patients who will experience 
an event before they die, answering the more pertinent question of the lifetime risk of the 
event.1,7-9  As is shown in Figure 1, the cumulative “actuarial” risk of reoperation for SVD 
(7.0% at 15 years) is higher than the “actual” patient risk of reoperation for SVD (4.3% 
at 15 years).
The guidelines for reporting morbidity and mortality after cardiac valve operations have 
also incorporated the actual method.4 Except for the cumulative incidence estimation, 
competing risk analyses in general do have the disadvantage of assuming that the compet-
ing events are independent. However, occurrence of an event (or reintervention) may alter 
the subsequent survival time, and alter the risk of reoccurrence of the event.   
An advantage of the KM method and the cumulative incidence method is that they 
can be performed using standard statistical software, and that they give a valid general 
impression of outcome in patient populations after valve replacement. However, there 
are several limitations to these methods. In both KM and cumulative incidence analysis, 
an event can only occur once in the same patient. After the occurrence of an event, 
the patient is excluded from the analysis. Furthermore, although the KM and cumulative 
incidence analyses permit any hazard function while the parametric exponential method 
requires a constant hazard, neither of these models take into account that event risk may 
change over time, and may change after occurrence of events. 
Simulation methods
If one would like to obtain optimal insight into outcome after valve replacement in a 
particular population, ideally all patients should be followed over time until everybody 
has died and all events (not only the first) that took place over time should be analyzed. 
In real life, the former is usually not a realistic option and the latter is difficult and time-
consuming to achieve using standard methods of outcome analysis. Simulation methods 
offer a complementary tool to standard methods of outcome analysis by simulating the 
lives of virtual patients until death and taking into account all complications that may occur 
over time (including repeating events and changing hazards over time, with the occurrence 
of prior events, or both).
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The two types of simulation models that have been used to model patient outcomes 
after AVR are the Markov state-transition model and the microsimulation model.2,10 The 
Markov model creates a virtual population of patients that is followed over different time 
intervals until all patients have died. At each time interval, a transition from one health 
state to the other can occur, depending on predefined operative mortality estimates, oc-
currence rates of valve-related events and their consequences (death or reoperation) and 
the probability of dying of other non-valve-related causes. Events can occur repeatedly 
over time, hazards can change with each time interval, but it is hard to change hazards 
following the occurrence of an event using a Markov model. 
A microsimulation model is a computer model that simulates a representative popula-
tion, but at the level of the individual: the ‘micro’ level. The remaining life (until death) of a 
single patient with a particular age and sex after AVR with a given valve type is simulated. 
It takes into account the morbidity and mortality that the patient may experience according 
to predefined estimates of operative mortality, event occurrence and their consequences 
(death or reoperation), and the probability of dying of other non-valve-related causes. By 
repeating this simulation multiple times (eg, 10,000 times) a virtual patient population is 
generated, consisting of identical patients with all possible outcomes after AVR. A detailed 
account of the microsimulation structure and methodology has been given previously.2,11 
We used the AVR microsimulation model, designed at our institution, to provide insight 
into the age- and sex-related life expectancy and lifetime risks of valve-related events after 
AVR with the CE-SAV bioprosthesis because it has several advantages over the Markov 
model. First, the microsimulation model allows simulation of the individual life histories of 
patients, starting directly after AVR and ending with the death of the patient (follow-up 
does not end at the event), rather than following a virtual population over time. By simulat-
ing multiple times the lives of identical virtual patients, all possible competing events that 
may occur during the remainder of life, and the time to occurrence of these events can be 
studied. Then, using this virtual closed cohort dataset, the average prognosis (including the 
lifetime risk of SVD and of other valve-related events) of an individual patient with these 
characteristics can be calculated. Furthermore, unlike the Markov model in which time is 
divided in intervals during which an event may or may not occur, the micosimulation model 
estimates the time to the next event based on the occurrence probability of that event. 
Finally, the microsimulation model allows for adjustment of event occurrence rates with 
time or based on the occurrence of prior events: eg, operative mortality increases with age 
and with each successive reoperation.
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Building a microsimulation model
Figure 2 shows the general structure of the microsimulation model including and itemizing 
the information that is needed to start building the model:
1. Operative mortality estimates
To obtain accurate (and age-related) estimations of operative mortality after AVR, these 
parameters were estimated using data derived from an earlier meta-analysis containing 
5837 patients with a total follow-up of 31,874 patient-years.11 Operative mortality was 
estimated as 2.6% for a 40-year old man, increasing with an odds ratio of 1.034 for age 
(per year). For a 69-year-old man, operative mortality would be 6.6%. The real operative 
mortality derived from the CE-SAV dataset for primary AVR (mean age 69 years) was 5.0%. 
2. Estimates of occurrence rates of valve related events
The estimates of occurrence rates of valve-related events are derived from the primary 
dataset described earlier (primary AVR patients only), and are depicted in Table 2. Assum-
ing a constant hazard over time, weighted mean estimates of linearized annual occur-
rence rates were calculated for valve thrombosis, thrombo-embolism, endocarditis and 
figure 2: General structure of the microsimulation model
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non-structural dysfunction respectively. The occurrence of hemorrhage was modeled as an 
age-dependent hazard of 0.076 with an age-dependent mortality of 0.034.12
A reoperation because of SVD is more relevant to the patient than the occurrence of SVD 
without consequences.7 Furthermore, the onset and severity of structural valve deteriora-
tion is difficult to measure. Hence, SVD was defined as ‘reoperation due to SVD’ or ‘SVD 
confirmed by means of autopsy’. The cumulative risk of SVD in a bioprosthesis decreases 
with increasing age of the patient at valve implantation and increases sub-exponentially 
with elapsing time since implantation.13 Grunkemeier and colleagues have shown that 
the Weibull distribution, a generalization of the exponential distribution, was efficient in 
summarizing SVD in biological valves.14,15 However, they stressed that at least 12 years of 
follow-up are needed to provide reliable estimates.14 We used primary data on the CE-SAV, 
with a 20-year follow-up, as described in the previous section, to calculate the parameters 
of the Weibull distributions.3 The value of the scale (s) parameter of the Weibull model, 
fitted to represent SVD depends on age: s = e 2.2240 + 0.0154 * age. The shape parameter (b) was 
estimated at 3.316. With the resulting age-dependent Weibull distributions for reopera-
tion due to SVD, median time to reoperation due to SVD in the supra-annular valves was 
19.2 (18.0 – 20.5), 22.4 (20.5 – 24.6) and 26.2 (23.1 – 29.7) respectively for 55-, 65-, and 
75-year-old male patients. 
3. Mortality risk associated with each valve related event
The estimates of mortality risk associated with each valve-related event are derived from 
the primary dataset described earlier and are depicted in Table 2.
4. Reoperation risk associated with each valve related event
The estimates of reoperation risk associated with each valve-related event are derived 
from the primary dataset described earlier and are depicted in Table 2.
5. Mortality risk associated with each reoperation
The estimates of reoperative mortality risk were also obtained from the previous meta-
analysis discussed above.11 For each first and following reoperation in a single patient, the 
operative mortality of 1.5% was increased with an odds ratio of 1.7. The mean age of 
the reoperated patients in the CE-SAV dataset was 53 years, so the expected reoperative 
mortality in the dataset would be 2.6%+1.034(53-40)+1.7=5.9%. Again this reoperative 
mortality was comparable to the observed reoperative mortality in the CE-SAV dataset, 
which was 5.4%. 
6. Estimate of mortality risk due to other causes (mortality risk of general population 
plus ‘excess mortality’)
The mortality of a patient after valve replacement is composed of the mortality of the 
general population, the operative mortality, the valve-related mortality, and an excess 
mortality. This excess mortality cannot be explained by valve-related events, but is due to 
mortality associated with underlying valve pathology, left ventricular function, increased 
occurrence of sudden unexplained unexpected cardiac death, and the underreporting of 
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valve-related events respectively.16-18 The model calculates patient outcomes by superimpos-
ing the morbidity and mortality estimates of valve-related events on the other components 
of patient mortality. 
The mortality of the general population was incorporated into the model by means of 
the life table of the relevant age and gender matched population, American males in this 
analysis.19 The excess mortality, not accounted for by the valve-related events, was repre-
sented by age- and sex-specific hazard ratios. These hazard ratios have previously been 
estimated by approximating age- and sex-specific survival curves produced by the model, 
which contained background morbidity and mortality caused by valve-related events, to 
the corresponding empirical curves obtained from data on stented porcine bioprostheses 
which contained all three components of patient mortality.20,21 The hazard ratios were 
2.9, 1.8, 1.2 and 0.8 for male patients aged 45, 55, 65 and 75 years respectively.16 The 
life expectancy (LE) of a 65-year-old patient, for example, was estimated at 10.6 years. 
This corresponds to a 10- year survival of 50%, which is comparable to survival in other 
reports.22-24 However, it is in contrast to a LE of 13.8 years for a 65-year-old male in the 
relevant general population, which translates to a 78% relative LE for the patient. The rela-
tive LE of a 65-year-old hypothetical patient who is immune from valve-related events and 
from operative mortality was about 90%. In the latter instance, the excess mortality of the 
patient may be related to underlying valve pathology, left ventricular residual hypertrophy 
and functional abnormality
Kvidal and colleagues, who investigated this excess mortality after heart valve replace-
ment, described an increasing excess hazard during follow-up and a decreasing excess 
hazard with advancing age of implantation.17 This supports a ‘multiplicative’ excess mortal-
ity, which was a structural assumption in our model. The use of an ‘additive’ model may 
overestimate LE estimates, especially in patients younger than 70 years. 
Running a microsimulation model
By repeatedly simulating individual life histories of male patients aged 55, 65 and 75 years 
a total of 10,000 times, the microsimulation model calculated actuarial patient survival, 
reoperation-free survival and event-free survival of male patients of different ages at 
valve implantation. The areas under the respective curves represent life expectancy (LE), 
reoperation-free life expectancy (RFLE) and event-free life expectancy (EFLE). LE, RFLE and 
EFLE for men at different ages of valve implantation are given in Figure 3. 
The microsimulation model also calculated the ‘actual’ or lifetime risks of valve-related 
events and SVD after valve implantation. The risk of SVD reduced with advancing age 
of implantation, namely 31.8%, 13.3% and 3.6% respectively for 55-, 65- and 75-year-
old males. The lifetime risk of having at least one event also decreased with increasing 
implantation age. 
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Testing a microsimulation model
Validation 
There are 2 types of validation: internal and external validation. Internal validation tests 
whether the results of the microsimulation model correspond to the outcome in the da-
taset from which the model was derived. For example, observed survival in the CE-SAV 
figure 3: Life Expectancy, Event-Free Life Expectancy and Reoperation-Free Life Expectancy for men at 
different ages of valve implantation
E-figure 1: External validation: microsimulation calculated survival compared to observed survival 
(Portland dataset)
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dataset was 27% at 15 years, while this was 21% using the microsimulation model for 
a 69-year-old patient (mean age of CE-SAV population). Furthermore, observed “actual” 
freedom from all cause reoperation in the dataset was 86% at 15 years, while this was 
82% for a 69 year-old patient by using microsimulation. 
External validation tests whether a model also performs satisfactorily for patients other 
than the ones from whose data the model was derived. E-Figure 1 displays the age- and sex-
specific survival results of the model with corresponding survival curves for the Carpentier-
Edwards standard bioprosthesis (Edwards Lifesciences LLC, Irvine, Calif). This dataset was 
obtained from the Providence Health System in Portland, Oregon.25 The survival outputs 
of the microsimulation model for 55- and 65-year old male patients compared favorably 
with the corresponding curves of the Carpentier-Edwards ‘standard’ Portland experience, 
through 25-years post-implantation: the 10-year-survival of a 55- and 65-year-old male 
patient was respectively 64% and 50% in the model versus 65% and 53% in the Portland 
dataset. However, the model showed a slight overestimation of mortality for 75-year-old 
males compared to the Portland dataset: the 10-year-survival was 32% in the model versus 
40% in the Portland dataset. Patients who undergo an operation in this age group do 
not strictly represent the average patient in this age group who actually requires AVR. In 
fact they represent a selection of relatively healthier patients with a relatively better life 
expectancy. Systematic variations in the patient profile, too, especially in the older age 
groups, might result in these differences between model output and comparison data. 
Sensitivity analysis 
The effect of uncertainty in the parameter estimates of the model, such as variability across 
subgroups, can be investigated by means of sensitivity analysis. In one-way sensitivity analy-
sis the value of one probability is varied while others are kept constant to test the stability 
of the analysis’ conclusions and to test whether the outcome might change depending on 
the characteristics of the subgroup.26 It ignores interactions between different parameters, 
and can therefore underestimate the level of uncertainty. Multivariate sensitivity analysis 
would be preferred, but then also the distributions of the parameters have to be known, 
which in our study is not yet possible. For this reason we performed one-way sensitivity 
analysis, and variation of the estimates by their 95% confidence intervals yielded only very 
small changes in the long-term outcomes. Therefore we defined larger ranges by increasing 
and decreasing the baseline estimates by 25%. The resulting life expectancy and event-free 
life expectancy of a 65-year-old male patient, for a plausible range of valve-related events 
and additional mortality, is given in Table 3. It shows that variation in the hazard ratio 
representing ‘excess mortality’ had the most pronounced effect on both LE and EFLE, and it 
underscores the importance of the excess mortality on the outcomes of patients after AVR. 
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dISCuSSIOn
Microsimulation has several important limitations. First, microsimulation is a simplification 
of reality, just like any other model. Adding more variables will result in more patient-
specific outcome estimates, and will bring the model closer to reality. We intend to study 
the effect of parameters like left ventricular function, cardiac rhythm and renal function 
etc. However, it is very difficult to derive the necessary data from published studies: more 
high quality primary datasets are needed for this refinement of the microsimulation model. 
In addition, currently the microsimulation model uses point estimates of the occurrence 
rates of valve-related events, ignoring the variation in these estimates. We are currently 
developing a new extension of the microsimulation model that allows entering not only 
point estimates of the occurrence rates of valve-related events but also the distribution 
Table 3: Summary of sensitivity analysis for a 65 year-old male patient after AVR with the CE-SAV
Parameter
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e 
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m
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Plausible Range * Life Expectancy 
(years)
Event-free 
Life Expectancy 
(years)
Reoperation-free
Life Expectancy
(years)
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Hemorrhage 0.52 0.39 0.65 10.7 10.4 9.3 9.1 9.9 9.8
Non-Structural
Dysfunction
0.24 0.18 0.30 10.6 10.6 9.3 9.2 9.9 9.8
Prosthetic Valve
Endocarditis
0.33 0.25 0.42 10.6 10.5 9.3 9.2 9.9 9.8
Structural Valve 
Deterioration +. 
22.4 28.0 16.8 10.8 10.6 9.7 8.7 10.3 9.2
Thrombo-
Embolism
1.12 0.84 1.40 10.7 10.5 9.4 9.1 9.9 9.7
Valve Thrombosis 0.03 0.02 0.04 10.6 10.6 9.2 9.2 9.8 9.8
Excess
Mortality 
(Hazard ratio)
1.2 0.9 1.5 12.0 9.5 10.2 8.4 10.9 9.0
* The baseline estimates were increased and decreased by 25% to estimate the plausible range. 
+ Median time to reoperation due to structural valve deterioration.
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of these estimates. Furthermore, in the model we assume (by definition) all patients with 
SVD either have a reoperation or die, while in reality a proportion of patients with SVD, 
particularly the elderly, will not receive a reoperation and will die of other causes. Therefore 
the model will slightly overestimate the risk of reoperation for SVD, especially in the higher 
age group. 
Second, the current simulation model is based on certain structural assumptions re-
garding mortality and morbidity after AVR. For example, a constant hazard was assumed 
for the valve-related events other than SVD. Certain hazards of complications, such as 
hazard of bleeding, will not be constant over time, but will increase with advancing age, 
or have a phase with high risk and a lower-risk phase such as endocarditis. Therefore, in 
our model there is an age-dependent risk and age-dependent mortality for ‘bleeding’. The 
model does not have a 2-period risk for endocarditis, because we do not have access yet 
to primary datasets to support these changing hazards over time. Furthermore, sudden 
unexpected unexplained death is incorporated in the ‘excess mortality’ because gaining 
insight into this determinant remains difficult.27
The third limitation is the fact that the quality of the model, as in any model, is directly 
dependent on the quality of the input. Especially for input in simulation models, high 
quality data are essential. Most of the model-input is obtained from meta-analysis of 
earlier published studies, largely with a retrospective design, which are generally known to 
underestimate the incidence of (valve-related) events. Furthermore heterogeneity between 
the studies and possible publication bias can diminish the quality of the model-input.
Finally, another disadvantage is the fact that the microsimulation software is not yet 
available in standard statistical software packages. However, the computer program along 
with an extensive manual to get started with microsimulation is available at www.cardio-
thoracicresearch.nl .
COnCluSIOnS
This study aimed to provide insight into microsimulation methodology and to give an 
overview of the advantages and disadvantages of simulation methods (in particular mi-
crosimulation) in comparison to standard methods of outcome analysis. It showed, using 
a large existing dataset,3 that microsimulation is capable of translating valve performance 
into patient outcome by providing age-related life expectancy and risk of reoperation for 
patients who underwent AVR with the CE-SAV bioprosthesis. These estimates of patient 
outcome may be used to compare the patient lifetime risk of reoperation with the CE-SAV 
bioprosthesis with the pericardial valves and with newer bioprostheses in a comparable 
patient population. 
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This study also showed that microsimulation has several disadvantages and limitations 
that need to be considered carefully and dealt with systematically when attempting to 
perform simulation studies. 
In conclusion microsimulation can be a quick, accurate and useful tool to assess patient 
outcome after AVR with a specific prosthetic heart valve. Outcomes after implantation of 
different prosthetic heart valves can easily be compared, in order to facilitate and optimize 
the choice of specific heart valve prosthesis for both physician and patient.
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AbSTRACT
Objective
Although results of aortic valve replacement with different valve prostheses are well docu-
mented in terms of survival, risks of (valve related) events are less well explored.  
Methods
We used a dataset of 3934 patients who had aortic valve replacement with either a biopros-
thesis (73%) or a mechanical prosthesis (27%) between 1982-2003 to simulate outcome 
of patients after aortic valve replacement with either valve type. Using microsimulation 
we compared total age and gender-specific life-expectancy, event-free life-expectancy, 
reoperation-free life-expectancy, and lifetime risks of reoperation and valve related events 
for both valve types. 
Results
Total follow-up was 26,467 patient-years. Mean follow-up was 6.1 years in the biological 
and 8.5 years in the mechanical arm. Mean age at implantation was 70 and 58 years 
for bioprostheses and mechanical prostheses respectively, and percentage of concomitant 
CABG 47% and 28%. For a 60-year-old male, simulated life expectancy in years for bio-
logical versus mechanical prostheses was 11.9 versus 12.2, event-free life expectancy 9.8 
versus 9.3 and reoperation-free life expectancy 10.5 versus 11.9  Lifetime risk of reopera-
tion was 25% versus 3%. Lifetime risk of bleeding was 12% versus 41%.
Conclusions
Even for patients aged 60, event-free life expectancy is better with a bioprosthesis: al-
though the chance of reoperation is higher, the lifetime risk of bleeding is much lower 
compared to a mechanical prosthesis. Comparing lifetime event risks between different 
types of valve prostheses provides more insight into patient outcome after AVR, and can 
help in patient selection and counselling.
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InTROduCTIOn
Biological and mechanical valve prostheses are the most commonly used valve substitutes 
for replacement of the native aortic valve. Each valve type has its own advantages and 
drawbacks. The risk of reoperation for structural valve deterioration (SVD) in patients with 
a biological valve increases with time and decreases with advancing age. In contrast, pa-
tients with a mechanical prosthesis need lifelong anticoagulation and the risk of bleeding 
events increases with advancing age.
Outcome after aortic valve replacement (AVR) with either valve type is well documented 
in literature. These results are mostly described in terms of cumulative survival, freedom 
from events and reoperation, and linearized occurrence rates of valve-related complica-
tions and their consequences. A patient’s lifetime risk of having a (valve-related) event 
after AVR is less well explored. Estimations of survival and valve related event risk for 
an individual patient after AVR are difficult to determine using standard time-to-event 
analyses.1 Nevertheless, these parameters are important in counselling a patient.  
The goal of this study was to calculate detailed and age-specific patient outcome after 
aortic valve replacement with mechanical prostheses and bioprostheses by using micro-
simulation. 
METhOdS
Patients 
Previously a report on a large single-center dataset on outcome after AVR from Vancou-
ver, Canada, was published using standard methods of data-analysis.2 For the input of 
the microsimulation model we used essentially the same primary dataset, but excluded 
reoperations and operations with concomitant procedures other than CABG, leaving 3934 
primary AVR procedures. Table 1 summarizes the dataset. 
Methods 
To simulate the lives of patients after AVR a microsimulation model was used. A micro-
simulation model is a computer model that simulates a representative population at the 
individual patient-level. This simulation model offers a complementary tool to standard 
methods of outcome analysis by simulating the lives of virtual patients until death and 
taking into account all complications that may occur over time (including repeating events, 
changing hazards over time and/or with the occurrence of prior events). It can provide 
insight into age- and sex-specific life expectancy and gives detailed information on the life 
time risk of valve-related events. Detailed descriptions on how to construct, test and run 
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this model, have previously been published.3-5 The model can be downloaded from www.
cardiothoracicresearch.nl. 
Model input 
The data needed to run the microsimulation model comprise: 1. occurrence of valve-related 
events and their outcome, 2. operative and reoperative mortality, 3. background mortality 
of the general population, and 4. excess mortality. Valve related events were defined in 
accordance with the guidelines. 6
1. Using the Vancouver dataset we calculated occurrence rates of valve related events 
and their outcome (e.g. death, reoperation), results are given in the appendix (Table 2). 
For most events, linearized occurrence rates were calculated, but for the occurrence of 
structural valve deterioration (SVD) a Weibull function was constructed. For bleeding we 
assumed an age-dependent incidence and -mortality. See details in the paragraphs below.
The cumulative risk of SVD in a bioprosthesis decreases with increasing age of the 
patient at valve implantation and increases sub-exponentially with time elapsed since 
implantation.7 Grunkemeier and colleagues have shown that the Weibull distribution, a 
generalization of the exponential distribution, is efficient in summarizing SVD in biological 
valves.8, 9 The formula for the hazard of SVD is: h(t) = e-(t/σ)^σ. Based on the Vancouver dataset 
we estimated the parameters of this distribution. The value of the scale (s) parameter of 
Table 1: Summary dataset description
Bioprosthesis Mechanical prosthesis
Number of patients 2860 1074
Percentage of total dataset 72.7 27.3
Follow-up (patient-years) 17,352 9,115
Mean follow-up (years) 6.1 8.5
Mean age (years) 70.0 57.6
Male (%) 65.7 71.4
Coronary Artery Bypass Grafting (%) 47.3 27.7
Atrial Fibrillation (%) 7.0 9.7
Prosthesis brands (%)
 Carpentier-Edwards Supra-Annular Valve porcine
 Carpentier-Edwards Perimount pericardial
 Medtronic Mosaic porcine
 St. Jude Medical
 Carbo Medics
56.5
23.0
20.5
0
0
0
0
0
53.3
46.7
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the Weibull model, fitted to represent SVD and depending on age: s = e 2.209 + 0.0153 * age. The 
shape parameter (b), which reflects the changing risk over time, was estimated at 3.211. 
The incidence risk of bleeding increases with advancing age, especially in patients with 
a mechanical valve who need life-long anticoagulation. The occurrence of bleeding in 
the biological group was modelled as an age-dependent hazard of 0.076 with an age-
dependent mortality of 0.0345.10 For the mechanical group, a Gompertz distribution was 
used (σ=0.076; σ=-8.71).11  
Because the risk of prosthetic valve endocarditis early after valve replacement is higher 
than later on, for prosthetic valve endocarditis two phases of constant risks were used. The 
linearized occurrence rate of the first phase, until 6 months after AVR, has an odds ratio 
of 5.8 for mechanical and 6.7 for bioprostheses compared to the second phase. These 
numbers are obtained from an earlier meta-analysis.12 The linearized occurrence rate of the 
second period was derived from the Vancouver dataset.
2. Operative mortality was calculated as 2.7% for a 40-year-old man, increasing with an 
odds ratio of 1.034 for age (per year),11 this corresponds to a 5.0% mortality for a 60-year-
old man. For each reoperation an additional odds ratio of 1.7 was used.4, 12-14 This odds 
ratio corresponds with the odds ratio of 1.6 that the STS risk calculator and also Rankin et 
al. use to calculate the risk of primary versus secondary AVR.15, 16
3. The background mortality, which is the mortality experienced by the normal popula-
tion, is the equivalent of the life expectancy in the normal population. This was calculated 
using age- and sex matched American life tables derived from the Vital statistics of the US 
1992, from the ‘Centers for Disease Control and Prevention’ and the ‘National Center for 
Health Statistics’.17 The life expectancy curves of the normal American, British Columbian 
and United Kingdom male populations are given in Figure 1.17-19 This figure also displays 
the microsimulation calculated life-expectancy after AVR. 
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figure 1: Life expectancy (LE) in men of different ages in British Columbia, Canada (BC), the United 
Kingdom (UK) and the United States (US) versus life expectancy after aortic valve replacement in British 
Columbian and United States patients.
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4. The excess mortality is the mortality difference between the general population 
and patient population that cannot be accounted for by valve related events, but can be 
ascribed to increased occurrence of sudden death, underreporting of valve related events 
and underlying pathology such as left ventricular hypertrophy.13,20 The hazard ratios after 
AVR are previously estimated as 2.9; 1.8; 1.2 and 0.8 for male patients aged 45, 55, 65 
and 75 years respectively.12
Model validation 
To assess the validity of the microsimulation model predictions, the microsimulation calcu-
lated survival for both patients with mechanical and biological prostheses was compared 
with the observed survival in the Vancouver dataset (internal validation). For external 
validation of the biological valve simulations a dataset from Portland, Oregon, was used.21 
The simulations of the mechanical valves were validated by comparison with a dataset on 
mechanical valve patients of the United Kingdom Heart Valve Registry.22 
Sensitivity analysis 
One-way sensitivity analysis was performed to study the effect of changing one of the 
input-parameters on model outcome (e.g. life expectancy, event-free life expectancy, 
reoperation-free life expectancy, and lifetime risk of events). The baseline estimates of 
the valve related events were varied by 25 percent to obtain favorable and unfavorable 
outcomes for a 60-year-old male after AVR. 
The authors had full access to the data and take responsibility for its integrity. All authors 
have read and agree to the manuscript as written.
RESulTS
As shown in Figure 1, life expectancy after AVR is comparable for bioprostheses and me-
chanical prostheses for patients among all studied ages. Also, life expectancy after AVR 
is substantially lower than the life expectancy of the general population, especially in the 
younger age groups. Life expectancy of the normal population differs between different 
countries (Canada>United Kingdom>USA).17-19 The differences in life expectancy between 
these countries disappear with increasing age.
In patients with bioprostheses the lifetime risk of reoperation is higher than in patients 
with mechanical valves, but in patients with mechanical prostheses the anticoagulation 
related bleeding risk is much higher, as seen in Figure 2. The risk of a bleeding event in the 
bio-group is not absent but about 12% in a 60-year-old male, neither is the lifetime risk 
of reoperation absent in the mechanical group which is about 3% in a 60-year-old male.  
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figure 2: Lifetime risks of reoperation and bleeding after aortic valve replacement with mechanical 
and bioprostheses. 
0
2
4
6
8
10
12
14
16
50 55 60 65 70 75
Age at valve implantation (yrs)
L
ife
 e
xp
e
ct
a
n
cy
 (
yr
s)
EFLE (US) BP
EFLE (US) MP
lCL EFLE BP
uCL EFLE BP
lCL EFLE MP
uCL EFLE MP
figure 3: Event-free life expectancy (with 68% confidence limits in grey) after aortic valve replacement 
with mechanical and bioprostheses in the the United States (US) population. lCL=lower confidence 
limit, uCL=upper confidence limit.
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For patients over 60 years of age, event-free life expectancy is better with a bioprosthesis 
(Figure 3), mainly because lifetime bleeding risk is lower. As shown in Figure 2, at age 
60, the bleeding risk in patients with a mechanical prosthesis is already higher than the 
reoperation risk would be if a patient of the same age received a bioprosthesis. However, in 
the Vancouver dataset, the observed mortality after a bleeding event was 22%. In contrast 
the mortality after a reoperation for SVD (n=137) was 7.3%. The mean age of this patient 
group was 54 years.
Internal validation 
E-Figure 1a of the appendix presents the overall observed survival for both patients with 
bioprostheses and mechanical prostheses in the Vancouver dataset versus the simulated 
survival of male patients with a bioprosthesis aged 70 and patients with a mechanical 
prosthesis aged 58 yrs. These are the mean ages of the respective groups. E-Figures 1b 
and 1c present the internal validation subdivided for each age group for biological and 
mechanical valves respectively. While validation appears adequate for the average patient 
in the dataset, a systematic underestimation of survival was observed in the simulated 
survival output, in particular in the older mechanical valve patient subgroups.
External Validation 
E-Figure 2a of the appendix depicts the external validation of survival of bioprosthesis 
patients, and E-Figure 2b describes the external validation of survival of patients with 
mechanical prostheses.
Sensitivity analyses 
E-Table 2a and 2b of the appendix show the summary of the one-way sensitivity analysis 
for the bioprosthesis and the mechanical prosthesis respectively. Variation of the input 
parameters of the model yielded only relatively small changes in the output, except for 
changes in the hazard ratios for excess mortality, and to a lesser extent changes in median 
time-to-SVD.
dISCuSSIOn
The estimates of lifetime patient risk of non-fatal events are obtained using cumulative 
incidence analysis. Sometimes Kaplan-Meier analysis is incorrectly used for this purpose. 
The issue of appropriate use of actuarial (Kaplan Meier) and actual analysis has been 
highlighted in several previous publications.23,24 For the present paper the differences in 
results with either analysis are illustrated in E-Figure 4 of the appendix. Actuarial analysis 
of all-cause reoperation in the Vancouver bio-group would give a cumulative risk estimate 
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of 30% at 15 years, clearly higher than the cumulative incidence (‘actual’) value which is 
16% at 15 years. 
Total life expectancy after aortic valve replacement is not much different whether the pa-
tient gets a mechanical valve or a bioprosthesis. Because reoperation-free life expectancy, 
event-free life expectancy and lifetime event risks do differ between both patient groups, 
these are more important factors in choosing which valve substitute should be implanted 
in a particular patient.
For patients after age 60, event-free life expectancy is better with a bioprosthesis, mainly 
because the risk of bleeding with a bioprosthesis is much lower compared to a mechanical 
valve. Of course this is at the cost of the higher risk of a reoperation for structural valve 
deterioration (SVD). However, the lifetime risk of a reoperation for a 60-year-old man in 
whom a biological valve is implanted is only 25% (risk of reoperation due to SVD is 22%), 
so three quarters of the 60-year-olds will never experience a reoperation. The lifetime risk 
of a bleeding event when the same patient would have a mechanical valve implanted, is as 
high as 41%. The overall observed mortality of a bleeding event in the Vancouver dataset 
was 22%, which implies that these bleedings are life-threatening events. In contrast, the 
mortality risk after reoperation for SVD was 7.3% in this dataset, certainly not negligible 
but far lower than the mortality of bleeding. This is in accordance with an earlier report on 
the same dataset.25 
As can be seen in Table 1, coronary artery disease (CAD) occurs more frequently in 
the bioprosthesis group, probably because the mean age is higher. Previous publications 
have shown that performing additional CABG does not have a significant impact on the 
crossing points of the life-expectancy and event-free life-expectancy curves.26 Patients who 
have CAD have a shorter life expectancy than those without CAD. Due to this shorter 
life expectancy both the lifetime risk of a reoperation in the bioprosthesis group and the 
lifetime risk of bleeding and thrombo-embolic events in the mechanical group is lower 
compared to patients without CAD. The end result is that the age cut-off point at which 
a bioprosthesis is preferable over a mechanical prosthesis doesn’t change and therefore it 
does not affect prosthetic valve selection.
The ACC/AHA guidelines generally recommend implantation of a bioprosthesis for pa-
tients older than 65 years.27 Guided by the simulation-data presented in this study, patients 
in younger age groups, even around 60 years of age, may benefit more from a biological 
than a mechanical prosthesis. This is in correspondence with the report by Chan et al. 
based on standard analysis of the same patient population.2 Newer biological prostheses 
may show even more reduction in the need for reoperation for SVD, and thus lower the 
threshold for implantation of a bioprosthesis even more. 
To reduce bleeding complications more emphasis should be put on new anticoagula-
tion strategies, new mechanical valve prostheses that require lower INR target rate, or 
simply by lowering the age threshold for implantation of a bioprosthesis. The negative 
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aspect of lowering this threshold is that not only more but also older patients will require a 
reoperation. This of course may increase the reoperative mortality. On the other hand, new 
less invasive techniques to replace the aortic valve are rapidly emerging in cardio-thoracic 
fields. The first reports on percutaneous and transapical approaches to replace the aortic 
valve are promising and their use is expected to rise.28,29 Although experience with these 
techniques is yet rather limited and each approach seems to have its own advantages 
and disadvantages, their potential is not limited to treat native aortic valve disease. Most 
likely these techniques are also applicable to replace deteriorated biological prostheses, the 
‘valve-in-valve’ concept.30 This could reduce operative morbidity and mortality in high risk 
subsets of patients, and may therefore offer a solution for the treatment of elderly patients 
who experience SVD. In contrast, at the moment it appears that the awareness of surgeons 
that structural valve deterioration may occur after implantation of a biological valve is far 
greater than the awareness of the incidence and impact of bleeding events after implanta-
tion of a mechanical valve. This gap in knowledge may affect the valve selection process. 
Limitations 
Microsimulation is capable of quite accurate and precise simulations, as long as the input 
of the model is based on significantly large and, more importantly, high quality datasets. 
The quality of the model output is directly dependent on the quality of the input. The data 
to feed microsimulation models are usually derived from historical cohorts with a consider-
able follow-up, and may not necessarily be applicable to 21st century practice. For instance, 
the mean age of the reoperated patients is quite low, which implies the patients were very 
young when they received their biological valve, reflecting surgical practice in the eighties 
of the previous century. Nowadays only few young patients get a bioprosthesis. Also, 
the age-specific operative mortality estimates by the model are based on previous meta-
analyses performed several years ago, and at the moment these estimates seem high. 
Perhaps new estimates should be established, although the effect of operative mortality 
on long-term outcome and life expectancy is only small, as can be seen in the sensitivity 
analyses (Tables 3a and 3b of the appendix). Further it can be argued that current valve 
prostheses have the same occurrence rates as prosthetic valves that were implanted in the 
past. Possibly nowadays these are lower. Despite this drawback, the Vancouver database 
consists of high quality data on an extensive number of patients who were interviewed 
by annual telephone calls and whose medical records (including echocardiograms) were 
reviewed to check if any events had occurred. In doing so it is likely that not many events 
have been missed. 
More high-quality datasets are needed to incorporate other variables than only age and 
sex. Other determinants of life expectancy after AVR are coexisting coronary artery disease, 
left ventricular-, pulmonary- and renal function or other co-morbid conditions such as 
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malignancies or neurological diseases. When these parameters would be taken into ac-
count, the model would represent survival much more tailored to the individual patient.
For now we can only perform one-way sensitivity analysis. It would be better to check the 
results in simulated outcome when the distributions of the input parameters are known. In 
this matter work is in progress.
Microsimulation models are not yet widely known and used in the cardio-thoracic fields, 
and are not available in standard statistical software packages yet. The model described 
in this paper is available by downloading the program along with instructions at www.
cardiothoracicresearch.nl. 
COnCluSIOn
Based on the Vancouver dataset it seems that even for patients aged 60 requiring AVR, 
implantation of a bioprosthesis generally may be considered superior over a mechani-
cal prosthesis. The risk of bleeding with a bioprosthesis is not absent, but compared to 
mechanical valves the risk-reduction of bleeding that can be achieved with bioprostheses 
outweighs the increased risk associated with structural valve deterioration.
Comparing lifetime event risks between different types of valve prostheses provides more 
insight into patient outcome after AVR, and can help in patient selection and counselling. 
When combined with careful assessment of individual patient preferences this will provide 
a new key to optimized informed decision making. 
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APPEndIx
Internal validation The overall survival that was calculated by the model showed a 
slightly worse survival for both prosthesis groups than observed in the Vancouver dataset 
(E-Figure 1a). When this dataset is split by different age groups the differences between 
simulated and observed survival increase, especially in the older ages and more in the 
mechanical group than in the biological group (E-Figures 1b and 1c). Apparently the excess 
mortality is lower in the Vancouver dataset than it is in our model. An explanation may 
be that the microsimulation model predicts life expectancy ‘a priori’ in a random patient, 
only knowing age and sex. The assumption is made that the excess mortality is equal 
for both patients who receive mechanical or bioprostheses. However, in clinical practice 
other patient-characteristics are also taken into account in the valve selection process; 
patients with a better life expectancy are more likely to receive a mechanical valve, while 
patients with a decreased life expectancy are more likely to receive a bioprosthesis. This 
patient selection process is probably responsible for the differences between observed and 
simulated survival.
External validation Although simulated survival after AVR with a bioprosthesis corre-
sponded quite nicely with the Portland dataset (E-Figure 2a), the simulated survival for the 
mechanical prostheses was again lower than the observed survival in the UK Heart Valve 
Registry (E-Figure 2b). The differences between the curves are considerable. Several factors 
can be responsible for this. First, patient selection is probably different among different 
medical centers, countries and continents. Second, prosthesis types and brands will differ 
between medical centers, only it is questionable whether this factor contributes much to 
the observed survival differences. Third, background mortality is different between dif-
ferent countries. This clearly influences life expectancy after AVR, as is shown in Figure 
1. However, difference in background mortality has hardly any influence on the point of 
indifference for the event-free life expectancy curves for both prostheses. To show this we 
simulated patients after AVR using both background mortalities from the United States, 
and from British Columbia, Canada. The effect on event-free life expectancy is displayed 
in E-Figure 3a. The curves will only shift upwards or downwards, but the age cut-off point 
at which a bioprosthesis is preferable over a mechanical prosthesis remains the same. This 
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E-figure 1: Internal validation.
a: simulated survival of 58-year-old mechanical- and 70-year-old bioprosthesis patients versus total observed survival 
in the bio- and mechanical prosthesis group of the Vancouver dataset.
b: simulated survival of 55-, 65- and 75-year-old male patients with a bioprosthesis versus the bioprosthesis group of 
the Vancouver dataset, subdivided in age categories.
c: simulated survival of 55-, 65- and 75-year-old male patients with a mechanical prosthesis versus the mechanical 
prosthesis group of the Vancouver dataset, subdivided in age categories.
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finding implies that the conclusions drawn from this article would remain the same for 
British Columbian patients or patients from other Western countries such as the United 
Kingdom. E-Figure 3b is a detail of Figure 3 and E-Figure 3a and displays the crossing point 
of the event-free life expectancy curves. The 68% confidence limits around the event-free 
life expectancy curves of the mechanical and the bioprosthesis group are also given The 
crossing 68% confidence limits demarcate the area in which the real crossing point of the 
event-free life expectancy curves lies (with a 95% certainty). 
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E-figure 2: External validation.
a: Simulated survival of 55-, 65- and 75-year-old male patients with a bioprosthesis versus the observed survival in the 
Portland dataset, subdivided in age categories.
b: Simulated survival of 55-, 65- and 75-year-old male patients with a mechanical prosthesis versus the observed 
survival in the United Kingdom Heart Valve Registry (UKHVR) mechanical dataset, subdivided in age categories.
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E-figure 3: Event-free life expectancy (EFLE) for men at different ages of valve implantation. 
a: EFLE for men with a mechanical valve (solid lines) versus a bioprosthesis (dotted lines). Black lines represent the 
United States population, grey lines represent the population in British Columbia, Canada. Background mortality 
changes among different populations, which has an effect on absolute EFLE, but hardly any effect on the age cut-off 
point at which a bioprosthesis is preferable over a mechanical prosthesis.
b: Detail of Figure 3 and E-Figure 3a. The crossing points of the 68% confidence limits around the EFLE curves 
demarcate the area in which the real EFLE age cut-off point lies (with a 95% certainty). lCL=lower confidence limit, 
uCL=upper confidence limit.
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E-figure 4: Actual versus actuarial analysis of all cause reoperation and reoperation for structural valve 
deterioration (SVD) in the biological group of the Vancouver dataset.
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E-Table 2a: Sensitivity analysis for a 60-year-old American male after AVR with a bioprosthesis
INPUT OUTPUT
Linearized Occurrence Rate Life Expectancy Event-free Life 
Expectancy
Reoperation-free 
Life Expectancy
Va
lv
e 
re
la
te
d 
ev
en
t
(b
as
el
in
e)
m
in
us
 2
5%
(fa
vo
ra
bl
e)
pl
us
 2
5%
(u
nf
av
or
ab
le
)
Fa
vo
ra
bl
e
Un
fa
vo
ra
bl
e
Fa
vo
ra
bl
e
Un
fa
vo
ra
bl
e
Fa
vo
ra
bl
e
Un
fa
vo
ra
bl
e
Bleeding 0.53 0.40 0.66 12.1 11.9 9.9 9.7 10.6 10.5
Non-Structural 
Dysfunction
0.23 0.17 0.29 12.1 12.1 9.9 9.8 10.7 10.6
Prosthetic Valve 
Endocarditis
0.29 0.22 0.36 12.2 12.1 9.9 9.8 10.7 10.6
Structural Valve 
Deterioration*
22.0 27.5 16.5 10.6 10.3 9.3 8.4 10.0 8.9
Thrombo-
Embolism
1.26 0.95 1.58 12.2 12.0 10.1 9.6 10.7 10.6
Valve 
Thrombosis
0.04 0.03 0.05 12.1 12.1 9.9 9.9 10.7 10.6
Operative 
mortality
5.0 % 3.8% 6.3% 12.1 11.8 9.9 9.6 10.7 10.4
Hazard
ratio
1.2 0.9 1.5 12.9 11.3 10.3 9.4 11.2 10.1
*Median time to SVD is 22.0 years
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E-Table 2b: Sensitivity analysis for a 60-year-old American male after AVR with a mechanical prosthesis
INPUT OUTPUT
Linearized Occurrence Rate Life Expectancy Event-free Life 
Expectancy
Reoperation-free 
Life Expectancy
Va
lv
e 
re
la
te
d 
ev
en
t
(b
as
el
in
e)
m
in
us
 2
5%
(fa
vo
ra
bl
e)
pl
us
 2
5%
(u
nf
av
or
ab
le
)
Fa
vo
ra
bl
e
Un
fa
vo
ra
bl
e
Fa
vo
ra
bl
e
Un
fa
vo
ra
bl
e
Fa
vo
ra
bl
e
Un
fa
vo
ra
bl
e
Bleeding Gompertz 12.9 8.7 11.0 4.1 12.6 8.5
Non-Structural 
Dysfunction
0.45 0.34 0.56 12.2 12.2 9.3 9.2 12.0 11.9
Prosthstic Valve 
Endocarditis
0.08 0.06 1.0 12.2 12.2 9.3 9.2 12.0 11.9
Structural Valve 
Deterioration
NA NA NA NA NA NA NA NA NA
Thrombo-
Embolism
1.33 1.00 1.66 12.3 12.1 9.5 9.1 12.0 11.9
Valve 
Thrombosis
0.06 0.04 0.07 12.2 12.2 9.3 9.3 12.0 11.9
Operative
Mortality
5.0% 3.8% 6.3% 12.1 11.8 9.9 9.6 10.7 10.4
Hazard
ratio
1.2 0.9 1.5 12.9 11.4 9.7 8.8 12.7 11.2
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dETERMInAnTS Of SuRvIvAl AfTER AvR 
Multiple interrelated factors (patient-, physician-, and prosthesis-related) affect patient 
survival after aortic valve replacement. Every aortic valve re-placement is associated with a 
risk of death due to the surgical procedure. This risk may vary with the type of prosthesis 
that is implanted, and ob viously increases with patient age and with each reoperation. In 
addition, the etiology of the valve lesion, concomitant procedures, and other well known 
risk factors may also affect operative mortality. Late survival of pa tients after aortic valve 
replacement differs considerably from survival of age-matched individuals in the general 
population. Figure 1 shows that life expectancy of male patients after aortic valve replace-
ment is significantly reduced compared to the age-matched population life expectancy. 
This dif ference in life expectancy is particularly evident in young adult patients. Operative 
mortality and the occurrence of valve-related events1 (valve -related mortality) can only in 
part explain this difference, as is illustrated in Figure 1 by the life expectancy of a patient 
who receives the – thus far hypothetical – perfect valve substitute, i.e., a valve substitute 
that has no as sociated valve-related complications. The remaining loss in life expectancy 
compared to the general population is depicted by the term excess mortal ity. 
For older patients after aortic valve replacement, survival is only slightly worse than 
observed survival in the general population. This is most likely due to the selection process 
that takes place prior to aortic valve replace ment: recent studies have shown that a consid-
erable proportion of older patients who require aortic valve replacement according to the 
current guidelines4,18 do not undergo surgery.3,5,7 
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figure 1: Absolute life expectancy (years) after aortic valve replacement with stented biopros theses, 
mechanical prostheses and allografts compared to the age-matched Dutch population. Hypothetical 
immunity from valve-related events is depicted by the uninterrupted solid line just above the life 
expectancy estimates of the different prosthetic valve types 
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What are the causes of excess mortality after aortic valve replacement? Aortic valve dis-
ease is not limited to the aortic valve itself: it affects the en tire heart. One can imagine 
that the strain posed on the myocardium by aortic valve disease will result in damage of 
the myocardium. Therefore, cardiac death is more common in patients with heart valve 
disease com pared to the general population. Also, sudden unexplained unexpected death 
is probably more common in the former group. These may partly ex plain the observed 
differences in mortality. A landmark study by Kvidal et al.12 investigated factors associated 
with observed and relative survival in a large patient cohort after aortic valve replacement. 
Risk factors asso ciated with increased observed late mortality after aortic valve replace-
ment included older patient age, pure aortic regurgitation, preoperative atrial fi brillation, 
advanced New York Heart Association class, and the presence of coronary artery disease. 
Interestingly, relative late survival (the ratio of ob served late deaths in aortic valve replace-
ment patients and expected deaths in the general age-matched population) was signifi-
cantly greater in younger adult patients compared to older patients confirming the findings 
depicted in Figure 1. In addition, pure aortic regurgitation, preoperative atrial fibrilla tion, 
and advanced New York Heart Association class were important fac tors associated with 
increased relative survival. 
After AVR, life expectancy, total event-free life expectancy and reopera tion-free life 
expectancy are highly dependent on the mortality in the gen eral (reference/source) 
population. This ‘background mortality’ differs be tween countries and is different over 
time periods (life expectancy around the world has increased dramatically during in recent 
decades). Figure 2 illus trates that even between developed countries, there are marked 
differences in population mortality that complicate the comparison of survival after aortic 
valve replacement between those countries. As can be seen in Figure 2, the life expectancy 
of, for example, a 60-year-old individual in the Cana dian population is approximately 21 
years, about 4 years longer compared to a 60-year-old in the US population. This will result 
in a 2–3 year differ ence in life expectancy after aortic valve replacement between patients 
re siding in Canada versus the US and may have implications for valve selec tion. The ob-
served differences in general population mortality and their ef fect on survival after aortic 
valve replacement complicate the comparison of outcome after aortic valve replacement 
with different valve substitutes, and it therefore remains a challenge to study the pos-
sible survival advan tage of certain biological valve substitutes (stentless bioprostheses and 
the Ross procedure). The following paragraphs provide an overview of re ported patient 
outcome with different biological valve substitutes. 
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PREdICTEd PATIEnT OuTCOME AfTER AvR 
A microsimulation model was designed at Erasmus University Medical Center, Rotterdam, 
The Netherlands, to predict specific outcome of patients after AVR.17 This computer model 
simulates a representative population at the individual patient level and offers a comple-
mentary tool to standard (e.g., Kaplan-Meier) methods of outcome analysis: it simulates 
the lives of virtual patients until death and takes into account all complications that may 
occur over time. The model can provide insight into age-and sex specific life expectancy, 
event-free and reoperation-free life expectancy, and provides detailed information on the 
lifetime risk of valve-related events. Detailed descriptions on how to construct, test, and 
run this model have been published.14,19 The model including detailed instructions for use 
can be downloaded at www.cardiothoracicresearch.nl. 
For conventional aortic valve surgery, one can choose between mechani cal prostheses, 
biological stented or stentless prostheses, autografts and allo-(or homo-) grafts. The 
mechanical prosthesis has the major advantage of great durability and virtually zero techni-
cal valve failures. However, to prevent valve thrombosis and thromboembolism, lifelong 
coumadin anti coagulation is absolutely necessary. Unfortunately, this results in a higher 
bleeding risk, especially in the elderly. Limited availability of coumadin therapy and ap-
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figure 2: Life expectancies for men in several general populations and life expectancy after im-
plantation of a prosthetic aortic valve. Reprinted with permission from 20; © American Asso ciation for 
Thoracic Surgery 
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propriate INR control in poorly developed countries result in a contraindication for the use 
of a mechanical prosthesis. 
The main advantage of biological prostheses including allografts and autografts lies in 
the fact that there is no need for long-term anticoagula tion, and the risk of bleeding 
approximates that of the normal population. The major downside of these biological valve 
types is structural deteriora tion of the valve apparatus which can lead to either regurgita-
tion or steno sis of the valve leaflets, or root dilatation in case of autografts. This process 
of structural valve deterioration (SVD) increases with advancing time after implantation, 
decreases with age, and often – and in particular in younger adult patients and children – 
necessitates a reoperation. 
In the following sections, microsimulation will be used to calculate pa tient outcome after 
aortic valve replacement with different biological valve substitutes. 
Stented bioprostheses 
Stented bioprostheses are the most commonly used biological valve substi tutes. This pros-
thesis type is composed of a sewing ring and an artificial frame in which three porcine, 
bovine or equine pericardial leaflets are sus pended. The prosthesis is relatively easy to 
implant and since it has been widely used large numbers of studies with long-term follow-
up are avail able. 
As mentioned before, the major downside of a (stented) bioprosthesis is the risk of 
SVD. This risk decreases as life-expectancy decreases (patients die before SVD develops). 
Therefore, current guidelines state that a bio prosthesis is generally preferable in patients 
over 65 years (without another indication for anticoagulation such as atrial fibrillation).4 
However, from our microsimulation studies and the work of Jamieson and others,6 it seems 
this age-threshold could be lowered to around 60 years: compared with mechanical valves, 
around this age the risk reduction of bleeding that can be achieved with a bioprosthesis 
outweighs the increased risk asso ciated with SVD. This results in a better event-free life 
expectancy, although total life expectancy after AVR remains comparable for mechani cal 
and bioprosthesis patients. For a 60-year-old man, simulated life ex pectancy in years for 
biological versus mechanical prostheses was 11.9 ver sus 12.2, event-free life expectancy 
was 9.8 versus 9.3, and reoperation-free life expectancy was 10.5 versus 11.9. Lifetime 
risk of reoperation was 25% versus 3%. Lifetime risk of bleeding was 12% versus 41%.20 
Stentless bioprostheses 
One of the downsides of the stented bioprosthesis is the relative obstruc tion that remains 
after the native valve has been replaced. This is caused by the valve opening, the sewing 
ring and its frame and could cause a ‘pa tient-prosthesis mismatch’ especially when the 
surgeon is forced to use a prosthesis of the smaller sizes (diameter 17–21 mm). Stentless 
biopros theses have a larger effective orifice area (EOA) which provides lower transval-
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vular gradients, better hemodynamics and, therefore, more reduc tion of left ventricular 
hypertrophy. Furthermore, some consider stentless bioprostheses to be more durable than 
conventional stented bioprostheses, all contributing to a possible survival advantage. A 
disadvantage is they are more difficult and time-consuming to implant. A recent random-
ized trial comparing 96 patients who received a stented bioprosthesis versus 127 patients 
who received a stentless bioprosthesis showed that there was a late survival advantage 
for stentless valve recipients.13 However, no cause effect relationship between lower trans-
valvular pressure gradients and im proved survival was found, and the need for additional 
trials studying this subject remains. 
Microsimulation studies of the Medtronic stentless Freestyle valve pre dicted for a 
65-year-old male a life expectancy of 13.1 years, which is close to that of the general 
population. The reoperation-free life expectancy was 11.2 years and the event-free life 
expectancy was 8.4 years.8 
Allografts 
The human donor valve (allograft) has excellent hemodynamics, low occur rence of throm-
boembolic events and endocarditis, and does not require anticoagulation. It is most often 
used in aortic root disease or destructive endocarditis, because it has redundant tissue 
attached and provides more possibilities for reconstructive surgery than bio-or mechanical 
prostheses. On the other hand, the allograft is not an ‘off the shelf’ item and requires 
special preparation, storage, and considerable surgical skills. The number of studies on 
long-term allograft outcome is limited and affected by a con siderable amount of bias/se-
lection, since it is mostly used in a highly se lected patient group. Microsimulation enabled 
multiple studies to be com bined and predicted for a 65-year-old male a life expectancy of 
12 years, a reoperation-free life expectancy of 10 years, and an event-free life ex pectancy 
of 9.7 years.15 
Finally, a microsimulation study that compared outcome after aortic valve replacement 
with either stented bioprostheses (Carpentier-Edwards supraannular and pericardial), 
stentless bioprostheses, or cryopreserved al lografts showed that when assuming uniform 
patient characteristics and excess mortality, the difference in performance between the 
four biological valve types is small.9 Patient selection and the timing of operation may 
explain most of the observed differences in prognosis after aortic valve re-placement with 
biological prostheses. 
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PREdICTEd PATIEnT OuTCOME AfTER ThE ROSS OPERATIOn In yOunG 
AdulTS 
The Ross operation or autograft procedure is mainly performed in children and young 
adult patients. In this operation, the patient’s pulmonary valve is used to replace the aortic 
valve either as a subcoronary implantation or as a full aortic root replacement, while the 
pulmonary valve is replaced with an alternative prosthesis, usually a pulmonary homograft. 
The poten tial advantages of the autograft or Ross procedure are the use of the pa tient’s 
own living valve with favorable hemodynamic characteristics, low endocarditis risk, low 
thrombogenicity, avoidance of anticoagulant therapy, and autograft size increase in chil-
dren. However, the Ross procedure is a technically demanding operation and both the 
autograft in aortic position and the valve substitute in the right ventricular outflow tract 
may develop structural failure over time. The Ross operation has been performed in small 
numbers, and long-term follow-up studies have been inconsistent, which makes analysis 
of long-term advantages and disadvantages difficult. 
Although survival of young adult patients after this procedure is almost uniformly excel-
lent and comparable with the general population, autograft durability is in some centers 
clearly superior to other biological valve con duits, while other centers report worrisome 
autograft reoperation rates. It remains unclear why these results diverge so much. A very 
recent systematic review and meta-analysis of reported outcome after the Ross procedure16 
shows that in young adult patients (mean age 39 years; range 11–71 years) the late survival 
pattern runs parallel to the general age-matched population (Figure 3). Early pooled mor-
tality was 3.24% (95% CI 1.47– 6.58%), while the late mortality rate was 0.64%/patient 
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figure 3: Cumulative survival after the Ross procedure in young adult patients
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year (95% CI 0.32– 1.26%/patient year). Figure 3 illustrates pooled estimated survival 
after the Ross operation in adults including 95% confidence intervals (best and worst case 
scenario). The review also illustrates that although the occurrence rates of most valve-
related complications are very low, the durability results of in particular the pulmonary 
autograft diverge considerably, espe cially 10 years postoperatively (95% CI for freedom 
from autograft failure at 10 years 86–96%). The question remains whether it is possible 
to opti mize autograft durability through better patient selection, more optimal application 
of the root replacement technique, and perhaps postoperative antihypertensive treatment. 
Remarkable is the excellent reported survival after the Ross operation in young adult 
patients, which appears to run parallel to the general popula tion. This is in contradiction 
to the observed impaired relative survival in young adult patients after aortic valve replace-
ment that was discussed in the first section of this chapter. It seems that excess mortality 
is virtually absent in patients after the Ross operation, and some authors suggest that this 
excellent survival advantage may be caused by the fact that the auto graft provides a living 
and hemodynamically superior valve substitute. An update of the ongoing randomized trial 
in the United King dom (Harefield) between allograft and autograft aortic root replacement 
(personal communication) suggests indeed that autograft patients have superior survival 
compared to patients who receive an allograft.2 On the other hand, the Ross operation 
is performed in a select group of patients, and their characteristics may also explain the 
observed survival pattern. For example, a single center observational study by Klieverik 
et al.11 in young adult patients who underwent aortic valve replacement found that in a 
univariable Cox regression model for late survival the Ross procedure appeared to carry a 
survival advantage over allografts and mechanical prostheses. However, in a multivariable 
Cox regression model that also in cluded preoperative renal impairment, preoperative im-
paired left ventricu lar function, concomitant mitral valve surgery, prior aortic valve surgery 
and patient age, the factor implanted valve substitute was no longer of in fluence on late 
survival. Another study by Klieverik et al.10 that com pared outcome after allograft or auto-
graft aortic root replacement in young adult patients with congenital aortic valve disease 
showed no difference in survival between the two groups. These observations suggest that 
patient characteristics are important determinants of late survival and that the im planted 
valve type is of minor importance. 
SuMMARy And COnCluSIOnS 
Late patient survival after aortic valve replacement is impaired compared to the general 
population. This difference can only in part be explained by the occurrence of valve-related 
complications. In particular in younger adult patients there is a considerable amount of 
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excess mortality that is due to patient-related factors. Regional differences in population 
mortality hamper studies on survival after aortic valve replacement and should be taken 
into account when assessing evidence on outcome after aortic valve replacement. 
Microsimulation studies show that patient outcome after implantation of stented and 
stentless bioprostheses or cryopreserved allografts is acceptable and that differences in 
patient outcomes are most likely explained by pa tient selection and the timing of opera-
tion, rather than differences in the performance of these valve substitutes. 
The pulmonary autograft appears to be the only biological valve sub stitute that carries 
a survival advantage. However, this survival advantage may very well be caused by patient 
selection. A randomized trial or a pro pensity score matching study of young adult patients 
who received either an autograft, allograft or mechanical prosthesis will elucidate whether 
there truly is a survival advantage. Durability of the autograft varies widely be tween report-
ed series and may be optimized through better patient selection, more optimal application 
of the root replacement technique, and perhaps postoperative antihypertensive treatment. 
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AbSTRACT
Objective 
Symptomatic severe aortic stenosis is an indication for aortic valve replacement. Some 
patients are denied intervention. This study provides insight into the proportion of conser-
vatively treated patients and into the reasons why conservative treatment is chosen. 
Methods
Of a patient cohort presenting with severe aortic stenosis between 2004 and 2007, medical 
records were retrospectively analyzed. Only symptomatic patients (n=179) were included. 
We studied their characteristics, treatment decisions and survival. 
Results
Mean age was 71 years, 50% were male. During follow-up (mean 17 months, 99% 
complete) 76 (42%) patients were scheduled for surgical treatment (63 conventional valve 
replacement, 10 transcatheter, 1 heart transplantation, 2 waiting list) versus 101 (56%) 
who received medical treatment. Reasons for medical treatment were: perceived high 
operative risk (34%), symptoms regarded mild (19%), stenosis perceived non-severe (14%) 
and patient preference (9%). In 5% the decision was pending at the time of the analysis 
and in 20% the reason was other/unclear. Mean age of the surgical group was 68 versus 
73 years for medically treated patients (p=0.004). Predicted mortality (EuroSCORE) was 
7.8% versus 11.3% (p=0.006). During follow-up 12 patients died in the surgical group (no 
30-day operative mortality), versus 28 in the medical group. Two-year survival was 90% 
versus 69%. 
Conclusions
A large proportion (56%) of symptomatic patients does not undergo aortic valve replace-
ment. Often operative risk is estimated (too) high or hemodynamic severity and symptom-
atic status are misclassified. Interdisciplinary team discussions between cardiologists and 
surgeons should be encouraged to optimize patient selection for surgery. 
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InTROduCTIOn
The prevalence of aortic stenosis increases with age to up to 8% in the elderly.1 Meanwhile 
the Western population increases to age during the last decades and this trend is expected 
to continue.2 Therefore aortic stenosis constitutes a growing health burden. 
While the treatment of asymptomatic patients with severe aortic stenosis remains debat-
able, both European and American guidelines on the management of valvular heart disease 
recommend that symptomatic patients have aortic valve replacement.3,4 This recommenda-
tion is not only based on the survival advantage that can be expected after surgery but also 
on the improvement in functional class, even in elderly patients.3-5 
Recent literature suggests that a considerable proportion (33-60%) of patients with 
symptomatic severe aortic stenosis does not receive aortic valve replacement (AVR).6-9 We 
sought to confirm that many symptomatic patients remain unoperated and were interested 
in the reasons and the consequences of the decision to operate or not. The goal of our 
study was therefore to gain insight into decision making and survival in patients with 
severe symptomatic aortic stenosis.
METhOdS
Study design and data collection
A retrospective search in the echocardiography database of our department revealed 115 
patients with severe aortic stenosis. An additional 140 patients were recruited from the 
echocardiography laboratories in the outpatient cardiology clinics of 7 hospitals in the 
Rotterdam region. All echocardiograms were made between October 2004 and December 
2007. Patients had at least one of the following inclusion criteria: aortic valve area < 1.0 
cm2, maximum aortic jet velocity > 4.0 m/s, peak aortic gradient > 64 mmHg or mean 
aortic gradient > 40 mmHg. To avoid missing low-output aortic stenosis, patients were also 
included if the ratio between the velocity time integral over the aortic valve and the left 
ventricular outflow tract was > 4.0. 
Information was gathered on medical history, cardiovascular risk factors and symptomatic 
status at the time of the echocardiogram. Asymptomatic patients were excluded from the 
eventual analysis. For all symptomatic patients, anticipated operative risk was calculated 
using the logistic EuroSCORE risk model (www.euroscore.org).
Treatment strategies and their reasons were retrieved from notes in the patients’ medical 
charts. Reasons for ‘conservative/medical treatment’ were classified in 6 main categories: 
1) anticipated 'high' operative risk (including advanced age or left ventricular dysfunction); 
2) only 'mild' symptoms; 3) stenosis 'non-severe'; 4) 'patient preference'; 5) decision not 
final yet; 6) other, including ‘reason unclear’. 
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The study protocol was approved by the institutional review board, patient informed 
consent was waived (MEC 06-066, MEC 08-022). The authors had full access to the data 
and take responsibility for its integrity. All authors have read and agree to the manuscript 
as written.
Study population
Of the 255 patients that were initially identified, 73 asymptomatic patients were excluded 
plus 3 patients of whom symptomatic status could not be retrieved, leaving 179 symptom-
atic patients in the study cohort. Mean age was 71 years, 50% were male. 
During follow-up (mean 17 months, median 13.6, range 0.1-40) 76 patients (42%) 
underwent AVR or were scheduled for surgery (Figure 1). There were 63 conventional 
aortic valve replacements, 9 percutaneous and 1 transapical valve implantations. Two 
patients were on a waiting list for AVR and 1 patient required a heart transplantation 
during follow-up. Medical treatment was given in 101 patients (56%). Two patients were 
lost to follow-up (99% completeness). Mean age of the surgical group was 68 versus 73 
years for the medically treated patients (P=0.004). Predicted operative mortality according 
to the logistic EuroSCORE was 7.8% versus 11.3% (P=0.009). More patient characteristics 
are given in Table 1. 
figure 1: Flow chart of main results.
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Statistical analysis
Continuous data are presented as mean ± 1 standard deviation, and median. Categorical 
data are presented as proportions.
Chi-square testing was used for comparison of categorical variables. Continuous variables 
were compared using the Student’s t-test. A p-value < 0.05 was considered significant.
Survival curves were estimated by the Kaplan-Meier method. Differences in survival were 
not statistically assessed.
Statistical analyses were performed with SPSS for Windows (release 15.0; SPSS Inc, 
Chicago, Illinois).
Table 1: Patient characteristics
Patient characteristics
AVR
n= 76
Conservative
n= 101
Age (mean ± SD in years) 67.9 ± 12.4 73.3 ± 12.3
Male (%) 49 51
Follow-up (mean ± SD in months) 20.3 ± 11.8 15.1 ± 11.5
Echocardiographic parameters (mean ± SD)
 Maximal transaortic velocity (m/s)
 Peak gradient (in mmHg)
 AV/LVOT VTI ratio
 Aortic Valve Area (cm2)
4.4 ± 0.8
82 ± 32
4.9 ± 1.8
0.68 ± 0.24
4.0 ± 0.8
66 ± 26
5.0 ± 2.3
0.71 ± 0.26
NYHA class (%)
 II
 III
 IV
 Missing
42.1
38.2
13.2
6.6
54.5
34.7
8.9
2.0
Left Ventricular Function (%)
 Good/impaired (EF >50%)
 Moderate (EF 30-50%)
 Poor (EF <30%)
 Missing
56.6
38.2
2.6
1.3
57.4
30.7
7.9
4.0
Logistic EuroSCORE (mean ± SD) 7.8 ± 7.9 11.3 ± 9.6
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RESulTS
There was no 30-day mortality. During follow-up 12 patients died in the surgical group, 
versus 28 patients in the medical group. One- and two-year survival was respectively 93% 
and 90% for the AVR group and for the conservative group 77% and 69% (Figure 1). 
Reasons for choosing non-surgical treatment were: operative risk deemed ‘too high’ 
(34%), symptoms regarded as ‘mild’ (19%), stenosis regarded as ‘non-severe’ (14%) and 
patient preference (9%). In 5% the decision to operate was still under consideration by 
cardiologist and/or patient. In 20 patients (20%) the reason behind decision making could 
not be retrieved accurately. Of the latter 20 patients, 11 were in NYHA class II, 6 were in 
NYHA III and 3 were in NYHA class IV. 
Of the 34 patients in whom the reason not to operate was ‘high risk’, the mean age 
was 75.7 years and the mean EuroSCORE was 11.6%. Eight of them had a history of 
malignancy or active malignancy (six of these patients eventually died during follow up). 
Eighteen patients had a EuroSCORE <10% and only 9 of the 34 patients in whom the 
operative risk was deemed too high had a EuroSCORE > 15%. 
dISCuSSIOn
Although treatment consensus seems to exist on symptomatic patients with severe aortic 
stenosis, it is not uncommon to diverge from these guidelines.6,8-10 Advanced age and left 
ventricular dysfunction are known reasons to deny surgery in a symptomatic patient.6,11 
Instead of using patient characteristics to predict whether a patient gets AVR or not, our 
study was designed to investigate the decision making. Therefore it provides a different 
perspective: in our cohort an overestimation of operative risk, underestimation of symp-
toms and misclassification of hemodynamic severity are common causes why symptomatic 
patients are denied AVR. Furthermore, we found that survival of the conservative group is 
not as pessimistic as reported by others.12,13
‘Overestimation’ of operative risk?
In a third of the patients who were treated conservatively, an anticipated high operative 
risk was the main reason not to go for AVR. This subgroup had a mean age of only 76 
years, and only 9 of the 34 patients had a EuroSCORE > 15%. Perhaps it is even more 
important that more than half (18 patients) had a relatively low operative risk with a 
EuroSCORE <10%. 
From literature it is known that remission of symptoms after starting medical treatment 
can be a reason to stay conservative and that patients who are treated conservatively 
are generally older and more often have impaired left ventricular function than surgically 
Martijn BW6.indd   120 03-01-13   11:14
C
H
A
PTER 7
Predicted patient outcom
e after bioprosthetic A
V
R and the Ross operation 
121
treated patients.6,7 Yet, both remission of symptoms, advanced age and depressed left 
ventricular function are debatable reasons not to operate on a symptomatic patient. Even 
elderly patients can be operated upon with acceptable morbidity and mortality, and can 
expect a considerable quality of life.5,11 
Note that 10 patients in the AVR group underwent a minimally invasive valve replace-
ment. They were deemed not amendable for surgery. This indicates that even in a region 
with a tertiary center that uses new percutaneous and transapical techniques to replace 
the aortic valve, the majority of patients are treated conservatively.
Eight patients had either a malignancy in medical history or an active malignancy, risk 
factors which are not taken into account by the EuroSCORE. Another issue with risk models 
is that they do not score characteristics such as ‘vitality’ or ‘biological age’. Furthermore 
there is a large variability between different risk models, and the one most commonly used 
(EuroSCORE) seems to overestimate the actual operative risk most.14 Perhaps this adds to 
the large variance in treatment advise that exists among cardiologists which was already 
found by Bouma et al.7
‘Underestimation’ of symptoms?
Due to inactivity or gradual adjustment of daily activities to developing symptoms, patients 
with aortic stenosis often do not acknowledge the presence of symptoms or attribute 
them to the ageing process. Exercise testing is recommended in asymptomatic patients 
with aortic stenosis in order to exclude symptoms with more certainty,15-17 and up to 37% 
of patients previously considered asymptomatic have limiting symptoms when they are 
tested.17 According to the European Heart Survey exercise testing is highly underused.3,18 
This could lead to an underestimation of the proportion of symptomatic patients treated 
medically that was reported by others and in the current study.6,8-10 
In this study, the classical aortic stenosis symptoms such as dyspnea, syncope or angina 
were documented for several patients but regarded as ‘mild’ or non-debilitating. Having 
only ‘mild’ symptoms does not exclude a patient from being an AVR candidate.3,4 It is 
furthermore known that even íf symptoms are recognized, the resulting functional dis-
ability is often underestimated by physicians.19 Symptomatic patients with severe aortic 
stenosis from our cohort suffer from both physical and emotional impairment hampering 
normal daily activities (unpublished data). These are clear reasons to assess symptomatic 
status accurately, and to reconsider a conservative approach when symptoms are present.
‘Underestimation’ of hemodynamic severity 
As much as 14% of the symptomatic patients who were denied surgery were not referred 
because the stenosis was classified ‘non-severe’ by the treating cardiologist during the 
initial assessment. According to the guidelines they should however have been classified 
as severe.3,4 Since only patients with a severe stenosis are recommended to have surgery, 
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these misclassified patients are at increased risk of left ventricular deterioration and sudden 
death.20
Even íf the stenosis severity is only just below the ‘severe’ threshold, it can be disputed 
that ’watchful waiting’ is the best treatment. Peak aortic gradient increases 10-15 mmHg/
year and aortic valve area decreases 0.1-0.12 cm2/year.21-23 Given these progression rates, 
borderline patients will enter the ‘severe’ category within a few months or at most a year 
later. Meanwhile left ventricular function will only get worse.
Survival in the conservative and in the surgical group
Survival in the medically treated group cannot easily be compared with the surgically treated 
group because the patients have quite different characteristics, which could account for a 
large part of the difference in survival. It is therefore questionable if, and to what extent, 
the survival of the total study group would have improved supposed more patients would 
have had aortic valve replacement. 
From the survival curve of the non-AVR group it can be seen that a decline in survival 
already occurs in the first year after the echocardiogram (Figure 2). Still, survival in the 
conservative group is not as bad as expected based on previous reports.12,13,20 Perhaps 
improvement in medical treatment over the past years plays a role, but survival in the 
conservative group highly depends on referral strategy as well; if more high risk patients 
are operated upon, the patients with a really bad prognosis are left for conservative treat-
AVR
Conservative
treatment
AVR
Conservative
figure 2: Kaplan Meier survival for the conservatively treated group and the AVR group.
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ment, resulting in low survival in this category. Therefore the relatively ‘good’ prognosis 
of our medically treated group could be a reflection of the conservative approach of the 
cardiologists in our region. 
Because of its dependence on referral, ‘natural history’ of aortic stenosis is very difficult 
to study. If one would like to gain a clear view on ‘natural history’, theoretically all eligible 
patients should be excluded from having AVR, or they should be randomised to receive 
either surgical or conservative treatment. In practice this would be impossible and ethically 
incorrect. 
Future prospects 
Microsimulation methods can accurately estimate life-expectancy for patients after AVR,24,25 
but have yet to be developed for patients who are treated conservatively. Our department 
intends to develop these models, but this requires large datasets with extensive numbers 
of variables and some patient factors, such as vitality, will be difficult to grasp in a model.
COnCluSIOn
A considerable proportion of patients with symptomatic severe aortic stenosis is not referred 
for surgery although theoretically they have an indication for aortic valve replacement. 
Often operative risk is estimated (too) high, and misclassification of both hemodynamic 
severity and symptomatic status occurs frequently. 
Most patients who were treated conservatively were simply not referred to a surgical 
department. Referral to surgical departments should be encouraged in order to have more 
interdisciplinary team discussions between cardiologists and surgeons. Hopefully, this will 
result in better patient selection for surgery, possibly resulting in better survival of patients 
with severe symptomatic aortic stenosis. 
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In reaction to ‘Prescribing statins in aortic stenosis: Little to lose, much to gain’ 1, we would 
like to provide the readership of this journal with some additional information concerning 
statin use — or underuse — in our study population.
In our observational prospective cohort study, we described treatment strategies in symp-
tomatic patients with severe aortic stenosis in the Rotterdam area, the Netherlands.2 In the 
patients observed, the so-called medical or conservative treatment was mostly aimed at 
relief of symptoms by diuretics, treatment of atrial fibrillation and systemic or pulmonary 
hypertension. To prevent endocarditis, all patients were treated with prophylactic antibac-
terial treatment before starting non-sterile surgical procedures. 
Approximately only half of the patients received lipidlowering drugs: 54% of the 76 
patients in the aortic valve replacement (AVR) group and 47% of the 101 patients in the 
‘medical/conservative’ group. 
Although we only documented drug prescriptions and have not studied why certain 
patients received statins (and why many did not), we doubt statin usage was aimed at 
slowing the progression of aortic stenosis. It is more likely statins were prescribed for 
(cardio-) vascular co-morbidity or dyslipidaemia. 
Statins may interfere with the progression of aortic stenosis, but to what degree and until 
which disease stage remains uncertain and has yet to be established in larger prospective 
series. Dr Paraskevas refers to a cohort study in which statins slowed the haemodynamic 
progression in patients with asymptomatic moderate-to-severe aortic stenosis,1 others re-
ported no clear effect on the progression of moderate-to-severe aortic stenosis in a recent 
randomized trial.3 Further, the SEAS trial he refers to, concerned patients with asymptomatic 
mild-to-moderate aortic stenosis.1,4 In his comprehensive review, Dr Paraskevas concludes 
statins improve cardiovascular outcomes in surgical patients (either coronary artery bypass 
graft (CABG) or patients who need valve replacement or other thoracic surgery).5 However, 
it remains to be seen whether statin therapy is useful in the cohort we studied: the symp-
tomatic patient with severe aortic stenosis in whom the decision to operate or not is yet to 
be made. Although interesting, this will be difficult to study because co-morbidities, age, 
the advanced state of the valve stenosis and treatment selection probably play a major role 
in clinical outcome. 
On the other hand, of course, one could also argue there is not much to lose. Since 
we have no hard data of our own to either support or reject this statement, we leave 
this subject open for debate. Nevertheless, we are grateful for Dr Paraskevas’ enthusiastic 
comments and discussion.1
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AbSTRACT
Objective 
To prospectively evaluate the clinical course of patients with severe aortic stenosis (AS) and 
identify factors associated with treatment selection and patient outcome.
Methods 
Patients diagnosed with severe AS in the Rotterdam area were included between June 
2006 and May 2009. Patient characteristics, echocardiogram, NT-proBNP, and treatment 
strategy were assessed at baseline, and after 6, 12, and 24 months. Endpoints were aortic 
valve replacement (AVR) / transcatheter aortic valve implantation (TAVI) and death.
Results 
The study population comprised 191 patients, 132 were symptomatic and 59 asymp-
tomatic at study entry. Two-year cumulative survival of symptomatic patients was 89.8% 
(95% CI 79.8-95.0%) after AVR/TAVI and 72.6% (95% CI 59.7-82.0%) with conservative 
treatment. Two-year cumulative survival of asymptomatic patients was 91.5% (95% CI 
80.8-96.4%). Two-year cumulative incidence of AVR/TAVI was 55.9% (95% CI 47.5-
63.5%) in symptomatic patients. Sixty-eight percent of asymptomatic patients developed 
symptoms, median time to symptoms was 13 months; AVR/TAVI cumulative incidence was 
38.3% (95% CI 23.1-53.3%). Elderly symptomatic patients with multiple comorbidities 
were more likely to receive conservative treatment.
Conclusions 
In contemporary Dutch practice many symptomatic patients do not receive invasive treat-
ment of severe AS. Two-thirds of asymptomatic patients develop symptoms within 2 years, 
illustrating the progressive nature of severe AS. Treatment optimization may be achieved 
through careful individualised assessment in a multidisciplinary setting.
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InTROduCTIOn
The prevalence of calcified aortic stenosis (AS) increases with the ageing of the population, 
and represents a growing health burden.1,2 According to the current ESC and ACC/AHA 
guidelines, aortic valve replacement (AVR) is indicated in patients with severe symptomatic 
AS.3,4 Even elderly patients with multiple comorbidities are usually eligible for AVR, and if 
surgery is not an option, transcatheter aortic valve implantation (TAVI) is often feasible.5,6 
Nevertheless, at least one third of patients with symptomatic AS do not undergo AVR 
although they have a clear indication.7-10 Advanced age, poor left ventricular function, and 
comorbidities are common reasons for non-referral for AVR.8-9,11-13
The aim of this study was to prospectively evaluate the clinical course of patients with 
severe AS in contemporary Dutch practice and identify factors associated with treatment 
selection and patient outcome. This information may facilitate treatment optimisation.
METhOdS
Patient population
The Aortic Valve RIJNmond (AVARIJN) Study is a multicentre prospective cohort study of 
patients diagnosed with severe AS in seven Cardiology clinics in the wider Rijnmond area 
between June 2006 and May 2009. Patients 18 years and older were included if they met 
one of the following echocardiographic criteria: aortic valve area (AVA) ≤ 1 cm2, peak 
transaortic jet velocity (Vmax) ≥ 4 m/s, or aortic valve / left ventricular outflow tract velocity 
time integral ratio ≥ 4. The study protocol was approved by the medical ethics commit-
tee of Erasmus University Medical Center (MEC 2006-066); all patients provided written 
informed consent.
Patient characteristics, i.e. medical history, cardiovascular risk factors, symptomatic status 
defined as presence of dyspnoea, angina, and/or syncope at study entry,3,4 echocardio-
graphic data including Vmax, peak and mean aortic gradient, AVA, left ventricular ejection 
fraction, and low-flow/low-gradient AS (mean aortic gradient < 30 mmHg and an AVA < 
1.0 cm2), brain natriuretic peptide (NT-proBNP), and treatment strategy (conservative or 
either AVR or TAVI) were assessed at baseline, and after 6, 12, and 24 months. Expected 
operative risk was calculated using the logistic EuroSCORE and the Society of Thoracic Sur-
geons’ risk model (www.euroscore.org; www.sts.org). Asymptomatic patients were invited 
for exercise testing at baseline; a positive exercise test outcome was defined according to 
the ACC/AHA guidelines.14 Patients with a positive test stayed in the asymptomatic group.
Treatment strategies were retrieved from the patients’ medical charts. Study endpoints 
were AVR or TAVI and all-cause death, which were documented using the hospital infor-
mation systems or information obtained through the treating physicians.
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Statistical analysis
Continuous data are presented as mean (SD) or median (interquartile range) and for com-
parison between groups the unpaired t-test or Mann-Whitney U test was used. Categorical 
data are presented as counts and proportions, and comparison was done with the Chi-
square test.
Kaplan-Meier analysis was used to assess patient survival and cumulative incidence of 
AVR/TAVI. Patient follow-up started at enrolment and ended at time of death (event), 
completion of study, or when the patient was lost to follow-up (censoring).
Logistic regression was used to evaluate the association between baseline characteristics 
and conservative treatment strategy. Cox proportional hazards analysis was used to analyse 
time-related events. Missing values were imputed by the mean. Univariable predictors with 
a p-value ≤ 0.05 were entered into the multivariable model using the enter method. In case 
of correlation between potential predictors, the potential predictor that was considered 
clinically most relevant was selected for the multivariable model. Age, male gender, smok-
ing, hypertension, diabetes, dyslipidaemia, chronic obstructive pulmonary disease, carotid 
disease, stroke, peripheral arterial disease, previous myocardial infarction, coronary artery 
disease, renal failure, symptomatic status, body mass index, body surface area, systolic and 
diastolic blood pressure, NT-proBNP, Vmax, AVAi (indexed by body surface area), left ven-
tricular ejection fraction, left ventricular hypertrophy (on electrocardiography), ischaemia 
(on electrocardiography), and aortic and mitral regurgitation ≥ grade II were considered 
as co-variables in the models (definitions in the Appendix). All statistical tests were two-
sided and a p-value ≤ 0.05 was considered significant. Statistical analyses were performed 
using SPSS for Windows, version 15 (SPSS Inc, Chicago, Illinois) and GraphPad Prism 5 for 
Windows (GraphPad Software, San Diego, California).
RESulTS
The study population consisted of 191 patients with severe AS, of whom 132 were symp-
tomatic and 59 were asymptomatic at study entry (Table 1).
Forty-seven of the 59 patients who were asymptomatic underwent an exercise test at 
baseline. Of these 47 patients, 15 (32%) tested positive (ST depression ≥ 2 mm (N=10), 
no increase blood pressure (N=2), collapse (N=1), angina (N=1), and dyspnoea (N=2)), 25 
(53%) patients tested negative, and in 7 (15%) patients the test was inconclusive. Twelve 
patients were unable to perform the exercise test due to impaired mobility, logistic reasons, 
or refusal.
Figure 1 displays the flow chart of patients during the study. Completeness of follow-up 
was 99%; 2 patients had emigrated.
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Table 1  Patient characteristics at baseline differentiated by symptomatic status
All
N=191
Symptomatic
N=132
Asymptomatic
N=59
P-value
Age (yrs) 72.6 (63.7-78.6) 74.0 (64.4-79.2) 69.9 (61.6-76.4) 0.034
Male gender (%) 62 56 76 0.008
Previous valve surgery (%) 1 2 0 0.343
Previous CABG (%) 6 8 3 0.272
Smoking (%) 61 56 71 0.049
Hypertension (%) 52 54 49 0.554
Diabetes (%) 20 19 22 0.622
Dyslipidemia (%) 49 49 47 0.820
COPD (%) 17 20 10 0.083
PAD (%) 13 15 7 0.108
History of MI (%) 13 15 8 0.207
Stroke (%) 19 18 20 0.725
Vmax (m/s) 4.3 ± 0.8 4.3 ± 0.8 4.2 ± 0.7 0.693
AVA (cm2) 0.74 (0.59-0.91) 0.72 (0.54-0.85) 0.80 (0.63-0.96) 0.026
LVEF (%) 61 ± 7 61 ± 7 62 ± 6 0.129
Low flow/low gradient AS (%) 13 15 8 0.207
AR grade ≥ II (%) 17 18 14 0.494
MR grade ≥ II (%) 11 15 4 0.025
LVH (%) 27 28 24 0.445
NT-proBNP (pmol/l) 50 (22-153) 89 (29-180) 31 (13-74) <0.001
Logistic EuroSCORE (%) 5.4 (3.1-8.2) 6.2 (3.9-9.6) 4.0 (2.1-6.9) <0.001
STS score (%) 4.5 (2.8-7.6) 5.1 (3.3-8.0) 3.8 (2.0-6.0) 0.002
CABG = coronary artery bypass graft, COPD = chronic obstructive pulmonary disease, PAD = peripheral 
arterial disease, MI = myocardial infarction, Vmax = peak transaortic jet velocity, AVA = aortic valve 
area, LVEF = left ventricular ejection fraction, AS = aortic stenosis, AR = aortic regurgitation, MR = 
mitral regurgitation, LVH = left ventricular hypertrophy, NT-proBNP = N-terminal pro-brain natriuretic 
peptide, 
STS = Society of Thoracic Surgeons. Normal distributed variables: mean ± standard deviation; skewed 
distributed variables: median (interquartile range 25 and 75%).
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Clinical course of symptomatic patients
Of the 132 symptomatic patients at baseline, 24 patients (18%) died during follow-up 
of whom 7 patients after AVR/TAVI due to: pneumonia (N=3), sudden unexpected unex-
plained death (N=1), subdural haematoma (N=1), mediastinitis (N=1), and unknown reason 
(N=1). Causes of death in the non-operated patients were congestive heart failure (N=11), 
sudden unexpected unexplained death (N=3), ruptured abdominal aortic aneurysm (N=1), 
pneumonia (N=1), and intestinal bleeding (N=1).
Sixty-four patients (48%) underwent AVR, 5 (4%) TAVI, and 63 (48%) were treated con-
servatively (Figure 1). Reasons for TAVI were informed patient preference in 1 patient (age 
53 years) and inoperability due to comorbidities in the other 4 patients (age >70 years).
Overall cumulative survival at 2 years was 81.7% (73.9-87.3%). For patients receiving 
AVR/TAVI, 2-year cumulative survival was 89.8% (95% CI 79.8-95.0%) and for patients 
who were treated conservatively 72.6% (95% CI 59.7-82.0%) (Figure 2). Older patient age 
(HR 1.05; 95% CI 1.001-1.101; p=0.046), previous myocardial infarction (HR 2.75; 95% 
CI 1.14-6.60; p=0.024), and a higher baseline NT-proBNP (HR 1.002; 95% CI 1.001-1.003; 
p<0.001) were independently associated with increased mortality rates. Although in the 
univariable model AVR/TAVI was associated with decreased mortality rates (HR 0.30; 95% 
CI 0.13-0.67; p=0.004), in the multivariable model it was no longer a significant factor (HR 
0.69; 95% CI 0.27-1.75; p=0.430).
figure 1: Flowchart of patient distribution during the study
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figure 2: Patient survival for symptomatic patients differentiated by treatment strategy
figure 3: Cumulative incidence of AVR/TAVI differentiated by symptomatic status 
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Cumulative incidence of AVR/TAVI at 2 years was 55.9% (95% CI 47.5-63.5%) (Figure 
3). Factors associated with a conservative treatment strategy are displayed in Table 2. 
Logistic EuroSCORE in symptomatic patients was 5.1% for those who underwent AVR/
TAVI and 7.2% for symptomatic patients who were treated conservatively (p<0.001). Low-
flow/low-gradient AS was more common in symptomatic patients who were conservatively 
treated compared to those who underwent AVR/TAVI (22% versus 9%; p=0.013).
Clinical course of asymptomatic patients
Of the 59 asymptomatic patients at baseline, 5 patients died during follow-up. Three 
patients died after AVR due to congestive heart failure (N=2: 1 < 30 days postoperative) 
and malignancy (N=1). One patient died of a pulmonary embolism and 1 patient died of 
unknown cause.
Forty patients (68%) became symptomatic, median time to symptom development was 
13 months (range 1-24 months); 19 underwent AVR. In addition, 3 asymptomatic patients 
underwent AVR for rapidly progressing very severe AS (n=2) and 1 for subvalvular AS with 
a gradient of 61 mmHg.
Overall cumulative survival at 2 years was 91.5% (80.8-96.4%). Of the 19 patients who 
became symptomatic and underwent AVR/TAVI, 2-year cumulative survival was 89.5% 
(95% CI 64.1-97.3%). For the 21 patients who became symptomatic during follow-up but 
were treated conservatively, survival was 90.5% (95% CI 67.0-97.5%), for the 16 patients 
who remained asymptomatic and were treated conservatively 100%, and for the 3 patients 
who remained asymptomatic but nevertheless underwent AVR, survival was 66.7% (95% 
CI 5.4-94.5%).
Table 2  Logistic regression analysis for conservative treatment in symptomatic patients at baseline
Odds ratio
        Univariable             p-value         Multivariable*         P-value 
Age (yrs) 1.09 (1.05-1.14) <0.001 1.10 (1.04-1.15) 0.001
PAD (%) 8.77 (2.42-31.25) 0.001 10.99 (2.32-52.63) 0.003
Vmax (m/s) 0.37 (0.22-0.63) <0.001 0.46 (0.25-0.85) 0.013
Previous MI (%) 5.95 (1.87-18.87) 0.003 5.26 (1.30-21.28) 0.020
Hypertension (%) 3.21 (1.56-6.58) 0.002 2.72 (1.11-6.67) 0.029
MR (%) 2.93 (1.04-8.26) 0.042 0.64 (0.17-2.34) 0.495
Low flow/low gradient AS (%)** 3.23 (1.15-9.01) 0.025
EuroSCORE (%)** 1.11 (1.04-1.19) 0.002
PAD = peripheral arterial disease, Vmax = peak transaortic jet velocity, MI = myocardial infarction, 
MR = mitral regurgitation, AS = aortic valve stenosis, () = 95% confidence interval. Univariable p-values 
≤ 0.05 were included in multivariable model. * Enter method. **Low flow/low gradient AS and 
EuroSCORE were highly correlated with ≥ 1 other co-variables and not entered in multivariable model.
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Symptom development rate was faster in patients with a higher Vmax at baseline 
(HR 2.06; 95% CI 1.29-3.27; p=0.002), those with CAD (HR 4.73; 95% CI 1.20-18.73; 
p=0.027), and prior myocardial infarction (HR 3.47; 95% CI 1.14-10.54; p=0.028).
Cumulative incidence of AVR/TAVI at 2 years was 38.3% (95% CI 23.1-53.3%) (Figure 
3). 
dISCuSSIOn
This study reflects current clinical practice for adult patients with severe AS in several 
ways. First, a significant proportion of asymptomatic patients have a positive exercise 
test, underlining the importance of exercise testing in asymptomatic severe AS patients. 
Secondly, a considerable proportion of symptomatic patients do not undergo AVR/TAVI. 
In particular, elderly symptomatic patients with multiple comorbidities and a relatively low 
peak transaortic gradient are not likely to undergo AVR, and have a poor survival. Finally, 
the majority of asymptomatic patients become symptomatic over a 2-year period of time. 
This illustrates the progressive nature of severe AS and the need for careful and frequent 
‘watchful waiting’ if a conservative strategy in the asymptomatic patients is pursued.
Challenges at diagnosis
A significant proportion of asymptomatic patients have a positive exercise test.13,15 The 
gradual decrease in physical functioning in the elderly can be attributed to advanced age, 
multiple comorbidities or to the worsening of AS, which might sometimes be difficult to 
differentiate. If it is not clear whether a patient with severe AS is symptomatic, exercise 
testing and/or measuring BNP can play an important role.16 Unfortunately, the European 
Heart Survey shows that exercise testing is underutilized and the true number of symptom-
atic patients may be much higher than is currently observed.18
Symptomatic patients
This study shows that symptomatic patients are usually older, more often female, and 
have more severe AS, more often concomitant mitral regurgitation, a higher NT-proBNP, 
and higher surgical risk scores compared to asymptomatic patients. Almost half of the 
symptomatic patients at study entry, as well as half of the asymptomatic patients who de-
velop symptoms, are treated conservatively. Confirming previous reports, in particular older 
patients with a lower Vmax and multiple comorbidities are more likely to be treated con-
servatively.8,12-13 Low-flow/low-gradient AS may possibly explain the association between 
lower Vmax and conservative treatment.19 Although a higher EuroSCORE is associated with 
conservative treatment, the average EuroSCORE of conservatively treated patients in our 
study was only 7.2%. However, EuroSCORE and other operative risk stratification models 
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do not consider patient factors related to ageing, such as frailty, which become increasingly 
important in determining short- and long-term outcome with advancing age.20-21 In this 
respect, there is a need for risk stratification models that better fit this elderly population.
We previously showed that important reasons for conservative treatment of symptom-
atic AS patients include misclassification of AS severity and symptoms, overestimation of 
operative risk, and patient preferences.13 Given the survival benefit of TAVI for inoperable 
patients,10 patients with severe symptomatic AS should be referred for multidisciplinary 
heart team discussion to assess individual feasibility of invasive treatment approaches.22
Although survival appears better in symptomatic patients who undergo AVR/TAVI versus 
those treated conservatively, this survival benefit disappears when corrected for patient 
age, NT-proBNP, and previous myocardial infarction. This suggests that patient survival is 
mainly driven by patient characteristics and to a lesser extent by treatment strategy. Our 
finding that NT-proBNP is associated with increased mortality confirms a previous report.23 
Although treatment strategy may not affect survival, it does influence quality of life.24 In 
elderly patients with severe AS, quality of life should play a key role in optimizing treatment 
strategies. With the steadily increasing application of TAVI it is expected that more elderly 
symptomatic AS patients will receive invasive treatment, and hopefully an improved quality 
of life.
Asymptomatic patients
Asymptomatic severe AS has a progressive course, evidenced by the fact that no less than 
two-thirds of asymptomatic patients in our study became symptomatic within 2 years. This 
is higher compared to a previous report in which only one third became symptomatic and 
may be explained by the higher prevalence of classical risk factors, more left ventricular 
hypertrophy, and smaller aortic valve areas in our study patients.25 AS severity was predic-
tive of symptom development in our study, and underlines the importance of frequent 
monitoring of asymptomatic patients with more severe AS. Of all asymptomatic patients 
who became symptomatic, less than half undergo invasive treatment, while there are also 
a few patients who remain asymptomatic, but actually receive AVR. This illustrates the 
ongoing debate on the timing of AVR in asymptomatic patients with very severe AS. 
Limitations
Some elderly patients refused participation which has undoubtedly resulted in a selection 
bias toward younger patients with milder symptoms and less comorbidity. The 15 patients 
who tested positive during exercise testing remained assigned to the asymptomatic group 
during data analysis. Exercise test results were sent to the treating cardiologists and may 
have influenced treatment strategy.
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COnCluSIOnS
In contemporary practice in the Rotterdam Rijnmond area nearly half of the patients with 
symptomatic severe AS, in particular elderly patients with multiple comorbidities, do not 
undergo invasive treatment. In addition, our observation that more that two-thirds of 
asymptomatic patients develop symptoms during a two-year period underlines the pro-
gressive nature of severe aortic stenosis and the need for stringent and frequent watchful 
waiting.
A systematic evidence-based multidisciplinary team approach is recommended to opti-
mize treatment selection for symptomatic patients with severe AS. There is an urgent need 
to optimize patient treatment strategy by taking into account clinical factors related to AS 
and comorbidities, costs and benefits of treatment strategies, patient preferences, quality 
of life, and anticipated life expectancy.
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APPEndIx: dEfInITIOnS
Body surface area: calculated with DuBois and DuBois formula.
Carotid disease: stenosis >50%, or previous or planned surgery.
Chronic obstructive pulmonary disease: diagnosis previously made by physician, or receiv-
ing bronchodilators. 
Congestive heart failure: hospital stay with clinical sign(s) of congestive heart failure.
Coronary artery disease: >50% stenosis in at least one coronary artery proved by coronary 
angiography, or previously coronary artery bypass grafting.
Diabetes: diagnosis previously made by physician, or receiving blood glucose lowering 
medication.
Dyslipidemia: diagnosis previously made by physician, or receiving lipid lowering medica-
tion.
Hypertension: diagnosis previously made by physician, or known blood pressure of ≥ 140 
mmHg systolic or ≥ 90 mmHg diastolic on at least two measurements, or receiving blood 
pressure lowering medication.
Ischemia: ST-depression ≥ 1 mm at J+60 ms in at least two electrocardiographic leads.
Left ventricular hypertrophy: S in V1 plus R in V5/V6 > 35 mm, R in V6 > R in V5, R in I and/
or aVL > 12 mm on electrocardiography at J+60 ms.
Myocardial infarction: diagnosis previously made by physician. 
Peripheral arterial disease: claudication, or previous or planned surgery of the lower limbs.
Renal failure: diagnosis previously made by physician or creatinin ≥ 200 mmol/L.
Smoking: smoking cigarette or cigar during ≥ 5 years in the past.
Stroke: diagnosis ‘transient ischemic attack’ or ‘cerebrovascular accident’ previously made 
by physician, or neurological disease severely affecting ambulation or day-to-day function-
ing.
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AbSTRACT
Background
The disease burden of patients with severe aortic stenosis is not often explored, while the 
incidence is increasing and many patients who have an indication for aortic valve replace-
ment are not referred for surgery. We studied the quality of life of 191 patients with severe 
aortic stenosis, hypothesizing that symptomatic patients have a far worse quality of life 
than the general population, which could enforce the indication for surgery.   
Methods
The SF-36v2 Health Survey was completed by 191 consecutive patients with symptomatic 
or asymptomatic severe aortic stenosis. 
Results
Asymptomatic patients (n=59) had health scores comparable to the general Dutch popu-
lation but symptomatic patients (n=132) scored significantly lower across different age 
categories. Physical functioning, general health and vitality were impaired, as well as social 
functioning and emotional wellbeing. There was no relation between degree of stenosis 
and physical or mental health scores.
Conclusions
Both physical and emotional problems have major impact on normal daily life and social 
functioning of symptomatic patients with severe aortic stenosis, regardless of age. If the 
aortic stenosis is above the ‘severe’ threshold, the degree of stenosis does not predict 
disease burden. These results encourage to reconsider a conservative approach in symp-
tomatic patients with severe aortic stenosis. 
Using the SF-36v2 Health Survey together with this study, an individual patient’s quality 
of life profile can be assessed and compared with the patient group or with the general 
population. This can assist in decision making for the individual patient.
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InTROduCTIOn
Degenerative aortic stenosis is the most common valvular heart disease in developed 
countries. The prevalence of aortic stenosis increases with age to about 8% in patients 
over 85 years of age.1-2 With the aging of the general population, aortic stenosis represents 
a growing health problem. 
Medical therapy does not slow the progression of aortic stenosis nor has it proven to re-
duce major adverse cardiac event rates.3-5 The only effective treatment of severe stenosis is 
replacement of the aortic valve. Surgical techniques and postoperative care have improved 
over the years and even patients with advanced age and comorbidities can be operated 
relatively safely.6-7 Recently transcatheter valve implantation has been introduced, which 
might be a treatment option in patients with high operative risk.8
The guidelines of both the American Heart Association / American College of Cardiology 
and the European Society of Cardiology on the management of patients with valvular heart 
disease, recommend prompt aortic valve replacement (AVR) once symptoms occur in pa-
tients with severe aortic stenosis.9-10 Nonetheless, recent studies show that many patients 
who have a clear indication for aortic valve replacement are denied surgery.11-13 Reasons to 
choose for conservative treatment are often advanced age, poor left ventricular function or 
otherwise high operative risk.11-12 Moreover, in a significant number of cases the operative 
risk is overestimated or hemodynamic severity and symptomatic status are misclassified.14 
Physicians frequently fail to recognize the functional disability of their patients, espe-
cially the full impact and resulting disease burden of certain symptoms are not always 
appreciated.15 Classical symptoms of aortic stenosis are dyspnea, angina and syncope, 
and although the severity of symptoms can be used as a rough surrogate for the quality 
of life, the impact of symptoms on daily life remains unknown. The NYHA classification is 
a functional measurement of physical performance or pain, and roughly reflects one’s cur-
rent health status but certainly not one’s desired health status or disease burden. Especially 
the social and emotional aspects are underreported and not taken into account in the New 
York Heart Association (NYHA) classification. An underestimation by the treating physician 
of the impact of symptoms on a patient’s quality of life might be one of the reasons why so 
many symptomatic patients with severe aortic stenosis are not referred for surgery. Some 
literature is available on the functional status and quality of life of (elderly) patients after 
AVR,16 but very little is known about the quality of life of patients in whom the decision 
to operate is yet to be considered. If these patients indeed present themselves with a low 
quality of life and better evidence about this burden of disease could be presented, one 
would have an additional argument to follow the clinical guidelines more strictly. The 
trade-off between anticipated operative risk and expected benefit for the patient after 
AVR should not solely be based on survival advantages, but also on gain in quality of life.
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This paper presents the results of the Short Form-36v2™ Health Survey (SF-36v2™) 
in patients with severe aortic stenosis compared to the general population in order to 
investigate if, and to what extent, patients experience impairment of their daily life. We 
hypothesized that in symptomatic patients quality of life is far worse than in the general 
population, both in younger and elderly patients, which could enforce the indication for 
surgery. Further we hypothesized that echocardiographic parameters are not good indica-
tors of disease burden, at least not in our patient group in whom the degree of stenosis is 
severe ‘per inclusionem’.
METhOdS
Patients
This study is part of a larger multi-center prospective cohort study in the Rotterdam area 
(the Netherlands) between July 2006 and April 2009 among patients with severe aortic 
stenosis. Patients were recruited from the echocardiography laboratories of the outpatient 
clinics of seven local hospitals if they had a severely stenosed native aortic valve and at 
least one of the following echocardiographic criteria were met: aortic valve area ≤ 1 cm2, 
maximal trans aortic jet velocity ≥ 4 m/s, peak aortic gradient ≥ 64 mmHg, aortic valve / 
left ventricular outflow tract velocity time integral ratio ≥ 4. All consecutive patients who 
met these criteria and who agreed to participate were included, regardless of whether 
they were referred for surgery or not. The study protocol was approved by the institutional 
ethical committee (MEC 2006-066) and all patients provided written informed consent.
Methods
All consecutive patients who complied to the criteria mentioned above were contacted 
by telephone and invited for a personal baseline study visit. At this visit each patient’s 
functional class was assessed by the principal investigator using the functional classifica-
tion according to the New York Heart Association. Based on patient characteristics and 
medical history an anticipated operative mortality was calculated -for descriptive purposes 
only- using both the EuroSCORE model and the STS risk model (www.euroscore.org , 
www.sts.org). We also made an echocardiogram according to a specific study protocol, 
focused on the aortic valve.
The quality of life assessment was made by means of the SF-36v2™ Health Survey. 
According to the guidelines given by Ware et al. this questionnaire was sent to the patient 
and completed at home before each study-visit.17 While establishing NYHA class, the 
investigator was blinded to the results of the health survey. 
To allow for comparison of burden between our study patients and the general popula-
tion we used the paper presented by Aaronson et al in 1998.18 They took a sample of the 
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general Dutch population, consisting of 1742 people (56% male, mean age 47.6 years), 
subdivided in different age-categories and presented their quality of life outcomes as mea-
sured by the SF-36 Health Survey to generate normative data for use in the Netherlands. 
Our study population was therefore subdivided in the same age-categories.
The SF-36v2™ Health Survey is a modification of the original Short Form-36® Health 
Survey developed from the Medical Outcomes Study.19 The questionnaire consists of 36 
scale rated health-related questions, grouped into eight multi-item domains which are not 
disease-specific and which measure functioning in different aspects of daily life: ‘Physical 
Functioning’, physical health related to age- and role-specific activities termed ’Role-
Physical’, ‘Bodily Pain’, ‘General Health’, ‘Vitality’, ‘Social Functioning’, personal feelings 
of performance in age- and role-specific activities termed ’Role-Emotional’, and ‘Mental 
Health’. The eight domains form two main components according to physical and mental 
health. The ‘Physical Functioning’, ‘Role Physical’ and ‘Bodily Pain’ domains contribute 
most to the scoring of the ‘Physical Component Summary’ measure. The ‘Mental Health’, 
‘Role Emotional’, and ‘Social Functioning’ domains contribute most to the scoring of the 
‘Mental Component Summary’ measure. 
The raw SF-36 scores given by Aaronson et al are linearly and step-wise converted to 
a norm-based score from 0-100 in which 50 represents the mean score of the general 
population in the United States and 10 points on the scale correspond to 1 standard 
deviation.18 When comparing group-data to the norm, a difference of more than 3 points 
on this norm-based scale (corresponding to a difference of 0.3 SD) indicates a significant 
difference from normal, while 8 points or more indicate a large difference 17, 20. A detailed 
explanation regarding data collection, scoring, interpretation and validation of the SF-
36v2™ is given by Ware et al.17 
Statistical analyses 
For the statistical analyses SPSS 13.0.1 software was used (SPSS Inc. 2001). Continuous 
variables are displayed as means ± standard deviation if normally distributed, skewed dis-
tributed variables as median with interquartile range. Categorical variables are displayed 
as proportions. One-sided Student’s T tests were used for comparisons of health scores of 
patient groups to the general population. A p-value below 0.05 was considered significant.
RESulTS
Between July 2006 and April 2009 a total of 459 patients with severe aortic stenosis were 
identified, informed by the principal investigator and invited to participate. 268 patients 
(mean age 76±14 years) could not be examined because they declined participation 
(n=185), had an operation scheduled (n=65) or died (n=18) before they could participate 
Martijn BW6.indd   155 03-01-13   11:14
156
in the study. Reasons to refuse participation were most often high age and severe disability 
resulting in personal logistic problems or perceived high burden (data not shown). 
One-hundred-ninety-one patients (mean age 70.6 years) agreed to participate. E-Table 1 
shows their characteristics. Fifty-nine patients were asymptomatic, 73 were in NYHA class 
II, 49 in NYHA class III and 10 in NYHA class IV. 
E-Table 1: Patient characteristics
Patient characteristics Total patient group Symptomatic patients
N=191 N=132
Age (median, interquartile range, in years)
Age category 
 ≤40
 41-60
 61-70
 >70
72.6 (63.7-78.6)
4 (2%)
28 (15%)
44 (23%)
115 (60%)
74.0 (64.4-79.2)
3 (2%)
18 (14%)
25 (19%)
86 (65%)
Male sex 119 (62%) 75 (57%)
NYHA class 
 I
 II
 III
 IV
59 (31%)
73 (38%)
49 (26%)
10 (5%)
Not applicable
73 (55%)
49 (37%)
10 (8%)
Sort of symptom (%)
 Only dyspnea
 Only angina
 Only syncope
 Combination
46.2
4.5
3.8
45.5
Cardiovascular history (%)
 Diabetes Mellitus
 Hypertension
 Dyslipidaemia
 Chronic obstructive pulmonary disease
 Renal failure
 Peripheral vascular disease
 Cerebro vascular accident (residual neurological deficit)
 Previous coronary artery bypass grafting
20
52
49
17
7
13
19
6
19
54
49
20
9
15
18
8
Logistic EuroSCORE (median, interquartile range) 5.4 (3.1-8.2) 6.2 (3.9-9.6)
STS score (median, interquartile range) 4.5 (2.8-7.6) 5.1 (3.3-8.0)
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Figures 1a, b and c display the results for the symptomatic patients versus the general 
Dutch population in three age groups: age 41 to 60 years (n=18); age 61 to 70 years 
(n=25); age over 70 years (n=86). In each age category almost all health domains were 
scored significantly lower than the general Dutch population except ‘Bodily Pain’. The 
‘Mental Component Summary’ in the younger patient group (age 41-60 years) was also 
comparable to the general population. More importantly, in most health domains the dif-
ferences compared to the general population were considerable especially in the 61-70 
years age group. E-Table 2 gives the exact norm-based scores and standard deviations of 
each group compared to the general Dutch population.
Figure 2 shows that quality of life outcomes in all domains are related to the NYHA 
classification. Asymptomatic patients showed a trend towards high scores in most domains 
compared to the general population, certainly given the higher mean age of the patients 
(71 vs 47 yrs). Patients in NYHA class II had lower scores on the ‘Physical Function’, ‘Role 
Physical’, ‘General Health’ and ‘Role Emotional’ scales. Patients in NYHA class III and IV 
had lower scores on all scales, and the differences compared with the general population 
were considerable. 
Echocardiographic measurements indicating stenosis severity –such as aortic valve area 
and maximal aortic jet velocity- were not related to either physical or mental health scores 
(data not shown).
Physical 
Component 
Summary
Mental 
Component  
Summary
Physical 
Function
Role 
Physical
Bodily    
Pain
General 
Health
Vitality
Social 
Function
Role 
Emotional
Mental 
Health
General Dutch population 41-60 yrs 48,4 51,6 49,8 48,0 48,4 48,8 53,6 50,0 50,1 50,4
Symptomatic patients 41-60 yrs (n=18) 41,2 48,5 41,1 40,7 48,1 40,1 47,9 43,5 44,0 46,7
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* p< 0.05
figure 1a: Quality of life of symptomatic patients with severe aortic stenosis (AS) aged 41-60 years 
(n=18) versus the general Dutch population aged 41-60 years.
* p<0.05 
Martijn BW6.indd   157 03-01-13   11:14
158
Physical 
Component 
Summary
Mental 
Component  
Summary
Physical 
Function
Role 
Physical
Bodily    
Pain
General 
Health
Vitality
Social 
Function
Role 
Emotional
Mental 
Health
General Dutch population >70 yrs   40,7 51,6 38,8 42,8 46,9 43,4 50,4 46,4 47,9 49,0
Symptomatic patients >70 yrs (n=86)    36,5 47,3 34,6 34,2 45,4 37,9 45,9 42,9 35,9 45,2
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* p< 0.05
figure 1c: Quality of life of symptomatic patients with severe aortic stenosis (AS) aged >70 years 
(n=86) versus the general Dutch population aged >70 years.
* p<0.05 
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Summary
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Component  
Summary
Physical 
Function
Role 
Physical
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Pain
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Health
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Function
Role 
Emotional
Mental 
Health
General Dutch population 61-70 yrs 44,1 53,2 44,4 45,9 47,9 44,8 53,2 49,3 49,9 51,1
Symptomatic patients 61-70 yrs (n=25) 36,2 47,8 34,8 34,3 46,7 36,0 47,0 41,6 36,1 46,6
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figure 1b: Quality of life of symptomatic patients with severe aortic stenosis (AS) aged 61-70 years 
(n=25) versus the general Dutch population aged 61-70 years.
* p<0.05 
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E-Table 2: Exact norm-based scores of symptomatic patients with severe aortic stenosis and the 
general Dutch population
Health Domain Norm-Based Score 
Symptomatic patients with severe aortic 
stenosis 
Norm-Based Score 
General Dutch population *
41-60 yrs
n=18
61-70 yrs
n=25
>70 yrs
n=86
41-60 yrs 61-70 yrs >70 yrs
Physical Component 
Summary
41.2 ± 9.9 36.2 ± 9.7 36.5 ± 9.8 48.4 44.1 40.7
Mental Component 
Summary
48.5 ± 9.9 47.8 ± 10.2 47.3 ± 12.7 51.6 53.2 51.6
Physical Function 41.1 ± 10.1 34.8 ± 10.1 34.6 ± 11.6 49.8 44.4 38.8
Role Physical 40.7 ± 10.5 34.3 ± 10.9 34.2 ± 11.1 48.0 45.9 42.8
Bodily Pain 48.1 ± 10.8 46.7 ± 12.3 45.4 ± 12.3 48.4 47.9 46.9
General Health 40.1 ± 8.1 36.0 ± 8.6 37.9 ± 9.0 48.8 44.8 43.4
Vitality 47.9 ± 10.2 47.0 ± 9.7 45.9 ± 12.1 53.6 53.2 50.4
Social Function 43.5 ± 10.6 41.6 ± 12.1 42.9 ± 13.7 50.0 49.3 46.4
Role Emotional 44.0 ± 13.9 36.1 ± 15.0 35.9 ± 15.3 50.1 49.9 47.9
Mental Health 46.7 ± 9.8 46.6 ± 11.1 45.2 ± 14.4 50.4 51.1 49.0
* Norm-Based Score calculated based on the paper by Aaronson et al 18
Physical 
Component
 Summary
Mental 
Component
 Summary
Physical 
Function
Role 
Physical
Bodily    
Pain
General 
Health
Vitality
Social 
Function
Role 
Emotional
Mental 
Health
Severe AS patients NYHA class 1 (n=59) 47,8 54,9 49,4 47,5 53,4 46,3 57,6 51,5 48,6 54,8
Severe AS patients NYHA class 2 (n=73) 43,0 50,2 42,8 41,3 50,0 41,3 51,8 48,0 41,9 48,3
Severe AS patients NYHA class 3 (n=49) 30,7 45,5 28,1 28,6 42,0 34,1 40,2 37,7 32,9 43,6
Severe AS patients NYHA class 4 (n=10) 26,5 41,6 22,7 24,3 37,0 31,0 38,0 31,2 25,2 40,2
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figure 2: Quality of life of patients with severe aortic stenosis (AS) according to symptomatic status. 
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dISCuSSIOn
Interpretation and discussion of main results
This study confirms the obvious finding that the quality of life decreases with increasing 
age  both in the general population and in the symptomatic severe AS patients (Figures 
1a, b and c). However, the key point is that the differences in quality of life between the 
general population and the symptomatic patients are large and remain significant for most 
health domains across all three age groups we studied. This indicates that patients in each 
age category suffer equally from severely impaired quality of life. 
While angina is one of the classical symptoms of aortic stenosis, it is notable that ‘Bodily 
Pain’ was scored almost normal, suggesting that pain itself only plays a modest role. This is 
confirmed by the anamnesis in which over 90% of the symptomatic patients complained 
of dyspnea or a combination of dyspnea and angina or syncope (Table 1).  The low scores 
on the ‘Role Physical’ domain indicate that patients do have severe physical constraints by 
dyspnea and that this affects daily life to great extent.
Not only the physical domains but also the mental health scores show large differences 
compared to normal. Figure 1b and 1c show that among patients aged over 60 years, the 
largest difference with the general population is observed in the ‘Role Emotional’ scale, 
meaning patients suffer from anxiety or a depressed state of mind which affects daily ac-
tivities. Also ‘Social Function’ is lower than normal. Apparently complaints are hampering 
patients in their social contacts e.g. visiting friends and relatives. Finally, the low ‘Vitality’ 
and ‘General Health’ scores indicate patients have lack of energy and a negative general 
view on their health.
There was no relation between stenosis severity and physical or mental quality of life 
in our patient cohort. Thus, whenever the aortic stenosis is above the ‘severe’ threshold, 
“objective” measures of aortic valve function do not correlate to functional status: the 
degree of stenosis does not predict disease burden. This is important to realize and relevant 
for clinical practice. However, we only studied the ‘severe’ category, therefore a relation 
between disease burden and stenosis severity in the whole patient population with either 
mild, moderate or severe aortic stenosis certainly cannot be ruled out. 
We did demonstrate that scores of the SF-36v2™ correspond well with the severity of 
symptoms according to NYHA classification (Figure 2). Asymptomatic patients don’t seem 
to have a worse health perception than the general population, especially on the mental 
part of the survey. Importantly, even patients in NYHA class II -thus having only ‘mild’ symp-
toms- experience clearly lower quality of life than asymptomatic patients or the general 
population. With the increase of the severity of the symptoms, scores are lower on both 
the physical and mental part of the survey. This is what one would expect and indicates 
that the SF-36v2™ is a valid measure of the quality of life in this patient population.
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Policy implication
As stated in the introduction, both American and European guidelines recommend AVR in 
symptomatic patients with severe aortic stenosis.9-10 Even elderly patients can be operated 
with acceptable risks of morbidity and mortality nowadays. They can expect improvement 
in functional class and prolonged survival compared to non-operated patients, and AVR is 
cost-effective.6-7, 16, 21-23 Still, 30 to 60% of (elderly) symptomatic patients with severe aortic 
stenosis do not undergo AVR.11, 21, 24-25 Exercise testing is reported to elicit symptoms in 
approximately 37% of all cardiac patients who were previously regarded ‘asymptomatic’.26 
However, although earlier advocated in asymptomatic aortic stenosis patients, exercise 
testing remains highly underused and shifted from a class 2a to a 2b recommendation 
in the ACC/AHA guidelines.9, 27 Therefore the proportion of patients who would deserve 
operative treatment could even be underestimated. 
There is a large variability between different risk models in cardiac surgery, and the 
one most commonly used (EuroSCORE) seems to overestimate the actual operative risk 
for AVR most.28 Perhaps this adds to the large variance in treatment advise that exists 
among cardiologists already found by Bouma et al.12 Previously we reported that part of 
the non-referral observed in current clinical practice is caused by patient refusal, by an 
overestimation of the anticipated operative risk and by misclassification of hemodynamic 
severity and symptomatic status.14 Years ago it has already been shown that doctors have 
difficulty to recognize functional disability in patients15 -not so much the symptoms them-
selves- and one could speculate this is even more true for emotional impairment. Although 
we are unable to draw any conclusions based on the results of the current study, one 
could hypothesize that underestimating the impact of symptoms or NYHA-class represents 
another cause to underestimate the need for treatment. Given the highly conservative 
approach of many cardiologists concerning symptomatic severe aortic stenosis, we feel 
that this burden should receive more attention.
Quality of life is of utmost importance for a patient, yet there is hardly any literature on 
this subject in patients with severe aortic stenosis. Some retrospective studies report on 
functional status and quality of life in patients after AVR: quality of life is supposed to be 
comparable to the normal population, and the major part of long-term survivors reported 
to be happy with the decision to be operated upon.7, 16, 29 In such studies all patients that 
did not survive on the long term cannot be included, while these are the most likely to have 
had a low quality of life before their death. Furthermore, these studies did not study quality 
of life in patients with aortic stenosis, but quality of life in patients with aortic stenosis who 
were referred (selected) for surgery. In our study we focussed not on the quality of life 
of –AVR selected- patients before or after AVR, but on the quality of life when the decision 
to operate or not is yet to be made. Therefore our results not only reflect the physical and 
mental state of the total patient group, but can also be used for decision making in the 
individual patient. A patient could fill in a questionnaire -online or on paper- prior to his or 
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hers doctor visit (www.qualitymetric.com). The cardiologist could then compare the results 
of the patient with the results of the general population, or with the results of similar 
patients (Figure 2a,b,c), and use this information in deciding whether or not to send the 
patient for AVR.
Limitations 
The study group described in this paper is a selected cohort. Although enrolment from the 
outpatient cardiology echocardiography departments was encouraged, some patients may 
not have been identified. We attempted to enrol every patient but were not able to do 
so because a substantial number of patients declined participation. Mostly these patients 
were the elderly, or the more sick patients for whom an extra study-trip to the hospital was 
unfeasible. Therefore it is likely that we even underestimated the magnitude of quality of 
life impairment in the total patient population with symptomatic severe aortic stenosis and 
are only able to present the tip of the iceberg.
A limitation of using the SF-36v2™ survey could be the number of questions. A minority 
of patients has difficulty answering the questions, mostly because they are somewhat 
time-consuming, and sometimes because the questions are regarded as ‘annoying’ or 
‘confronting’. Other useful -but often less specific- surveys have been developed, such as 
the EuroQOL survey, which contains only five questions and is therefore easier and faster 
to answer for the patient, and easier to analyze and interpret for the doctor (www.euroqol.
org).
COnCluSIOnS
Our results encourage to reconsider a conservative approach in symptomatic patients with 
severe aortic stenosis. If the aortic stenosis is above the ‘severe’ threshold, the degree 
of stenosis does not predict disease burden. This study provides a quantification of this 
burden, especially in symptomatic patients with severe aortic stenosis: even minor symp-
toms have major impact on patient well-being and result in a strongly impaired quality 
of life compared to the general population. Not only physical complaints affect daily life 
to a great extent, patients also suffer from emotional problems hampering normal daily 
activities and social functioning. When considering to send a patient for aortic valve re-
placement or to treat conservatively, one should not only consider the operative risks and 
the lifespan gained after AVR, but also the current state of the patient including his or hers 
physical and mental quality of life. A good way of doing this is by standardized surveys like 
the SF-36v2™. Using the SF-36v2TM Health Survey together with this study, an individual 
patient’s quality of life profile can be assessed and compared with the patient group or 
with the general population. This can assist in decision making for the individual patient.
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AbSTRACT
Background 
Although symptomatic patients with severe aortic stenosis have a high disease burden 
and guidelines recommend aortic valve replacement, many are treated conservatively. This 
study describes to what extent quality of life is changed by AVR relative to conservative 
treatment.  
Methods 
This observational study followed 132 symptomatic patients who were subjected to a SF-
36v2TM Health Survey. If patients were treated medically the survey was repeated 6, 12 
and 24 months after baseline; if they underwent aortic valve replacement, the survey was 
repeated 12 months after surgery.
Results 
At baseline 84 patients were treated conservatively, 48 were referred for AVR. In the 
conservative group 15 patients died during a mean follow-up of 18 months (Kaplan Meier 
survival was 85% and 72% at 1 and 2 years respectively) and 22 patients crossed over 
to the AVR group. Of the resulting 70 patients in the AVR group 3 patients died during 
a mean follow-up 11 months (survival 95% at 1 year). Physical functioning, vitality and 
general health improved significantly one year after AVR and emotional role showed a 
tendency toward improvement. In conservatively treated patients physical quality of life 
deteriorated significantly over time while general health, vitality and social functioning 
showed a declining trend. Mental health remained stable in both groups.
Conclusions 
AVR improves physical quality of life and vitality in patients with symptomatic severe AS, 
most evident in the physical health components, but also present in general health and 
vitality. Besides having a low life expectancy, conservatively treated patients experience 
deterioration of physical quality of life.
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InTROduCTIOn
Degenerative aortic stenosis (AS) is the most common valvular heart disease in developed 
countries. Aortic valve calcification increases with age and the prevalence of aortic stenosis 
increases concomitantly. Because the Western population continues to age, aortic stenosis 
constitutes a growing health burden.1 
The classical and most frequent symptoms of aortic stenosis are angina, syncope and 
dyspnea. Prognosis of symptomatic patients is poor when treated conservatively, and ac-
cording to the ACC/AHA and ESC guidelines patients should be referred for aortic valve 
replacement (AVR) without delay when they become symptomatic.2-3 However, in daily 
practice many symptomatic patients with severe aortic stenosis do not receive operative 
treatment.4-6 Underestimation of disease burden and the effect of AVR on quality of life 
could in part be responsible for the observed under-treatment, yet there is hardly any 
literature on this subject. Therefore it is important to investigate the quality of life of 
patients with severe AS and the outcome after surgical versus conservative treatment.
Previously we compared the quality of life of symptomatic patients with severe AS to 
the general age-matched population and found it is much lower: even mild symptoms 
result in both physical and emotional problems which have a major impact on normal 
daily life and social functioning.7 The objective of our current study is to investigate if -and 
to what extent- AVR improves this disease burden, and to compare these outcomes with 
the quality of life of the conservatively treated patients during follow-up. This is a novel 
approach compared to other studies, which only describe subgroups of patients selected 
for surgery.8-10
METhOdS 
Patients
Patients with severe aortic stenosis were recruited from the outpatient clinics of 7 hospitals 
in the Rotterdam region in the Netherlands from July 2006 until April 2009. Patients were 
included if one of the following echocardiographic criteria for severe aortic stenosis were 
met: aortic valve area ≤ 1 cm2, maximal trans aortic jet velocity ≥ 4 m/s, peak aortic gradi-
ent ≥ 64 mmHg, aortic valve / left ventricular outflow tract velocity time integral ratio ≥ 4.
The current study is part of a larger prospective observational cohort study in which 
patients who fulfilled the described criteria were invited to our hospital for several clinical 
investigations and a quality of life assessment. Patients were categorized according to 
New York Heart Association (NYHA) classification by the investigators and relevant medi-
cal history was documented. Based on patient characteristics and medical history -and 
for descriptive purposes only- an anticipated operative mortality was calculated using the 
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EuroSCORE model (www.euroscore.org). This paper focuses on the on the quality of life, 
measured by the SF-36v2TM Health Survey at different points in time, of the symptomatic 
subgroup of the described population with severe aortic stenosis.
After the baseline measurements, patients were followed to register treatment selection, 
major adverse cardiac events and survival. Since the design of this study was strictly obser-
vational, the investigators did not interfere with treatment selection. For observational and 
analysis purposes we divided patients into 2 groups: an AVR group and a conservatively/
medically treated group. Unless they had AVR or died in the meanwhile, medically treated 
patients were re-invited to our hospital after 6, 12 and 24 months to be examined again. 
Patients who were referred for AVR (by their treating cardiologist) were re-invited only 
once, namely one year after AVR. Patients who were initially treated conservatively but 
referred for AVR later on, were accounted for in the conservative group and crossed over 
to the AVR group at the time of operation (and therefore accounted for in both groups). 
Because the distinction between both groups is based on selection, we deliberately chose 
not to compare baseline characteristics or survival between both groups and therefore 
no p-values or log-rank tests are given. In the patients who crossed to the AVR group, 
all measurements of the last ‘conservative’ visit (both of the SF-36v2TM Health Survey and 
echocardiography data) were carried forward as ‘pre-AVR measurements’. By doing so all 
AVR patients had recent pre-operative data, instead of data collected at the start of the 
study. Follow-up of the entire patient cohort continued until May 1st 2011.
AVR patients generally had conventional AVR through a median sternotomy using extra 
corporal circulation, cold crystalloid cardioplegia and mild hypothermia. A minority of AVR 
patients had a percutaneous valve implantation, using the retrograde transfemoral ap-
proach and a Core Valve® device. Transapical valve implantations were performed through 
a small intercostal incision. All procedures were performed electively.
The study protocol was approved by the institutional ethical committee (MEC 2006-066) 
and all patients provided written informed consent.
Quality of life measurement
The SF-36v2™ Health Survey is a validated, well accepted and widely used questionnaire 
originating from the Medical Outcomes Study.11 The survey consists of 36 multiple-choice 
health-related questions, grouped into eight multi-item domains measuring quality in dif-
ferent aspects of daily life: ‘Physical Functioning’, physical health related to age- and role-
specific activities termed ’Role-Physical’, ‘Bodily Pain’, ‘General Health’, ‘Vitality’, ‘Social 
Functioning’, personal feelings of performance in age- and role-specific activities termed 
’Role-Emotional’, and ‘Mental Health’. 
The eight domains form two main components according to physical and mental health. 
The ‘Physical Functioning’, ‘Role Physical’ and ‘Bodily Pain’ domains contribute most to 
the scoring of the ‘Physical Component Summary’ measure, but also a little -negatively- to 
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the ‘Mental Component Summary’. The ‘Mental Health’, ‘Role Emotional’, and ‘Social 
Functioning’ domains contribute most to the scoring of the ‘Mental Component Summary’ 
measure, and a little –also negatively- to the ‘Physical Component Summary’. 
Comparing quality of life results of (long-term) survivors with the results of all patients 
alive at baseline, constitutes a bias since a selection of the healthier patients takes place 
over time. Therefore patients who died or denied participation in a certain time-interval 
–either in the AVR or in the conservative group- were withdrawn for comparisons of health 
survey results over that time-interval. 
Statistics
For the statistical analyses SPSS 17.0 software was used (SPSS Inc.). Continuous variables 
with a normal distribution are displayed as means ± standard deviation. If data were not 
normally distributed the median and interquartile range are given. Categorical variables are 
displayed as percentages. 
Raw SF-36v2™ scores are linearly and step-wise converted to a norm-based score from 
0-100 in which 50 represents the mean score of the general population in the United 
States and 10 points on the scale correspond to 1 standard deviation. When compar-
ing group-data to the norm or to other groups, a difference of more than 3 points on 
this norm-based scale (corresponding to a difference of 0.3 SD) is generally considered 
significant, while 8 points or more indicate the difference between the groups is large.12-13 
A detailed explanation regarding data collection, scoring, interpretation and validation 
of the SF-36v2™ is given by Ware et al.12 Previously Dutch norms have been established 
by Aaronson et al.14 by using the first version of the SF-36 Health Survey. Their scores are 
raw SF-36 scores and have been transformed to norm-based-scores to allow for useful 
comparison in this paper.
Paired t-test analyses were used to compare quality of life outcomes between different 
points in time within each group. P values lower than 0.05 were considered statistically 
significant. 
Survival was explored using Kaplan Meier analysis in patients who had AVR during 
follow-up and separately in conservatively treated patients.
RESulTS
Details on categorisation of patients and follow-up are displayed in the flow chart (Figure 
1). Of all 191 participating patients with severe aortic stenosis, the symptomatic patients 
(n=132) formed the current study group. At baseline, 84 of them were treated conserva-
tively and 48 were referred for AVR. Their baseline characteristics are given in Table 1.
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figure 1: Flow Chart
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The baseline quality of life in the AVR group was slightly worse over all health domains 
compared to the baseline of the conservative group (Figure 2). Figure 2 also shows that 
quality of life in both groups was much worse over all health domains compared to the 
general age-matched Dutch population, except for ‘Bodily pain’ (data presented previously 
7).
Conservative group
Of the study cohort, 84 symptomatic patients were initially treated medically. In this group 
15 patients died during a mean follow-up of 18 months, of whom nine died within one 
year. A total of 22 patients were referred for AVR after initial conservative treatment, 
therefore these patients crossed over to the AVR group (Figure 1). Sixty-seven patients 
completed the SF-36v2TM Health Survey after 6 months, 58 after one year and 30 after two 
years of conservative treatment. Kaplan-Meier survival in the conservative group was 85% 
at one year and 72% at two years. 
In medically treated patients who survived and were able to complete the follow-up 
questionnaires, the quality of life remained virtually unchanged across all health domains 
Table 1: Patient characteristics
    Conservative (n=84) AVR (n=70)
Mean follow-up (months) 19.6 (± 10.1) 22.2 (± 10.7)
Mean age (years) 73.2 (± 10.9) 67.8 (± 12.2)
Male gender (%) 61 49
NYHA class (%)
 II
 III
 IV
Mean NYHA class
62
32
6
2.4 (± 0.6)
45
45
9
2.6 (± 0.7)
Logistic EuroSCORE 8.2 (± 6.3) 6.0 (± 6.0)
Echocardiography
 Vmax (m/s)
 Peak gradient (mmHg)
 Mean gradient (mmHg)
 AVA (cm2)
 AV/LVOT VTI ratio
 EF (%)
4.1 (± 0.7)
68.0 (± 23.7)
38.5 (± 13.6)
0.76 (± 0.25)
4.5 (± 1.4)
52.2 (± 12.8)
4.6 (± 0.8)
88.3 (± 32.5)
50.8 (± 20.1)
0.74 (± 0.31)
4.7 (± 1.7)
48.3 (± 11.5)
Medical history (%)
 Smoking (current or past)
 DM
 Renal failure / dialysis
 Hypertension
 Dyslipidaemia
 COPD
 CVA (infarction/bleeding)
 OHO in past
60.0
18.8
11.8 / 2.4
60.0
51.8
20.0
4.7
7.1
53.0
15.1
6.1 / 0
43.9
48.5
19.7
7.6
6.1
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Physical 
Component 
Summary
Mental 
Component 
Summary
Physical 
Functioning
Role Physical Bodily Pain
General 
Health
Vitality
Social 
Functioning
Role 
Emotional
Mental 
Health
Baseline 39,1 49,3 38,1 37,3 48,1 39,0 48,0 45,0 40,0 47,5
6 months  37,0 48,4 36,4 35,9 45,3 37,1 47,0 43,5 37,4 46,9
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60
N
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m
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re *
*
* p< 0.05
figure 3a: QOL of conservative group, baseline vs 6 months
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Summary
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Summary
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Functioning
Role Physical Bodily Pain
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Health
Vitality
Social 
Functioning
Role 
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Mental Health
AVR group
25
30
35
40
45
50
55
60
N
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m
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ed
 S
co
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Conservative group
36.3 47.6 35.4 34.3 45.4 36.5 44.9 43.3 37.8 45.3
37.7 48.8 36.5 36.1 46.8 38.1 47.8 43.7 38.6 46.8
45.1 52.0 45.1 44.0 49.7 45.6 54.7 49.0 47.1 51.1
41.8 50.1 39.7 40.0 48.6 44.3 51.7 46.2 44.0 48.9
Dutch norm 61-70yrs
Dutch norm >70 yrs
figure 2: Baseline QoL vs general population
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Physical 
Component 
Summary
Mental 
Component 
Summary
Physical 
Functioning
Role Physical Bodily Pain
General 
Health
Vitality
Social 
Functioning
Role 
Emotional
Mental 
Health
Baseline 39,1 50,1 38,1 37,9 48,5 38,9 49,0 45,6 40,7 48,2
12 months 37,9 49,4 36,4 36,7 47,3 38,2 48,5 44,5 38,9 47,3
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figure 3b: QOL of conservative group, baseline vs 12 months
Physical 
Component 
Summary
Mental 
Component 
Summary
Physical 
Functioning
Role Physical Bodily Pain
General 
Health
Vitality
Social 
Functioning
Role 
Emotional
Mental 
Health
Baseline 40,3 49,3 38,6 39,1 48,4 40,4 49,1 46,7 39,6 47,0
24 months                      35,9 49,6 34,1 33,8 46,3 38,2 48,1 43,8 37,5 47,3
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35
40
45
50
55
60
N
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m
 B
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*
* *
* p< 0.05
figure 3c: QOL of conservative group, baseline vs 24 months
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until one year after baseline visit (please see Figure 3a and b). The 30 patients who reached 
two years of follow-up and were able and willing to complete a survey at that time, 
showed worsening of their physical health outcomes. The ‘Physical Component Summary’ 
is significantly worse after two years compared to the baseline value. The physical subscales 
‘Physical Functioning’, ‘Role Physical’, are significantly worse but ‘Bodily Pain’, ‘General 
Health’, ‘Vitality’ and ‘Social Function’ only show a tendency to worsen yet not significant 
with these small numbers of patients. ‘Mental Health’ remains stable (Figure 3c). 
AVR patients
Initially 48 patients were referred for AVR within six months, during follow-up another 
22 patients who were initially treated conservatively were referred for AVR (Figure 1). 
Sixty-two patients had conventional AVR, five had a percutaneous and one patient had a 
transapical valve implantation. Thirty-day mortality was zero but three patients died within 
one year after AVR. The mean follow-up in the AVR group was 11 months. Kaplan-Meier 
survival was 95% at one year. Fifty-nine patients completed the survey one year after AVR 
(Figure 1). 
Quality of life in surviving AVR patients improves in most health domains (Figure 4). Es-
pecially the physical components have improved, as reflected by the ‘Physical Component 
Summary’ but also ‘Vitality’ and ‘General Health’ scales are significantly better than pre-
operatively. ‘Physical functioning’, ‘Bodily pain’, ‘General health’ and ‘Vitality’ approach 
Physical 
Component 
Summary
Mental 
Component 
Summary
Physical 
Functioning
Role Physical Bodily Pain
General 
Health
Vitality
Social 
Functioning
Role 
Emotional
Mental 
Health
Before AVR 37,7 48,9 36,8 36,2 46,6 38,0 46,5 45,1 38,5 47,0
12 months after AVR     44,3 47,2 43,5 41,4 48,6 43,6 50,6 45,0 41,3 45,0
25
30
35
40
45
50
55
60
N
or
m
 B
as
ed
 S
co
re
* *
*
*
*
* p< 0.05
figure 4: QOL of AVR group, before vs 12 months after AVR
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the scores of the general age-matched Dutch population. The ‘Role Emotional’ scale shows 
a trend towards improvement yet not significant, ‘Mental Health’ and ‘Social Functioning’ 
remained unchanged. 
dISCuSSIOn
Quality of life in symptomatic patients with severe aortic stenosis is lower in almost all 
health domains than in the age-matched general Dutch population, both in patients 
selected for surgery as well as conservatively treated patients. This has been discussed 
more elaborately in a previous paper, in which we also showed a clear association between 
NYHA class and the SF-36v2TM outcomes.7
Conservative group
The conservatively treated patients who survived 2 years showed a slight deterioration of 
their physical health status after one and two years. Yet the degree of deterioration seems 
to be less than what might be expected based on the low life expectancy of symptomatic 
AS patients reported in literature.15-16 However, besides a higher mortality also the number 
of patients that were not capable to complete the subsequent questionnaires is larger 
in the conservative group compared to the AVR group. The baseline quality of life of 
these withdrawn patients was lower than that of the rest of the group (data not shown). 
Therefore the observed quality of life in our study overestimates the real quality of life over 
time in the total conservative group.
AVR group
Although patients in the conservative group are older, the quality of life of the AVR patients 
seems slightly lower at baseline (Figure 2). This is a reflection of clinical practice in which 
patients with severe symptoms are more likely to be referred for surgery than the ones who 
have only mild symptoms. 
The patients who had AVR and were alive at one year follow-up, showed a markedly im-
proved quality of life after one year compared to pre-operatively, except in ‘Mental Health’. 
The improvement is quite large in the physical domains, and -although not significant- a 
positive trend is clearly visible in the ‘Bodily Pain’ and ‘Role Emotional’ scales.  
We assumed a period of one year after AVR would be enough to eliminate most direct 
postoperative emotional problems, and assumed a relatively stable health after that period. 
It is interesting to see that ‘Mental health’ does not improve after AVR, and remains much 
lower than in the age-matched general population. Whether concentration, memory, emo-
tional or other cognitive problems are at the basis of this observation, and whether this 
could be explained by the operation or postoperative recovery remains only speculative. 
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Implications
Patients who are selected for AVR have a (non-significant) lower baseline quality of life 
as measured by the SF-36v2TM, a higher NYHA classification and a lower risk score than 
conservatively treated patients. Therefore the gain of surgery in the former group might 
be higher than it would be in patients who are currently treated conservatively. Colak et 
al. described that high-risk cardiac surgery patients (predominantly CABG) have a lower 
pre-operative quality of life and greater improvement after surgery than low-risk patients.17 
At first sight this seems in contrast with our findings, however it is important to realize that 
Colak’s patients –although high risk- were already accepted for surgery. 
Whether the improved quality of life in operated patients can be extrapolated to the 
total symptomatic population with severe aortic stenosis remains yet a matter of debate. 
From these data it cannot be determined how the outcomes, both in terms of survival 
and quality of life, would have been supposed all patients would have had AVR. Such 
a scenario probably results in lower survival and lower quality of life than is currently 
observed in the AVR group one year postoperatively, but it could show improved overall 
survival and improved quality of life in the total group of symptomatic AS patients. In 
reality, some (elderly) patients are not surgical candidates or simply refuse to be operated 
upon. Therefore projection of the study results to the entire symptomatic patient popula-
tion is only speculative. 
On the other hand one could argue that current treatment selection seems good: in the 
patients who were selected for AVR, the quality of life improves over several domains after 
AVR. Compared to other reports in literature the observed mortality in the conservative 
group is low and the presented quality of life outcomes in the surviving patients show only 
a slowly and borderline significant deteriorating quality of life over time.15-16 
Timing of surgery in patients with aortic stenosis is an important and continuing issue 
of debate. An underestimation by the treating physician of the impact of symptoms on a 
patient’s quality of life might be one of the reasons why so many symptomatic patients 
with severe aortic stenosis are not referred for surgery. Based on our previous study and 
the current paper, we argue in favour of using quality of life survey’s in the pre-operative 
assessment when the choice between surgery or conservative treatment has to be made.6,7 
Literature
Although other studies describe quality of life in cardiac surgery patients,8-10, 18-23 quality 
of life studies by objective survey’s such as the SF-36v2TM have -to our knowledge- not 
been performed in patients who have (symptomatic) aortic valve disease and in whom the 
decision to operate or not is yet to be made. Most studies we found did not study quality 
of life in patients with aortic stenosis, but quality of life in patients with aortic stenosis who 
were referred (selected) for surgery. Some of them describe quality of life only in long-term 
survivors after intervention and do not have a baseline (pre-operative) value.18-19 In such 
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designs all patients that did not survive on the long term can obviously not be included, 
while these are the most likely to have had a low quality of life before their death. 
Some studies use NYHA classifications as raw reflection of quality of life rather than 
objective health survey’s, other studies only concern selective subgroups.18, 22-23 The NYHA 
classification is a functional measurement of physical performance or pain, and roughly 
reflects one’s current health status but certainly not one’s desired health status or disease 
burden. Especially the social and emotional aspects are underreported and not taken into 
account in the New York Heart Association (NYHA) classification. In contrast, the SF-36v2TM 
Health Survey is an objective and validated questionnaire, available in multiple languages 
and widely used. It describes multiple physical and emotional domains (not just Physical 
Component Summary and Mental Component Summary) and is therefore a better and 
more objective reflection of one’s health status than simply using the NYHA classification. 
Perhaps most important, comparison of quality of life in long-term survivors with the 
general age-matched population might be interesting,18-19, 21, 23 but is not entirely fair since 
the patients who have deceased were more likely to have had a lower quality of life before 
death. Such analyses constitute a selection bias in which only the healthier patients are 
subjected to a survey (survival of the fittest).
Limitations
For adequate functional and echocardiographic assessment we believed it to be necessary 
to invite the patients to our hospital each time a quality of life assessment was done. We 
attempted to enrol every identified patient but were not able to do so because a substan-
tial number of patients denied participation because of perceived high burden of the extra 
study hospital visits. Often these were the elderly, more sick patients for whom an extra 
study-trip to the hospital was unfeasible. Therefore it is likely that we underestimated the 
magnitude of quality of life impairment in the total patient population with symptomatic 
severe aortic stenosis. 
We described only the symptomatic subgroup of patients with severe aortic stenosis. In 
doing so we described patients with one primary aetiology -severe aortic valve stenosis- and 
therefore our results may not be applicable to patients with a different primary disease. 
An obvious limitation is the fact that some of the patients –and most likely those with 
low quality of life- die or refuse further cooperation over time which precludes further 
observations.  
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COnCluSIOnS 
AVR offers improved quality of life in selected symptomatic patients with severe aortic 
stenosis. The beneficial effect is most evident in the physical components, but also general 
health perception, vitality and emotional aspects improve after AVR to the level of the 
general age-matched population. Mental health remained one year after AVR. In conserva-
tively treated patients who survive on the long term, especially the physical quality of life 
worsens over time.
Besides considering life-expectancy and risks with either conservative or operative treat-
ment, quality of life should be taken into account when making treatment decisions in 
patients with severe aortic stenosis. A health survey like the SF-36v2TM could be a valuable 
tool in monitoring the burden of disease for an individual patient and offer additional help 
in decision making. Whenever the health survey shows a large deviation from normal or 
signs of increasing disease burden, one should consider an interventional conservative 
approach.
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InTROduCTIOn
The shifting age demographic of the adult population has affected every area of contem-
porary medical and surgical practice. Many more people are living well, not just into their 
70s but into their 80s and beyond. Their expectations of treatment for every illness have 
shifted markedly upwards at the same time. Despite the decline in cases of rheumatic 
fever in Westernised populations in recent times, the ageing population has led to no 
decline in the prevalence of valvular aortic stenosis. This is now realised to be an active 
pro-inflammatory disease, rather than a degenerative process. Thus the condition has 
remained in the mainstream and continues to be responsible for considerable morbidity, 
hospitalisation and mortality among the elderly and very elderly.
Management has always been based on the triage of cases for direct intervention to the 
valve by surgery. Just as expectations have risen from patients, the techniques, application 
and monitoring of cardiac surgery have also made huge strides forward to meet this aspira-
tion. More and more, surgeons are routinely asked to consider procedures in frailer, more 
elderly patients with more severe disease and co-morbidity. Managing the stenosis is rarely 
the only issue confronting the operating surgeon. Attempts to provide alternatives to open 
valve replacement surgery on cardiopulmonary bypass have now emerged. These are based 
around the transcutaneous placement of a valve prosthesis. While these technologies were 
initially highly selective in their application, they have now reached a stage to be compared 
with contemporary standards of cardiac surgical practice. In this debate we have invited 
two international experts from the fields of cardiac surgery (Professor Jahangiri) and inter-
ventional cardiology (Professor Kappetein and colleagues) to take deliberately opposing 
positions on the evolving management of valvular aortic stenosis in the very elderly. We 
have asked them to try to consider the strengths of each route. Both approaches provide 
options for patients that only a few years ago might have been regarded as essentially 
untreatable.
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TAvI And SuRGERy In hIGh-RISk AORTIC vAlvE PATIEnTS
M Jahangiri
With the advent of transcatheter aortic valve implantation (TAVI) and its recent expansion,I,2 
the number of patients being referred for the management of aortic valve (AV) disease has 
increased. It is also perceived that the less invasive TAVI is associated with better outcomes. 
Previously medically managed patients with AV disease are now being referred for inter-
vention. A European heart survey on valvular heart disease showed that 33% of patients 
with severe symptomatic aortic stenosis (AS) did not undergo surgery.3 Other surveys have 
shown that approximately half of patients with severe AS did not undergo surgery, where 
the operative risks were thought to be 5-I2%.4 This may be due to a lack of knowledge 
of referring physicians about surgical risk scoring and the results of surgery. Bach and 
colleagues reported that among 30 patients who were thought to have prohibitive risks 
for surgery, calculated operative risk was less than 5% in II and less than I0% in I7 of them 
and only half were evaluated by surgeons.4
The advent of TAVI has created a resurgence of interest in the multidisciplinary meeting 
as a process. There are several reports of outcome of patients who have undergone TAVI.2,5
The risk of aortic valve replacement (AVR) in octogenarians is reported to be approxi-
mately 5-8%.6 In the national database of cardiac surgery over a six-year period, this figure 
was approximately 5.5%, with the overall risk of stroke less than 2%.1 2 
To this date, data from various registries from both the UK and other surveys within 
Europe7 show comparable mortality and length of hospital stay for both TAVI and surgical 
AVR. However, the risk of stroke in TAVI (6-8%) is significantly higher than in patients 
undergoing surgical AVR (2%). In a recent study, cerebral ischaemia was assessed by 
neurological testing and serial cerebral diffusion-weighted magnetic resonance imaging in 
patients who underwent TAVI compared with AVR.8 The authors detected clinically silent 
new foci of restricted diffusion on magnetic resonance imaging in 84% of TAVI patients 
with a multiple dispersed pattern suggesting cerebral embolisation. This may be due to the 
showering of emboli from the aorta, particularly the arch, or the dislodgement of aortic 
leaflet plaques. If emboli from the arch play a more significant role, it may be that transapi-
cal delivery systems potentially reduce the risks of embolisation. Some have suggested 
the use of distal protection devices to prevent emboli reaching the brain.9 However, the 
potential benefits of these future devices have to be balanced against their own invasive-
ness, prolongation of the procedure and existing results of surgery.
Furthermore, the need for pacemaker implantation following TAVI, especially with some 
of the devices, such as CoreValve, is as high as 25% in the TAVI population, compared with 
nearly zero in surgical patients. Additionally, up to half of TAVI patients develop mild to 
moderate aortic regurgitation following the procedure.7,9
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Although data from registries are not randomised and therefore subject to the inherent 
deficiencies of non-randomised studies, they reflect ‘real-world’ practice. Some of the data 
from the ‘real-world’ practice include outcomes of all high-risk patients discussed at multi-
disciplinary meetings for consideration of TAVI. There are as yet no randomised studies 
to compare the outcome of patients undergoing surgical AVR and TAVI, particularly the 
quality of life following treatment. The results of the PARTNER trial in the US, a large ran-
domised trial comparing TAVI with surgical AVR in patients suitable for both, are pending.
The new techniques of surgery, including mini-AVR and sutureless valves, deserve at-
tention. The mini-AVR is performed via a limited sternotomy or a small right-sided lateral 
thoracotomy. Several large studies have shown excellent outcomes, especially shorter time 
to extubation and improved pulmonary function.I0 The future sutureless valves will also 
allow shorter cross clamp and cardiopulmonary bypass times.
An expanding and promising use of TAVI is in patients with previous cardiac surgery, be 
it coronary artery bypass graft or valvular heart surgery where there are patent grafts or a 
malfunctioning tissue prosthesis present, the so-called valve-in-valve procedure. The risk of 
re-do surgery, particularly in the elderly, in this cohort can be high. However, the age of the 
patient and complexity of the operation should be weighed against the potential durabil-
ity and complications of the transcatheter valve. The notion that all patients who have 
undergone previous cardiac surgery no longer qualify for re-do operations is not correct.
Transcatheter AV implantation is a promising and important development in the field 
of cardiovascular intervention. However, its current reported mortality, significantly higher 
stroke rate, mild to moderate aortic regurgitation and a high rate of pacemaker implanta-
tion should be considered before its wider application, especially to a younger population. 
This is particularly important considering the very good results of surgery in the UK for AV 
disease. Furthermore, the referring physicians should be made aware of the current very 
good results of surgery in the elderly.
Transcatheter AV implantation is a promising development. Its use must be considered 
in the setting of a multidisciplinary meeting where interventional and non-interventional 
cardiologists and cardiac surgeons are present.
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ThE EvOluTIOn Of AdvAnCEd TEChnIquES fOR MAnAGEMEnT 
Of SyMPTOMATIC AORTIC STEnOSIS In ThE EldERly POPulATIOn. 
PROMISInG RESulTS WITh TRAnSCAThETER vAlvE IMPlAnTATIOn, buT 
MORE dATA ARE nEEdEd
A. Pieter Kappetein, Martijn W.A. van Geldorp, Ad J.J.C. Bogers
Aortic valve stenosis (AS) is the most frequent valvular heart disease in the adult population 
in developed countries affecting approximately 2 to 4% of people over 65 years of age1 2. 
Increased life expectancy has resulted in a growing elderly population and, consequently, 
an increase in the number of patients with aortic valve disease. This results in approxi-
mately 3 million people with AS in Europe alone. One in five will eventually progress to 
symptomatic AS representing 600,000 patients. 
Once symptoms appear, the prognosis is very poor. Median survival averages only 2- 
5 years after symptom onset of angina, syncope and heart failure.3 Medical therapy is 
unlikely to modify the course of the disease, especially once symptoms or left ventricular 
dysfunction become manifest. Balloon aortic valvuloplasty has only a limited role in the 
treatment of AS, as the results are not long-lasting.4 Surgical aortic valve replacement 
(AVR) is the reference treatment and guidelines on valvular heart disease stress the need 
for surgical aortic valve replacement (SAVR) once symptoms develop or in case of impaired 
LV function (Level of evidence grade 1).5 6 
Despite these well-established guidelines, one in every three patients with symptom-
atic AS is not offered surgery mostly because of age, left ventricular dysfunction and 
co-morbidities.7 8 Elderly patients and patients suffering from severe co-morbidities face 
higher operative risks and this definitely underscores an unmet clinical need. Undoubtedly 
this reality and patients’ and physicians’ preferences for lesser invasive strategies have 
fuelled the on-going interest in developing minimally invasive therapies. Minimised access 
AVR was established, which decreased surgical trauma, but still required extracorporeal 
circulation with its associated complications.
Transcatheter aortic valve implantation (TAVI) met the need for a less-invasive solution to 
treat severe aortic stenosis in the high-risk elderly population, in whom few options were 
available. Feasibility studies validated the proof of concept.9 10 There are now 2 different 
TAVI systems clinically available with CE mark approval since 2007, Edwards SAPIEN valve 
(Edwards Life Sciences, Irvine) and CoreValve (Medtronic, Minneapolis).  Numerous single-
centre and multi-centre observational registries followed with dazzling speed suggesting 
the safety and efficacy of the TAVI technology.11 12 
The availability of both trans-femoral and transapical approaches increased the number of 
those patients, in comparison with the use of the trans-femoral approach alone. Although 
the mortality rate with TAVI was higher in earlier reports, the 30-day mortality of around 
8% in patients with high or prohibitive operative risk appears promising and resembles 
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short-term outcome in high-risk cohorts in the surgical literature.13-16 The SOURCE registry, 
which has the largest patient population reported a 30 day mortality of 8.5%, with respec-
tive mortality rates of 6.3% and 10.3% in the transfemoral and transapical groups.17
Numerous studies have documented a dramatic reduction in the left ventricle–aortic 
gradient and a marked increase in the valve area. On the basis of postoperative echocar-
diograms, the effective orifice area of the transcatheter prosthesis is as good as, if not 
better than, that of valves placed in open surgery.17 The only concern is a higher incidence 
of paravalvular leakage. A less than grade 2+ regurgitation seems to be well tolerated 
without heart failure or hemolysis, but the long-term effect remains unclear. 
This innovation in cardiovascular therapeutics has been a collaborative effort by both 
interventional cardiologists and surgeons and has resulted in a rapid acceptance of TAVI 
in Europe. The TAVI technology comes with its own complications: vascular injury, stroke, 
cardiac injury, malposition, coronary obstruction, cardiac perforation, aortic regurgitation 
and heart block. The non-uniformity in presenting respective data makes comparison of 
results from different centres hazardous and impractical.18 The Valvular Academic Research 
Consortium, a FDA approved collaboration between academic research organizations and 
professional societies in the United States and Europe is an initiative to generate a consen-
sus statement on TAVI related definitions aiming to create order and uniformity making 
data more prone to analysis and comparison.
Technical refinements and commercial entrepreneurship have made the technology ac-
cessible to many centres worldwide. This might pose future implications especially in the 
current era where randomized trials with TAVI are strikingly lacking. 
Randomized controlled trials comparing TAVI with SAVR with longer follow-up are 
the next step and will help to better define the safety and durability, and subsequently, 
indications of the technique, and the respective places of transfemoral and transapical 
approaches.
The ongoing PARTNER trial (Placement of AoRTic TraNscathetER Valve Trial) in the United 
States is the first to randomize patients. In Cohort B inoperable patients are randomized to 
TAVI or medical therapy whereas in Cohort A patients with high operative risk are random-
ized to SAVR or TAVI. The trial completed its randomization early 2009. One-year outcome 
results will be reported in the forthcoming months. By study design, findings will only apply 
to this highly selected patient cohort representing only a fraction of the global AS burden.
For a new technology to be accepted as a new asset in the armamentarium for treating 
symptomatic AS several essential questions need to be answered: does the technology 
work? Which patients are likely to benefit (patient selection)? How does this new strategy 
compare with the alternatives? And what’s the cost of the intervention? The proof of 
concept has been validated. The innovative less invasive transcatheter strategy should be 
at least as effective but safer than traditional SAVR or have proof of superiority for both 
safety and efficacy compared to medical therapy. 
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While anticipating the results of the Partner US trial, over 18000 patients worldwide 
have been treated with TAVI by May 2010. Currently, TAV is restricted to elderly patients 
who are considered at very high risk for conventional surgery but unavoidably, with in-
creased operator experience and access to the device, physicians will shift their attention 
to younger patients with a less pronounced operative risk. Similar to what happened in the 
coronary revascularization arena19 the blending of surgical and interventional expertise has 
created unique interdisciplinary dynamics reinforcing these new endeavours and paving 
the way for a randomized trial comparing TAVI with SAVR in a surgical moderate to high-
risk patient population. 
In high-risk patients, TAVI meets the criteria of ease of insertion, safety, and excellent 
orifice area but for lower risk patients a new randomized trial is necessary. The objective 
of the so called SURTAVI trial is to assess whether in patients with symptomatic severe 
aortic stenosis and at intermediate risk, Transcatheter Aortic Valve Implantation (TAVI) is 
non-inferior to Surgical Aortic Valve Replacement (SAVR) with respect to the event free 
survival time of the combined endpoint of all-cause mortality and stroke at a median 
follow-up duration of 2 years. Ultimately these patients need to be followed for a longer 
time to determine long-term durability of these valves.
Secondary objective is to compare patients with symptomatic severe aortic stenosis 
and at intermediate risk treated with TAVI to SAVR with respect to quality of life, clinical 
benefit, and health economics.
The interdisciplinary approach with cooperation between surgeons, cardiologists, and 
anaesthesiologists, the so-called Heart Team, is crucial in this trial. This team will decide 
whether patients with intermediate risk can be randomized. If in opinion of the heart team 
the surgical risk is deemed low, the patient will be operated. In case the interdisciplin-
ary team judges the risk too high for surgery the patient will receive TAVI and for those 
patients where there is doubt which treatment offers the best outcome the patient will be 
randomized. This SURTAVI trial is likely to start in 2011.
Theoretical benefits of these transcatheter instrumentations in a beating heart avoiding 
the need of musculoskeletal incisions, cardioplegic arrest, aortic cross clamping, full car-
diopulmonary bypass (including subsequent LV septal motion abnormality) seem evident. 
Ultimately the cost-effectiveness will determine whether the new treatment strategy is a 
valid option to be considered for reimbursement by governmental health institutions. The 
price–tag of the device is essential and will ideally cover the company’s capital investment 
made during research and development. The cost-effectiveness relationship will only be-
come favourable once competitive companies enter the market and introduce alternative 
devices at lower prices. Randomized trials that address these issues are needed now.
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AbSTRACT
This thesis describes the current knowledge on the pathology and progression of aortic 
stenosis, the clinical presentation of patients with this disease and the currently available 
treatment options. One could call this widely used approach “the doctor perspective”.
Perhaps more important, this thesis intends to highlight aortic stenosis from another 
point of view: “the patient perspective”. Whenever a patient is confronted with the deci-
sion to perform surgical aortic valve replacement, often the choice between a mechanical 
or biological valve prosthesis remains a difficult issue. Use of the microsimulation meth-
odology as presented in this thesis facilitates patient counseling by providing more -and 
for the patient understandable- insight in (event-free) life expectancy after AVR with a 
certain prosthesis. Besides exploring prognosis in terms of quantity of life, quality of life of 
patients with severe aortic stenosis was studied over time, both for surgically and medically 
treated patients. When studying treatment utilization we observed that many patients 
are not offered surgical treatment although new techniques to correct aortic stenosis are 
rapidly emerging. By identifying several modifiable determinants of treatment utilization, 
we hope that eventually more patients are offered some form of treatment or at least are 
well informed about their options. 
The next section discusses in more detail the research questions as they were posed 
in the introduction, and provides general conclusions and recommendations for future 
research.
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‘nATuRAl hISTORy’ Of AORTIC STEnOSIS
Aortic stenosis (AS) is the most common valvular heart disease in developed countries. 
Nowadays its cause is mostly degenerative, and while aortic valve calcification increases 
with age, the prevalence of severe aortic stenosis increases concomitantly. Prevalence 
estimates range from 1% in people below the age of 65 years, to 2-3% in those aged 
75-85 years and to nearly 6% in people who are over 85 years.1-2
In the past, many papers have attempted to describe the ‘natural history’ of aortic steno-
sis,3-9 something that might have been possible five decades ago when treatment options 
were very limited. Nowadays ‘natural history’ of a disease like aortic stenosis is virtually 
impossible to study because all kinds of decision or selection processes and interventions 
should be taken into account. If one would like to gain an unbiased view on ‘natural 
history’, theoretically all eligible patients should be excluded from an intervention, or they 
should be randomized to either the intervention or conservative treatment. Of course in 
practice this would be impossible and ethically incorrect. 
In Chapter 3 we systematically reviewed all available literature on the progression of 
aortic stenosis. Of over 1300 hits in the first search, we finally retrieved 27 papers describ-
ing aortic stenosis progression rate as observed with Doppler echocardiography, and per-
formed a meta-analysis. We found a striking variability both in observed stenosis-severity 
and stenosis-progression and also in the parameters that were used to record this severity 
or progression. Most often peak aortic gradient was used as primary parameter. Measured 
by peak aortic gradient, pooled annual AS progression was 3.7 mmHg/year as reported by 
randomized clinical trials (RCTs) and 6.0 mmHg/year in observational studies. Whether the 
true rate of progression is somewhere in between remains unsure, and probably it is not 
constant over time.10 The finding that the rate of progression was higher in studies that 
concerned patients with more severe initial stenosis complies with this theory. Also other 
patient-related factors seem to play a role in the progression of aortic stenosis, therefore 
the rate of progression is largely dependent on the patient-population being studied.2 The 
systematic review did bring an important point to attention, namely the need to establish 
consensus about reporting aortic stenosis severity. This will remain a difficult issue since jet 
velocities or pressure gradients –either peak or mean aortic gradient- are the parameters 
most widely reported although they are subjective to left ventricular function. In these 
cases the use of velocity-time-integral ratios would provide more accurate and uniform 
parameters. The degree of valvular calcification and inflammation also play a role in AS 
progression, but are currently difficult to measure. Recent promising studies have shown 
that positron emission tomography could fill this gap by offering reproducible measures of 
both valve inflammation and calcification.11-12
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ThERAPEuTIC OPTIOnS fOR PATIEnTS WITh SEvERE AORTIC STEnOSIS 
The ACC/AHA and the ESC guidelines for the management of patients with valvular heart 
disease recommend medical therapy and close monitoring of all patients with truly asymp-
tomatic severe aortic stenosis with at least one new echocardiogram annually to prevent 
deterioration of the left ventricle. The guidelines also present clear consensus to treat 
symptomatic patients with severe aortic stenosis with a replacement of the aortic valve 
(Class 1, level of evidence B).13-14 
Medical therapy
Anti-hypertensive medication, beta blockers and diuretics can help to relieve symptoms of 
congestive heart failure resulting from aortic stenosis but do not act on the valve pathology 
itself. Lipid lowering drugs are the only drugs reported to have a beneficial effect on the 
progression of aortic stenosis but their usefulness remains subject of much debate. 
The cohort studies we used for our meta-analysis in Chapter 3 showed a trend toward 
a slower progression rate in patients who received statins. This slower progression rate is 
confirmed by a meta-analysis of mainly observational studies showing statins are likely to 
delay the progression of aortic stenosis.15 However, several randomized clinical trials failed 
to demonstrate a difference in progression between the experimental and control arms: 
the SALTIRE trial (Scottish Aortic stenosis and Lipid lowering Trial, Impact on REgression) 
showed that intensive lipid-lowering therapy did not halt progression and did not induce 
regression of aortic stenosis.16 The TASS (Tyrolean Aortic Stenosis Study) trial did not sup-
port the concept that atorvastatin slows down progression.17-18 Recently, the ASTRONO-
MER (Aortic STenosis pRogressiON Observation: Measuring the Effects of Rosuvastatin) trial 
showed no reduction in progression in patients with mild to moderate aortic stenosis who 
received rosuvasatin daily.19 Furthermore, there was no reduction in composite endpoint of 
combined aortic valve and ischemic events in patients with asymptomatic mild-to-moderate 
aortic stenosis according to the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial.20 
As a reaction on the study presented in Chapter 7, Dr. Paraskevas wrote a letter to 
the editor of the European Journal Cardio-thoracic Surgery,21 in which he advocates the 
use of statins in patients with aortic stenosis. In this letter he refers to a cohort study 
in which statins slowed the hemodynamic progression in patients with asymptomatic 
moderate to severe aortic stenosis.22 Further he stresses in an earlier review that statins 
improve cardiovascular outcomes in surgical patients (either CABG or patients who need 
valve replacement or other thoracic surgery).23 Both patient categories are different from 
the one we studied, namely a cohort of patients with severe aortic stenosis who are not 
(yet) selected for surgery. Although statins may interfere with the progression of aortic 
stenosis, it remains uncertain to what degree, in which patients and until what disease 
stage. Recent positron emission tomography studies have confirmed that in the aortic 
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valve inflammatory features are increased in mild to moderate aortic stenosis, but that 
inflammation has largely disappeared in severe cases.11-12 Whether statin therapy is useful 
in the patient with severe aortic stenosis is therefore doubtful and has yet to be established 
in larger prospective series.24-25 Probably comorbidity, old age, the advanced state of the 
valve stenosis and the possible indication for surgical treatment play a major role in this 
patient population and prohibit effective studies to either prove or reject a beneficial effect 
of lipid lowering drugs. 
Conventional options for valve replacement 
In 1952 the first aortic valve prosthesis was implanted by Hufnagel in the descending 
aorta to correct aortic regurgitation.26 In the meanwhile extracorporeal circulation was 
developed and shortly thereafter orthotopic aortic valve replacement became common 
practice. In more recent years improvements in myocardial protection, cardiac anesthesia 
and postoperative care have led to increased willingness of surgeons to operate on elderly 
and high risk patients. Nowadays operative results are acceptable even in octogenarians, 
with an operative mortality of around 8% for single AVR.27 Operative mortality in middle-
aged otherwise healthy patients is approximately only 1%.28
 Several types of valve prostheses are available, each having their own advantages 
and limitations. Most frequently used are the mechanical and the biological prosthesis. 
Mechanical prostheses have a long lasting durability but necessitate anticoagulation to 
prevent valve thrombosis and thrombo-embolic complications, leading to increased risk 
of bleeding. Bioprostheses do not require long-term anticoagulation but are subject to 
structural valve deterioration which increases the risk of reoperation. Valve related events 
which can occur with either prosthesis are paravalvular leakage, prosthetic valve endocar-
ditis, prosthetic valve thrombosis and thrombo-embolic events. Overall, the occurrence of 
prosthetic valve-related morbidity and mortality together is around 3-4% per year.13 The 
choice between a mechanical or biological valve prosthesis remains a difficult issue: patient 
age, comorbidity, additional anti-coagulant indications and patient preference can all play 
a role in this choice, let alone developments in surgical or transcatheter techniques and 
valve substitutes. In any case, accurate patient assessment is necessary to optimize patient 
selection for (surgical) treatment, and patient perspectives should be taken into account 
in this process. If indeed the decision for AVR has been made, microsimulation can help in 
individual decision making for a particular valve prosthesis.
Microsimulation models to study patient outcome after AVR were previously developed 
by Takkenberg and Puvimanasinghe some years ago.29-36 Microsimulation appears difficult 
to grasp and is not yet commonly used in the fields of cardio-thoracic surgery, therefore an 
extensive introduction is given in Chapter 4.37 The model described in this thesis is available 
by downloading the program along with instructions at www.cardiothoracicresearch.nl. 
Microsimulation provides accurate estimates of age-related life expectancy and lifetime 
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event risks after AVR with a particular valve prosthesis, based on systematically accumu-
lated published evidence or primary datasets. 
A reoperation for structural valve deterioration of a bioprosthesis can pose a serious 
challenge for both patient and surgeon. On the other hand, since patient monitoring is 
largely done by the referring cardiologist, a cardiac surgeon is hardly ever confronted to a 
patient with a major cerebro-vascular accident in the long-term postoperative period after 
mechanical valve implantation. Experiences with such reoperations or lack of personal ex-
perience with anti-coagulant related major bleedings could therefore influence a surgeon’s 
counseling in future patients. Using microsimulation, lifetime event risks between different 
types of valve prostheses can easily and quickly be compared, providing more insight into 
patient outcome after AVR. This not only helps in patient selection but also facilitates 
patient counseling and when combined with individual informed patient preferences, it 
improves optimized informed decision making for specific heart valve prosthesis in a par-
ticular patient. The challenge remains to effectively translate the evidence-based estimates 
from microsimulation models to the doctor and the patient who are facing the decision 
between an mechanical or biological valve prosthesis. Implementation of microsimulation 
estimates in patient decision aids, employing non-numerical visualization of risks rather 
than providing percentages, may facilitate this transfer of knowledge.38
Based on the Vancouver dataset provided by Dr. Jamieson we have shown that life-
expectancy after AVR is quite similar for patients who have a mechanical prosthesis 
implanted compared to patients with a biological prosthesis, at least for patients aged 
between 45 and 80 years. Stoica et al took the microsimulation method to the next level 
by adding confidence limits to their point estimates for (event-free) life-expectancy, and 
came to the similar conclusions: life-expectancy is similar for patients with biological com-
pared to mechanical valve prostheses, and even event-free life-expectancy is comparable.39 
The difference lies in the nature of the valve-related events. For patients over the age of 
60, implantation of a bioprosthesis generally can be considered a good option. The risk 
of bleeding with a bioprosthesis is not absent, but compared to mechanical valves the 
risk-reduction of bleeding that can be achieved by avoiding coumadins outweighs the 
increased risk associated with the feared structural valve deterioration. If these results 
were to be followed, the current age-threshold for implantation of a bioprosthesis could 
thus be lowered from 65 to 60 years. The negative aspect of lowering this threshold is that 
not only more but also older patients will require a reoperation in the future, which could 
increase re-operative mortality. On the other hand, the emerging TAVI technique may offer 
a solution in patients with high re-operative risk: the ‘valve-in-valve’ concept has already 
shown to be effective to substitute deteriorated biological prostheses in a few cases.40-41 
Of note, long-term durability of the TAVI procedure has not yet been established, and 
therefore a durability comparison between surgical bioprostheses and ‘TAVI bioprostheses’ 
is not yet possible. Quality of life after cardiac surgery in general and especially after AVR 
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is yet relatively unexplored. High-quality studies on quality of life after AVR with either 
valve prosthesis are urgently needed in the near future to shed some extra light on this 
issue in order to optimize patient information.42 Altogether, since there is no clear survival 
advantage between the two prosthesis types, the choice should be driven by shared deci-
sion making based on individual patient preferences.38
TREATMEnT Of SEvERE AORTIC STEnOSIS In COnTEMPORARy dAIly 
PRACTICE 
Like stated before, the ACC/AHA and the ESC guidelines for the management of pa-
tients with valvular heart disease recommend prompt aortic valve replacement as soon 
as a patient with severe aortic stenosis becomes symptomatic. Remission of symptoms 
after starting medical treatment, advanced age and depressed left ventricular function are 
known, yet debatable, reasons to deny surgery in a symptomatic patient.43-45 
In contemporary practice cardiac surgeons are more willing to operate on elderly 
patients with associated morbidities than a few decades ago. Progress in operative and 
postoperative care which have led to decreased mortality and morbidity (especially in the 
high-risk patients), form the basis of this shift. Especially since TAVI became available in 
clinical practice, surgeons and interventional cardiologists feel they deny AVR only in a 
minority of patients. Therefore it is surprising to find several articles reporting that up 
to 60% of symptomatic patients with severe aortic stenosis do not undergo AVR.44, 46-49 
In the studies presented in this thesis we found similar results, implying that even in a 
region with a highly specialized tertiary center where new percutaneous and transapical 
valve implantation techniques were being implemented, more than half of the patients 
are not treated by aortic valve implantation or replacement.49 Most of these patients were 
simply not referred for invasive treatment. In chapter 7 we studied why so many patients 
are not referred by their cardiologists and found four main reasons for the non-referral of 
symptomatic patients: preference of the patient (reported in 9% of cases), perceived high 
operative risk (34%), underestimation of hemodynamic severity (14%) and underestima-
tion of symptoms (19%). These reasons will be discussed in more detail in the following 
paragraphs.
Patient preference
One of the reasons to choose for conservative treatment instead of AVR was patient 
preference. Of course, ultimately the patient should be the one to make the final informed 
decision whether to agree with an operation or not. However, one can imagine patient 
preference for a certain treatment is largely dependent on the doctor providing the infor-
mation.38, 50 Cardiologists and surgeons often rely on different information sources and can 
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have different opinions about operative risk and expected benefit after treatment.51 The 
surgical team should at least be involved not only in decision-making, but also in supplying 
information to the patient about risks and expected benefits of surgical procedures. Ideally, 
a multidisciplinary team approach is used, the patient is provided with comprehensible 
objective information on the benefits and risks of the different treatment strategies and 
given time to explore the options in his/her own context.52 Patient decision aids may be of 
help for these potentially value-sensitive decisions.
Perceived high operative risk 
Of the patients with perceived high operative risk as described in Chapter 7, more than 
half had a relatively low estimated operative risk with a logistic EuroSCORE below 10%. 
Similar findings were reported by other groups who confirm this mismatch between per-
ceived and calculated operative risk, raising the question that possibly many patients are 
wrongly denied AVR.44, 46-47, 53 Apart from this mismatch also truly high risk patients should 
at least be considered for surgery since these are the ones most likely to benefit from valve 
replacement once they have overcome these risks. This is also known as the risk-treatment 
paradox 54-55. 
An important issue with current risk models is that characteristics such as ‘vitality’, 
‘frailty’ or ‘biological age’ are difficult to measure and incorporate in a risk model. Fur-
thermore there are many risk models available and there is a large variability between 
the different models, in model output and even in definition of ‘operative mortality’.28, 
56-58 For valve surgery patients, the EuroSCORE risk model –which is the one most com-
monly used in the Netherlands- overestimates the current actual operative risk greatly.59 
Recently, a new version of this risk model has been released: the EuroSCORE II.60 It has 
been recalibrated, contains new risk factors, while the weight of the established risk fac-
tors has been reassessed. Factors related to ageing and frailty have not been added. The 
applicability of this new model to the elderly patient population with severe AS has to be 
evaluated in the upcoming period. Another approach that may more adequately describe 
contemporary outcome in elderly patients and other heart surgery subgroups would be to 
model outcome dynamically, using contemporary large data registries representing current 
clinical practice. Then a systematic approach can be applied with contemporary modeling 
methods that employ advanced estimation and validation techniques such as penalization 
and bootstrapping. These systems should be dynamic both with regard to the weight (and 
type) of co-variables and with regard to the calibration of outcomes.61
Most medically treated patients are not referred to a surgical department and therefore 
do not undergo a full clinical assessment of e.g. pulmonary function, presence of coronary 
or peripheral artery disease or pulmonary hypertension. It is questionable if one can make 
a clear judgment about operative risk and the possible benefits a patient would have from 
treatment when these issues are not addressed. 
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The majority of publications on operative risk-modeling in cardio-thoracic surgery is 
written by surgeons and is published in cardiac surgery journals. Since not every cardiolo-
gist has expertise with operative risk assessment, referral of any patient with severe valve 
pathology to an expert ‘heart team’ or ‘heart valve team’ seems to be a better option. This 
‘heart valve team’ should ideally include a cardiologist, interventional cardiologist, cardiac 
surgeon, and a specialized anesthesiologist to check the indication and discuss all possible 
treatment options with their associated risks. Even the family physician could be consulted. 
In case of doubt, e.g. about vitality, the patient could be invited to the outpatient clinic to 
be examined, both by the surgical team and also by other specialists like a geriatrician. For 
the patient this would be the opportunity to be informed about benefits and risks of the 
different treatment options, to discuss these options and finally make a well-informed deci-
sion.52 Such a patient centered team approach would promote evidence-based medicine 
and well-informed decision making.38, 54
Underestimation of hemodynamic severity
As much as 14% of symptomatic patients (Chapter 7) who were not referred for surgery 
were classified as having a ‘non-severe’ stenosis by the treating cardiologist, although the 
echocardiographic parameters clearly complied to a severe valve stenosis. These patients 
are at risk of left ventricular deterioration and sudden death.3, 6 Even if the stenosis severity 
is only just below the ‘severe’ threshold, it can be disputed whether ’watchful waiting’ is 
the best treatment. Although in our meta-analysis in Chapter 3 the progression rate of 
3.7-6.0 mmHg/year in terms of peak aortic gradient appears to be lower than previously 
anticipated,62-64 the rate of progression was higher in patients having more severe stenosis. 
Borderline patients will therefore enter the ‘severe stenosis’ category within a short period 
of time. Meanwhile the left ventricle is at risk for hypertrophy and deterioration, resulting 
in more severe symptoms, worse quality of life and increased risk of sudden death. Since 
long-term outcome after AVR is worse when left ventricular hypertrophy is more outspo-
ken, in particular these ‘borderline’ patients should be monitored frequently and once AS 
becomes severe, referred promptly for surgery.65 
Underestimation of symptoms
We reviewed all cardiology chart documentation on our study patients and often found 
descriptions of the classical aortic stenosis symptoms such as dyspnea yet described as 
‘mild’ or non-debilitating. In 19% of symptomatic patients this was the main reason not 
to refer to surgery. Apart from the fact that having only ‘mild’ symptoms does not exclude 
a patient from being an AVR candidate,13-14, 66 the patient’s functional disability is often 
underestimated by physicians 67 and disease burden is high, even in NYHA class 2 patients 
(as is discussed in one of the next sections and also in Chapter 10 and 11).
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ChAllEnGES AT TREATMEnT SElECTIOn And ThEIR EffECT On OuTCOME 
In order to gain more insight into factors related to treatment selection and their effect 
on clinical outcome in patients with severe aortic stenosis, we designed the Aortic vAlve 
RIjnmond study (Chapter 9). Grossly, treatment selection in this patient population is 
based on the presence of symptoms that can be attributed to the aortic stenosis. What 
seems like a clear distinction at first glance appears to be a remarkably difficult issue: 
which patient is symptomatic and who is not? Often, as the stenosis gradually progresses, 
patients attribute symptoms to co-morbidities or the ageing process, introducing both 
patient- and doctor delay once symptoms become more clear. Exercise testing used to be 
recommended in asymptomatic patients with severe aortic stenosis in order to exclude 
symptoms with more certainty.68-70 Up to 37% of previously considered ‘asymptomatic’ 
patients have limiting symptoms or signs when they are tested.69 Yet exercise testing 
remains highly underused -also in the Rotterdam region- and shifted from a Class 2a to 
a 2b recommendation in the latest ACC/AHA guidelines.13, 71 If physically possible, we 
performed exercise testing in the asymptomatic part of the AVARIJN cohort and found 
similar results: one-third of the patients has blood-pressure drops, significant ST-segment 
changes or limiting symptoms such as severe dyspnea, angina or near-syncope when tested 
(Chapter 9). Therefore the underuse of exercise testing could lead to an underestimation of 
the true proportion of symptomatic patients leading to an even greater number of patients 
treated medically than as reported by others and by ourselves.44, 46-48 This implies that we 
are only observing the tip of the iceberg and even more patients could be eligible for aortic 
valve replacement or TAVI.
Factors associated with therapeutic strategy 
Two-thirds of the AVARIJN patients reported to be symptomatic and in this group we 
studied the factors that were related to treatment strategy by multivariable analysis. Age, 
peripheral arterial disease, previous myocardial infarction and hypertension were associ-
ated with a conservative policy, stenosis severity was related to operative treatment. This 
confirms earlier reports of years ago that many of these factors form debatable reasons for 
either surgical or conservative treatment and illustrates the urgent need for an evidence-
based multi-disciplinary team approach.44-46, 48, 52
Prognosis  
A decline in survival in medically treated symptomatic patients already occurred in the 
first year after inclusion.49, 72 Still, survival in the conservative group is with 73% at 2 
years not as bad as expected based on previous reports by others.3, 5, 73 Although survival 
appears to be better in symptomatic patients who undergo AVR/TAVI versus those treated 
conservatively, the survival benefit disappears when corrected for age and several comor-
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bidities. This suggests that patient survival is mainly driven by patient characteristics and 
to a lesser extent by treatment strategy. On the other hand, the relatively ‘good’ prognosis 
of our medically treated group could be a reflection of the conservative approach of the 
cardiologists in our region because this group also contains misclassified ‘asymptomatic’ 
and misclassified ‘high risk’ patients. Further the AVARIJN cohort represents another tip 
of an iceberg: the included patients are a selected sample from a larger population; many 
potential AVARIJN candidates refused to participate in the study because of old age and 
multiple comorbidities. Therefore, the patients included in AVARIJN represent most likely a 
relatively “healthy” subgroup of patients with severe AS.
As expected, the asymptomatic patients had a far better prognosis in terms of survival: 
92% were still alive at 2 years. On the other hand, as much as 68% became symptomatic 
with a median time to symptom development of 13 months, only 38% had valve replace-
ment. This stresses the progressive nature of the disease at this stage and at least urges the 
need of close follow-up or perhaps even a shift to a more aggressive treatment policy.65
Quality of life 
The study presented in chapter 10 shows that asymptomatic patients from the AVARIJN 
cohort seem to have a similar health perception compared to the general population. 
Symptomatic patients however, suffer from both severe physical and emotional impairment 
hampering normal daily life.74 The differences in health perception of symptomatic patients 
compared with the age-matched Dutch population are large across most health domains. 
Further there was no association between stenosis severity and physical or mental quality 
of life in our patient cohort. Thus, whenever the aortic stenosis is above the ‘severe’ thresh-
old, “objective” measures of aortic valve function do not correlate to functional status: 
the degree of stenosis does not predict disease burden. This is important to realize and 
relevant for clinical practice. However, we only studied the ‘severe’ category: an association 
between disease burden and stenosis severity in the whole patient population with either 
mild, moderate or severe aortic stenosis certainly cannot be ruled out. 
Elderly patients can expect a good quality of life after surgery,9, 43 but these results should 
be placed into perspective: most studies describe quality of life in those selected patients 
with aortic stenosis who were referred for surgery.75-83 Some of these studies even lack 
a baseline (pre-operative) quality of life measurement and only describe quality of life in 
long-term survivors after intervention.76-77 These issues have also been addressed by Noyez 
and colleagues in a recent paper.42 They performed a meta-analysis of multiple studies 
on quality of life, often found shortcomings in methodology and came up with several 
recommendations in order to stimulate and improve future research on this subject. The 
quality of life study that is described in Chapter 11 was undertaken in patients in whom 
the decision to operate or not still had to be made, and we repeated the measurements 
over time, both in medically and surgically treated patients. AVR indeed offers improved 
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quality of life in –for surgery selected- symptomatic patients.84 The beneficial effect is not 
only evident in the physical component of the SF-36v2™ Health Survey, also general health 
perception, vitality and emotional aspects improve to the level of the general age-matched 
population. 
Besides considering life-expectancy and risks with either conservative or operative treat-
ment, the possible gain in quality of life should be an important consideration when as-
sessing symptomatic status, and might be a reason to reconsider a conservative approach 
when only ‘mild’ symptoms are present. Standardized surveys like the SF-36v2™ should be 
added to the armamentarium of the cardiologist as a simple diagnostic tool in order to aid 
decision making. The cardiologist –or preferably: the ‘heart team’- could then compare the 
results of the patient with the quality of life of the general population, or with the results 
of similar patients from our cohort, and use this information to reconsider or confirm a 
conservative approach. 
Whether the improved quality of life of the operated patients can be extrapolated to 
the total patient population with symptomatic severe aortic stenosis remains yet a mat-
ter of debate. From the data presented in Chapter 11 it cannot be determined how the 
outcomes, both in terms of survival and quality of life, would have been when all patients 
would have had AVR. Such a scenario probably results in lower survival and lower quality of 
life than is currently observed in the AVR group, but it could show improved overall survival 
and quality of life in the total group of patients with symptomatic aortic stenosis. In reality, 
some (elderly) patients are simply not surgical candidates or refuse to be operated upon. 
Using surveys like the SF-36v2 Health Survey during follow-up of -either medically or 
surgically treated- patients still leaves a problem to be solved: all patients who have died 
cannot be taken into account. In order to do so, another type of analysis can be used. 
The EuroQOL is a simple survey containing only five questions with three possible answers 
each.84-86 Analysis of this survey can determine the number of ‘quality adjusted life years 
(QALY’s)’: the number of life years gained by a certain therapy corrected for the quality of 
life. Insurance companies use this information and reimbursement policies are often based 
on this type of analysis. For the AVARIJN cohort we have all these data since we subjected 
the patients not only to the SF-36v2, but also to the EuroQOL survey. These data will be 
studied and used for cost-effectiveness studies in the near future.
Limitations of the AVARIJN study
The AVARIJN study group described in this thesis is a selected cohort. Although enrolment 
from the outpatient cardiology echocardiography departments was encouraged, some 
patients may not have been identified. We attempted to enroll every patient but were 
not able to do so because a substantial number of patients denied participation: of the 
459 patients we invited, only 191 agreed to participate. Also a few patients who initially 
consented denied participation during follow-up.72 Often these patients were the elderly, 
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or the more sick patients for whom an extra study-trip to the hospital was unfeasible. 
Therefore we have a less representative patient population than we initially hoped for. It 
is likely that this leads to an underestimation of the proportion of symptomatic patients 
which in turn leads to an underestimation of the real undertreatment. Also this would lead 
to an underestimation of the magnitude of quality of life impairment, and a too optimistic 
view on prognosis in conservatively treated patients.
nEW dEvElOPMEnTS In ThE MAnAGEMEnT Of PATIEnTS WITh SEvERE 
AORTIC STEnOSIS 
Since aortic stenosis nowadays has a mainly degenerative origin, it is clear that it is becom-
ing an increasingly important health problem in developed countries. As the life expec-
tancy of the population continues to increase, concomitantly the number of chronically ill 
patients increases, as a result the need for valve replacement is expected to triple by the 
year 2050.85 Not only is the number of patients with aortic stenosis still increasing, also 
the proportion of patients that is eligible for surgical valve replacement or transcatheter 
valve implantation will increase. So will the costs per patient, especially with the latter 
technique which currently still is very expensive. In contrast, it is expected that from 2025 
onward the number of people working in healthcare will only decrease. These prospects 
not only pose a medical problem, but also tremendous financial and social challenges, 
calling for an efficient healthcare system. It is in this light that the Dutch government 
has introduced a new cost-system for hospitals in 2012 (http://www.rijksoverheid.nl/
documenten-en-publicaties#ref-minvws). This new cost-system aims to guarantee sustain-
able healthcare while keeping costs contained at the same time. No longer will hospital 
budgets be determined by the number of treatments provided, but by the quality of treat-
ment. Therefore new developments in treatment will have to meet high standards, not 
only in medical efficiency but also in terms of efficacy and effectiveness. Intensive research 
and publication of treatment results, as well as transparency to society will play a key role 
to get reimbursement.
Transcatheter Aortic Valve Implantation (TAVI) 
Many patients in the AVARIJN cohort followed with great interest the news concerning 
the implementation of the new TAVI technology in the Erasmus Medical Center. Even 
elderly patients were often well informed by (local) media, family and friends and were 
enthusiastic for the less invasive procedure. Yet medical information was strikingly lacking 
at that time: the indications for the TAVI technique, the disadvantages such as peripheral 
vascular complications, cerebral embolism, paravalvular leakage, conduction disorders and 
the uncertain long-term durability were not yet clearly documented. 
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We encountered many possible candidates for TAVI in the AVARIJN cohort, some of 
whom were previously treated conservatively and were only referred to our department 
after the introduction of the TAVI technique. Interestingly, the majority of these patients 
underwent surgical AVR, and only a few were treated with TAVI. New treatment options 
thus have led to increased patient referral and caution is advised not to bypass the ‘heart 
team’. Initially, the TAVI procedure was reserved for the very high risk patient who was 
rejected for conventional AVR. With time the indications for this lesser invasive technique 
are steadily shifted to younger patients with lower operative risk while the long-term du-
rability of the TAVI technology is still not established. The SOURCE registry has the largest 
patient population until now and shows a total 30-day mortality of no less than 8.5%, with 
respective mortality rates of 6.3% and 10.3% in the transfemoral and transapical groups.88 
This observation underlines that TAVI is not without considerable risk for early mortality.
Fortunately a number of randomized clinical trials are ongoing in order to clarify the 
indications for either the surgical or percutaneous technique. The PARTNER trial (Placement 
of AoRtic TraNscathetER valve trial) allocated patients in two cohorts: in cohort A high 
risk patients were randomized to either surgical valve replacement or TAVI, in cohort B 
inoperable patients were randomized to TAVI or conservative treatment.86 In the PARTNER 
A cohort TAVI was associated with more vascular and cerebral complications, but atrial 
fibrillation and postoperative bleeding were more common after surgical AVR. The TAVI 
procedure was associated with increased paravalvular regurgitation, but its clinical impor-
tance remains yet unexplored. The main finding was that the TAVI procedure had similar 
mortality as AVR after one year and was therefore found to be ‘non-inferior’ to AVR in 
high risk operable patients with severe AS, at least in the short term. The B cohort showed 
a lower mortality in the patients treated with TAVI compared to conservative treatment at 
the expense of a higher incidence of stroke and vascular complications. The SURTAVI and 
PARTNER II trials have recently been designed to randomize intermediate risk patients to 
TAVI or surgical AVR.90-91 It is important to await the results of these trials before further 
lowering the indications for this new and promising transcatheter technology.
Advances in surgical aortic valve replacement 
Several different approaches have been used in order to avoid median sternotomy, trying 
to retaining thoracic stability in order to reduce wound associated morbidity and mortality 
and to improve cosmetic results. Some of the possibilities are a reversed “C” minister-
notomy, a right anterior minithoracotomy, or a “J” shaped incision.92-95 Most of these 
techniques are feasible and safe, some studies suggest improved pulmonary function, a 
faster recovery, less complications and less chest pain resulting in more patient satisfaction, 
less rehabilitation and less costs.87 97-99 Others find no difference, except for the better 
cosmetic result.100-101
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An interesting new technique to replace the diseased native aortic valve is introduced by 
Berreklouw and colleagues.102-103 In order to reduce cross-clamp time and cardio pulmonary 
bypass time, they developed a Nitinol ring to attach contemporary and FDA approved 
prostheses -both biological and mechanical - without sutures in the aortic position after 
surgical excision of the native aortic valve. This concept is proven to be feasible in experi-
mental animal settings and could have several advantages over the TAVI technique, such 
as reduction in conduction abnormalities, coronary obstruction, paravalvular regurgitation, 
mitral valve damage and cerebral complications. A major advantage is the fact that also 
mechanical valves can be implanted. Hopefully the concept proves to reduce operative 
mortality associated with long cross-clamp times in multiple valve procedures and  facilitate 
the conventional or ministernotomy AVR. 
New anticoagulant therapy 
For many years Vitamin K antagonists have been the anticoagulants of choice in preventing 
thrombo-embolic events after AVR with a mechanical prosthesis. Their unpredictable and 
highly variable response, narrow therapeutic window and extensive drug interactions make 
dose management complex but also very important since 60% of all anti-coagulation relat-
ed complications occur when the INR is out of the therapeutic range.104 In the Netherlands, 
self control programs have been shown to be effective in maintaining the therapeutic 
range compared to the conventional control by the Thrombosis Service and it results in 
improved quality of life.88 
Recently new anticoagulant drugs have entered the market of which Dabigatran seems 
most promising. This thrombin inhibitor is short acting, has few side-effects and can be 
used without monitoring. Recent trials showed that in the treatment of atrial fibrillation 
Dabigatran has similar rates of stroke and systemic embolisation compared to Warfarin but 
with a lower rate of major bleeding.106-107 If also anti-coagulant related bleeding complica-
tions after mechanical valve surgery could be reduced in combination with improved drug 
management, a new era in favor of the mechanical valve could start. Theoretically this 
could widen the indications for conventional, minimal invasive and sutureless mechanical 
AVR at the expense of bioprostheses or TAVI.
COnCluSIOnS And RECOMMEndATIOnS 
With regard to the ‘natural history’ of aortic stenosis this thesis has added the observa-
tion that pooled annual increase in peak aortic gradient is highly variable and estimated 
to be somewhere between 3.7 and 6.0 mmHg/year. There is a large variability both in 
observed stenosis-severity and –progression, most likely the rate of progression is largely 
dependent on the patient-population being studied. Assessment of valvular calcification 
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and inflammation by (PET-)CT may have additional value in identifying fast progression 
of aortic stenosis. Further, the parameters that were used to display stenosis severity or 
progression are highly variable. More uniformity in these parameters would be helpful for 
a better comparison between different studies and a better estimate of the ‘true’ rate of 
progression.  
This thesis applied microsimulation to compare patient outcomes after implantation of 
biological versus mechanical valve substitutes. It was demonstrated that using microsimula-
tion, lifetime event risks between different types of valve prostheses can easily and quickly 
be compared, providing more insight into the different events that patients encounter 
in life after AVR. Such information not only helps in treatment selection but can also 
improve patient counseling when the microsimulation interface would be used embedded 
in a patient decision aid in face-to-face contact with the patient in the out-patient clinic 
setting. It improves visualization of the advantages and disadvantages of the different 
prosthesis options and thereby optimizes informed decision making when combined with 
individual patient preferences.
Important insights were obtained in this thesis from the research that concerned the 
treatment of severe aortic stenosis in contemporary practice. In more than half of the 
symptomatic patients the current clinical practice guidelines are not followed and patients 
are not treated by valve replacement. This seems a remarkably high proportion. Patient 
preferences play an important role, but also other more debatable issues such as perceived 
high operative risk, underestimation of hemodynamic severity and underestimation of 
symptoms. Multivariate analysis further showed age, peripheral arterial disease, previous 
myocardial infarction and hypertension to be associated to a conservative policy, stenosis 
severity was related to operative treatment. In order to optimize patient and treatment 
selection any patient with severe valve pathology should be referred to a ‘heart team’ 
or ‘heart valve team’. This ‘heart valve team’ should ideally include a cardiologist, in-
terventional cardiologist, cardiac surgeon and specialized anesthesiologist, to check the 
indication and discuss all possible treatment options with their associated risks. Such 
team effort could eliminate inappropriate ‘competition’ between surgical, transcatheter 
or conservative strategies. Standardized surveys like the SF-36v2™ should be added to the 
standard armamentarium of the cardiologist and the ‘heart team’ as a simple diagnostic 
tool in order to aid decision making. In case of doubt about vitality, frailty or other issues, 
the patient should be examined in the outpatient clinic by members of the heart team. 
Last but certainly not least: the patient should be centered in informed decision making.
The general conclusion following from this thesis is that there is a lot to gain in the 
management of patients with severe aortic stenosis. Progress can be made in the areas 
of diagnosis, treatment selection and treatment utilization. Both doctors and patients 
should and can be better informed about prognosis after each treatment modality, also 
in terms of quality of life. This will improve decision making especially when the patient is 
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placed right in the center of this evidence-based multi-disciplinary process. As long as the 
life-expectancy of the general population continues to rise and medical options to halt or 
prevent aortic stenosis are lacking, surgical and transcatheter technical developments and 
their indications will continue to expand provided reimbursement by society. Optimiza-
tion of treatment decision making starts with an evidence-based patient-centered team 
approach that considers not only morbidity and mortality, but also patient benefits and 
societal costs.
Future research
Since at least part of the symptoms associated with severe AS are more likely to be caused 
by the effects on systolic and diastolic left ventricular function rather than by the stenosis 
itself, it is important to gain more insight into left ventricular function. Tissue Doppler 
Imaging is an ultrasound technique that measures left ventricular wall motion and provides 
objective means to quantify global and regional left and right ventricular function even 
before the occurrence of (subjective) symptoms.89 We are currently analyzing all AVARIJN 
echocardiograms in order to investigate whether it is useful to add Tissue Doppler Imaging 
to the standard echocardiographic evaluation. 
Several studies found that B-type natriuretic peptides (BNP) are useful in discriminating 
cardiac versus non-cardiac dyspnea, is related to the severity and progression of aortic 
stenosis, related to symptom development and accurate in discriminating symptomatic 
and asymptomatic patients, and predictive of patient outcome.109-114 We have saved serum 
samples of all AVARIJN patients at each study-visit and will study whether the assessment 
of Nt-proBNP indeed has predictive value in the AVARIJN cohort, and whether it should be 
added to the standard clinical evaluation of the patient with severe aortic stenosis. 
Microsimulation methods are obviously also applicable for other diseases, e.g. they could 
also be developed for patients who are treated conservatively. The development of prog-
nostic models that weigh not only the pros and cons of AVR related to mortality, but also 
related to quality of life, are the next step towards optimized decision making whether to 
operate or not on a patient with severe aortic stenosis. Our department intends to develop 
these models, although this requires large datasets with extensive numbers of variables 
and some patient factors, such as vitality, are hard to measure and will therefore be difficult 
to grasp in a model. In addition we intend to build evidence-based patient decision aids 
that in an objective and comprehensible manner inform patients of the benefits and risks 
of different treatment options, and allow patients to weigh these options in their own 
personal context, in order to facilitate objective evidence-based shared decision making.
Since even patients with ‘mild’ symptoms clearly suffer from both severe physical and 
emotional impairment, we recommend assessing quality of life in patients with severe 
aortic valve pathology. We intend to develop a Dutch online tool to measure quality of 
life –related to the general population, and the patient population- resulting in only very 
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little extra work for a cardiologist or heart team. Further we plan to study whether quality 
of life measurements can predict hospital (re)admissions and survival, like it can in other 
heart diseases.115-116
Eventually reimbursement policies will largely determine whether new treatment mo-
dalities such as the TAVI technique will be used on a large scale. Therefore it is important 
to evaluate and compare the costs and benefits of all available treatment options. We 
are currently working on a cost-effectiveness study using the EuroQOL method in order 
to evaluate the efficacy of conservative treatment compared to conventional AVR in the 
AVARIJN cohort. The next step would be to compare the efficacy of surgical AVR (currently 
the ‘gold standard’) to the TAVI technique. 
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Summary
Chapter 1 presents the introduction, the hypotheses and outline of this thesis. Degenera-
tive aortic stenosis is the most common valvular heart disease in developed countries. The 
aim of this thesis is to explore and expand the current knowledge of severe aortic stenosis 
concerning diagnosis, treatment and prognosis. Disease progression, utilization of differ-
ent treatment options and their effect on prognosis were studied, both in terms of survival 
and quality of life. 
Chapter 2 provides a general overview of knowledge on patients with aortic stenosis. The 
causes and pathology of aortic valve stenosis, the clinical presentation of a patient and also 
current diagnostic tools and treatment options are discussed. Although new techniques to 
correct degenerative aortic stenosis are upcoming, surgical aortic valve replacement is the 
current gold standard, and so it will be in the next few years. 
The 3rd chapter presents a systematic literature review that was undertaken to estab-
lish the rate of progression of aortic stenosis in adult patients. From the meta-analysis 
comprising 27 papers, a large variability in reported progression rates was found. Further, 
different studies used different parameters to report this progression. Mostly used was 
peak aortic gradient. Pooled annual progression in peak aortic gradient was 3.7 mmHg/
year as reported by clinical trials randomizing between statin and non-statin users, and 6.0 
mmHg/year in observational studies. Progression rate appeared to be higher in patients 
with a more severe aortic stenosis, as is reported by others. Since patient-related factors 
and timing of the first measurement play a role in establishing a progression rate, this rate 
is largely dependent on the patient-population being studied. 
Chapter 4 explains how the microsimulation methodology can be used as a prognostic 
tool to estimate age- and gender-specific life-expectancy after AVR. The advantages and 
limitations are discussed extensively in this chapter. The microsimulation model can help 
in patient selection for AVR and facilitate patient counseling when choosing between a 
bioprosthesis and mechanical prosthesis or even other types of valve prostheses. Thereby 
it improves optimized informed decision making for a specific heart valve prosthesis in a 
particular patient especially when combined with individual patient preferences.
In the 5th chapter the microsimulation model was used to study  age- and gender-specific 
life expectancy, event-free life expectancy and reoperation-free life expectancy after aortic 
valve replacement with either a mechanical- or biologic valve prosthesis. For patients over 
60 years, the risk of bleeding with a bioprosthesis is not absent, but compared to me-
chanical valves the risk-reduction of bleeding that can be achieved by avoiding coumadins 
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outweighs the increased risk associated with reoperations for the feared structural valve 
deterioration. 
Chapter 6 is a book chapter that illustrates how microsimulation can be used to 
compare patient outcome after AVR with several valve substitutes: stented- and stentless 
bioprostheses, allografts and autografts. Patient outcome after implantation of stented 
and stentless bioprostheses or cryopreserved allografts appears to be acceptable and dif-
ferences in patient outcomes are mostly explained by patient selection and the timing of 
operation, rather than differences in the performance of these valve substitutes.
 In the last decade several papers report a striking discrepancy between the guidelines 
-either by the ACC/AHA and the ESC- and daily practice concerning the management 
of symptomatic patients with severe aortic stenosis: many patients do not receive the 
recommended surgical treatment. Chapter 7 deals with this discrepancy by studying the 
reasons why 56% of the 179 patients studied, received medical treatment during an 18 
month follow-up. Operative risk, hemodynamic severity and symptomatic status appear to 
be misclassified frequently leading to an undertreatment of this patient category.
 On account of the paper presented in Chapter 7, Dr. Paraskevas wrote a letter to the 
editor of the European Journal of Cardio-thoracic Surgery in which he shortly discusses the 
role of statins in the treatment of patients with aortic stenosis. After reviewing available 
literature on this subject we replied in Chapter 8 that although statins may interfere with 
the progression of aortic stenosis, it remains uncertain to what degree, in which patients 
and until what disease stage. Statin therapy is probably not useful in the cohort we stud-
ied: the patient with severe aortic stenosis. Comorbidity, high age, the advanced state of 
the valve stenosis and the possible indication for surgical treatment play a major role in this 
patient population and prohibit effective studies to either prove or reject this hypothesis. 
Chapter 9 provides the objectives, design and early results of the AVARIJN study: a 
multi-center prospective observational study among 191 patients with severe aortic 
stenosis in the Rotterdam region (the Netherlands). Patients were followed for 2 years 
and received clinical and echocardiographic assessments at different time intervals. In 
this chapter an overview of patient characteristics relative to treatment strategy is given 
and survival is analyzed by using uni- and multivariable Cox regression and Kaplan-Meier 
analyses. Symptomatic conservatively treated patients had a survival of approximately 73% 
at 2 years. Two-thirds of asymptomatic patients developed symptoms during this 2-year 
period underlining the progressive nature of aortic stenosis and the need for frequent 
‘watchful waiting’.
 In order to assess the quality of life of both symptomatic and asymptomatic patients with 
severe aortic stenosis the AVARIJN study patients were subjected to the SF-36v2 Health 
Survey at each study visit. Chapter 10 discusses the results of these health questionnaires: 
quality of life among symptomatic patients with severe aortic stenosis is severely impaired 
compared to the general age-matched Dutch population, both on the physical and on the 
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emotional level. The study provides a quantification of this burden and it illustrates how 
the SF-36v2™ Health Survey can assist in decision making for the individual patient
 Chapter 11 elaborates further on the quality of life of symptomatic patients with severe 
aortic stenosis, and shows the results during follow-up either with medical treatment or 
after AVR. AVR improves not only physical quality of life, but also general health per-
ception, vitality and social function. Besides a low life expectancy, conservatively treated 
symptomatic patients experience severe physical deterioration emphasizing their need for 
treatment. Therefore quality of life should be taken into account when making treatment 
decisions in patients with severe AS. 
Chapter 12 gives a glance at the evolving aspects of treatment elderly or high risk 
patients with (severe) aortic stenosis. Several multi-center randomized trials are ongoing 
or have recently been performed, exploring safety, benefits, limitations and cost-aspects of 
the new TAVI technique compared to the conventional surgical aortic valve replacement. 
The main finding of the PARNTER trial was that the TAVI procedure had similar mortality as 
AVR after one year and was therefore found to be ‘non-inferior’ to AVR in high risk oper-
able patients with severe AS, at least in the short term. The SURTAVI trial has recently been 
designed to randomize intermediate risk patients to TAVI or surgical AVR. It is important 
to await the results of this trial before further lowering the indications for this new and 
promising transcatheter technology.
Chapter 13 provides a general discussion, conclusion and recommendations following 
from this thesis. There is a lot to gain in the management of patients with severe aortic 
stenosis. Progress can be made in the areas of diagnosis, treatment selection and treatment 
utilization. Both doctors and patients should and can be better informed about prognosis 
after each treatment modality, also in terms of quality of life. This will improve decision 
making especially when the patient is placed right in the center of this evidence-based 
multi-disciplinary process. 
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Samenvatting
hoofdstuk 1 bevat de introductie, de hypotheses en een algemene uiteenzetting van 
dit proefschift. Aortaklepstenose is de meest voorkomende hartklepziekte in de westerse 
wereld. Het doel van dit proefschrift is om de huidige kennis over patiënten met ernstige 
aortaklepstenose te onderzoeken en uit te breiden wat betreft diagnose, behandeling en 
prognose. Daartoe werd onder andere de progressie van aortklepstenose bestudeerd eve-
nals het gebruik van de verschillende behandelmogelijkheden en hun effect op prognose, 
zowel wat betreft levensduur als kwaliteit van leven.
hoofdstuk 2 verschaft een algemeen overzicht van de huidige kennis over patiënten 
met aortaklepstenose. De onderliggende oorzaken en pathologie van aortaklepstenose, de 
klinische presentatie van een patiënt, gangbare diagnostische methoden en behandelopties 
worden in dit hoofdstuk besproken. Hoewel in hoog tempo nieuwe technieken worden 
ontwikkeld om aortaklepstenose te behandelen, is de chirurgische aortaklepvervanging tot 
op heden de gouden standaard. Waarschijnlijk blijft dat zo in de nabije toekomst. 
Het derde hoofdstuk bestaat uit een systematische review van de literatuur die uitgevo-
erd werd om de mate van progressie van aortaklepstenose bij volwassenen te onderzoeken. 
Uit de meta-analyse van 27 studies viel op dat er een grote variabiliteit in gerapporteerde 
progressie bestond. Ook gebruikten verschillende studies verschillende parameters om 
de progressie te meten. Gepoolde progressie in piek gradiënt over de aortaklep was 3,7 
mmHg per jaar in studies die randomiseerden tussen statine gebruikers en patiënten die 
geen statine gebruikten. Uit observationele studies kwam een gepoolde progressie van 6,0 
mmHg per jaar. Verder bleek de progressie hoger bij patiënten met een ernstiger stenose 
als uitgangspunt. Omdat patiëntgerelateerde factoren en timing van de eerste meting een 
rol spelen bij de mate van progressie is deze mate dus voor een groot deel afhankelijk van 
de bestudeerde populatie.
hoofdstuk 4 toont hoe microsimulatie gebruikt kan worden als hulpmiddel om 
geslacht- en leeftijdspecifieke levensverwachting na aortaklepvervanging te schatten. De 
methodologie wordt stap voor stap uitgelegd en de voor- en nadelen komen uitvoerig aan 
bod. Het model verschaft inzicht in de levensverwachting na aortaklepvervanging met een 
bepaalde klepprothese en in de mogelijke complicaties op de lange termijn. Daarmee kan 
het helpen bij de keuze tussen de diverse typen klepprothesen bij de individuele patiënt en 
kan het  bovendien de patiëntvoorlichting verduidelijken. 
In hoofdstuk 5 wordt het microsimulatie model gebruikt om geslacht- en leeftijdspecieke 
levensverwachting, event-vrije levensverwachting en reoperatie-vrije levensverwachting 
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na aortaklepvervanging met mechanische of biologische klepprothese te bestuderen. De 
levensverwachting blijkt vergelijkbaar, maar de event-vrije levensverwachting is hoger na 
implantatie van een bioprothese voor patiënten vanaf een leeftijd van 60 jaar. Doordat na 
implantatie van een bioprothese op lange termijn geen (coumarine) antistolling noodzake-
lijk is -in tegenstelling tot de mechanische prothese- weegt de risicoreductie op antistolling 
gerelateerde bloedingen op tegen de hogere kans op reoperaties wegens klepdegeneratie. 
hoofdstuk 6 is een hoofdstuk in het boek ‘Aortic Root Surgery’ dat illustreert hoe met 
behulp van microsimulatie de resultaten na aortaklepvervanging met diverse types proth-
esen zoals gestente en stentloze bioprothesen, allografts en autografts vergeleken kunnen 
worden. De levensverwachting op de lange termijn is voor patiënten na klepvervanging la-
ger vergeleken met de algemene bevolking en dit verschil kan niet alleen verklaard worden 
door klepgerelateerde complicaties. Waarschijnlijk is vooral bij jonge patiënten een groter 
deel bepaald door patiëntgerelateerde factoren. Ook lijken de patiënt uitkomsten voor de 
verschillende kleptypes vergelijkbaar en meer bepaald te worden door patiëntfactoren dan 
door verschillen in de klepprotheses zelf.
In de laatste jaren zijn er diverse publicaties verschenen die een grote discrepantie aan-
geven tussen heersende richtlijnen voor de behandeling van symptomatische patiënten 
met ernstige aortaklepstenose en de dagelijkse praktijk: veel patiënten krijgen niet de 
aanbevolen (minimaal invasieve) chirurgische behandeling. In hoofdstuk 7 is gezocht 
naar de redenen waarom meer dan de helft van de bestudeerde 179 symptomatische 
patiënten niet chirurgisch werden behandeld gedurende een follow-up van anderhalf jaar. 
Vaak bleek het operatierisico te worden overschat; hemodynamische ernst van de stenose 
en symptomatologie werden regelmatig onvoldoende ernstig bevonden om tot chirurgie 
over te gaan. 
Naar aanleiding van de publicatie die werd beschreven in hoofdstuk 7, schreef dr. 
Paraskevas een brief naar de editor van ‘the European Journal of Cardio-thoracic Surgery’ 
waarin hij de rol van statines in de behandeling van patiënten met aortaklepstenose wilde 
benadrukken. Na literatuur onderzoek op dit gebied te hebben gedaan hebben wij een 
antwoord geschreven naar de editor, dit is hoofdstuk 8. Hoewel statines waarschijnlijk 
de progressie van aortaklepstenose vertragen is het onduidelijk in welke mate, bij welke 
patiënten en tot welke gradatie van stenose. In de patiënten groep waarop dit proefschrift 
betrekking heeft, namelijk patiënten met een ernstige stenose, heeft behandeling met 
statines waarschijnlijk weinig meerwaarde, althans om de progressie te vertragen. Co-
morbiditeit, hoge leeftijd en de vergevorderde staat van stenose met daarbij de mogelijke 
indicatie tot chirurgie spelen een grote rol en bemoeilijken onderzoek naar de rol van 
statines in deze patiëntpopulatie.
hoofdstuk 9 beschrijft de doelen, de opzet en de vroege resultaten van de AVARIJN 
(Aortic VAlve RIJNmond) studie: een multi-center observationele studie onder 191 patiënten 
met ernstige aortaklep stenose in de regio Rotterdam Rijnmond. Deze patiënten werden 
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gedurende twee jaar gevolgd waarbij klinische en echocardiografische onderzoeken op 
diverse tijdsintervallen werden verricht. In dit hoofdstuk worden patiënt karakteristieken 
gerelateerd aan behandelstrategie en wordt overleving geanalyseerd met behulp van Cox 
regressie en Kaplan-Meier analyses. Symptomatische patiënten die conservatief werden 
behandeld hadden een overleving van ongeveer 73% na twee jaar. Twee-derde deel 
van de asymptomatische patiënten ontwikkelde klachten in deze periode van twee jaar 
hetgeen het pogressieve karakter van deze ziekte toont en de noodzaak tot frequente en 
nauwkeurige follow-up bekrachtigt.
Om de kwaliteit van leven te onderzoeken bij symptomatische en bij asymptoma-
tische patiënten met ernstige aortaklepstenose, werden alle patiënten van de AVARIJN 
studie bij ieder studie bezoek gevraagd een SF-36v2™ gezondheid vragenlijst in te vullen. 
hoofdstuk 10 bespreekt de resultaten van deze vragenlijsten: de kwaliteit van leven bij 
symptomatische patiënten blijkt ernstig beperkt ten opzichte van de algehele bevolking, 
zowel fysiek als geestelijk. Deze studie verschaft inzicht in de ziektelast die veel patiënten 
ervaren en toont  tevens de meerwaarde van een dergelijke survey bij het uitstippelen van 
een behandelplan voor een individuele patiënt.  
hoofdstuk 11 gaat verder in op de kwaliteit van leven van symptomatische patiënten 
met ernstige aortaklepstenose en toont de resultaten gedurende follow-up na conservatieve 
behandeling en na aortaklepvervanging. Aortaklepvervanging blijkt niet alleen de fysieke 
kwaliteit van leven te verbeteren, maar ook de algehele gezondheidperceptie, vitaliteit 
en sociale interactie. Naast een lagere levensverwachting blijken conservatief behandelde 
patiënten forse fysieke achteruitgang door te maken, hetgeen de noodzaak onderstreept 
chirurgische behandeling te overwegen. Gezien deze bevindingen is het belangrijk naast 
de levensverwachting ook de kwaliteit van leven bewust mee te nemen in de overwegin-
gen op het moment dat er beslissingen over de behandeling moeten worden genomen.
hoofdstuk 12 bespreekt de snel evoluerende rol van nieuwe behandelmodaliteiten voor 
aortaklepstenose bij oudere patiënten of patiënten met een hoog operatie risico. Recent zijn 
meerdere multi-center gerandomiseerde trials uitgevoerd of nog gaande om de veiligheid, 
de voor- en nadelen en het kostenaspect van de transcatheter techieken te vergelijken met 
conventionele aortaklepvervanging. De voornaamste bevinding van de PARTNER trial was 
dat TAVI (transcatheter aortic valve implantation) ‘non-inferior’ is bij operabele hoog risico 
patiënten omdat na TAVI de 1-jaars mortaliteit vergelijkbaar was met die na chirurgische 
aortaklep vervanging. De recent opgestarte SURTAVI trial randomiseert patiënten met 
een matig hoog operatie risico voor TAVI dan wel chirurgische aortaklepvervanging. De 
resultaten van deze trial zullen moeten worden afgewacht alvorens de indicaties van de 
veel belovende TAVI procedure verder te verlagen. 
hoofdstuk 13 bevat de algemene discussie, conclusie en aanbevelingen die volgen uit 
dit proefschrift. Er kan op allerlei terreinen nog winst worden geboekt in de behandel-
ing van patiënten met ernstige aortaklepstenose. Zo zou in de nabije toekomst zowel 
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dokter als patiënt beter geïnformeerd moeten zijn over de prognose na de verschillende 
behandelmodaliteiten, zowel wat betreft levensverwachting als kwaliteit van leven. Dit zal 
de besluitvorming omtrent de behandeling ten goede komen, vooral wanneer de patiënt 
centraal wordt geplaatst in dit evidence-based multi-disciplinaire proces. 
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Dankwoord
Allereerst wil ik alle patiënten en hun familieleden bedanken voor hun bereidwilligheid, 
tijd en moeite om de onderzoekingen te ondergaan. Dit terwijl voor velen een tripje buiten 
de deur een aanzienlijke lichamelijke, geestelijke en logistieke inspanning vergde.
Sommige patiënten kan ik helaas niet meer persoonlijk bedanken. Mijn dank wil ik dan 
ook uitspreken aan hun nabestaanden. Hopelijk biedt dit proefschrift een tastbare herin-
nering dat hun inspanningen niet voor niets zijn geweest.
Professor bogers, hartelijk dank voor de begeleiding in de afgelopen jaren. U was er 
altijd voor een helder overleg en een stappenplan voor de toekomst. Het gezag en de rust 
die u daarbij uitstraalde is indrukwekkend en blijkt zich niet alleen te beperken tot dit soort 
vergaderingen of patiënten besprekingen. Onlangs heb ik die haast serene rust ook in de 
operatiekamer mogen ervaren, gecombineerd met uw chirurgische vaardigheden verheft 
dit uw operaties tot ware kunst. En mócht plan A of B niet lukken, is er altijd nog een plan 
C t/m F om een probleem op te lossen. Dit is waar ik het meest van heb geleerd. Mijn grote 
dank hiervoor.
Professor Takkenberg, beste Hanneke, je bent gepromoveerd. Niet alleen op de 
auto- en allografts, maar ook van co-promotor tot mijn promotor! Dank voor de vele 
uren begeleiding tijdens korte werkonderbrekingen die je voor me inruimde. We hebben 
optimaal gebruik gemaakt van moderne media als telefoon, e-mail, msn en skype. Ook 
tijdens je verblijf in de USA en later tijdens de meest onzekere periode in je bestaan bleef je 
op deze manier bereikbaar voor een vraag of methodologisch probleem. Je betrokkenheid 
en aanwezigheid bij de diverse presentaties in binnen- en buitenland heb ik altijd zeer 
gewaardeerd. Dankjewel!
Professor kappetein, beste Arie Pieter. Nog zo’n duizendpoot, maar dan anders: het 
is werkelijk ongelooflijk hoe je al je werkzaamheden op de verschillende continenten weet 
te combineren. Volgens mij breng je meer tijd door in het vliegtuig dan ik in de auto! Vaak 
zat je in een spagaat tussen internationale vergaderingen en de lokale problematiek van 
deze onderzoeker. Je kritische en heldere analyses van diverse artikelen hebben me dikwijls 
verrast en soms verbaasd. Ik ben blij dat we er goed uitgekomen zijn en ben zeer dankbaar 
jou als begeleider te hebben gehad.
Professor van Swieten, ik ben er trots op dat u in ‘mijn’ promotiecommissie hebt 
willen plaatsnemen om dit onderzoek te beoordelen. U hebt aan de basis gestaan van 
mijn carrière en tevens vormde u de stimulus dit promotieonderzoek te starten. Ik heb 
nog nooit ergens zo veel geleerd als in mijn eerste tijd, in het Antonius Ziekenhuis. Vooral 
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leerde u mij goed en kritisch na te denken, goed naar patiënten te luisteren en hen te 
observeren. En verder om allerlei diagnostiek, technieken en meningen van anderen -en 
van mijzelf- kritisch tegen het licht te houden. Daar probeer ik me nog steeds in te trainen. 
Elk detail telt.
Professor Zijlstra en professor de jaegere, hartelijk dank voor uw aandeel in deze 
promotiecommissie en de tijd en moeite die u beiden hebt genomen om dit proefschrift 
te onderwerpen aan een kritische blik. Uw beider cardiologische visie op dit proefschrift 
is voor mij zeer belangrijk aangezien een groot deel van het onderzoek zich bevindt op 
cardiologisch vlak, echter verricht vanuit cardio-chirurgisch perspectief. Ik ben benieuwd 
naar uw mening!
Professor jamieson, thank you for your excellent dataset and even more for your 
enthusiasm, your ideas and your support that have helped me working on the micro-
simulation papers, Chapters 4 and 5 of this book. The trip to Canada was a great way to 
join business with pleasure, although I didn’t get to see much of Vancouver: the weather 
prohibited vision of more than a few meters but the snow was great! 
helena heuvelman, dank voor het voortzetten van de AVARIJN studie. Het was niet 
altijd gemakkelijk maar mede dankzij jouw zorgvuldigheid en toewijding kon de studie en 
daarmee dit proefschrift goed worden afgerond. Hopelijk bevalt je nieuwe carrière en zal 
jouw boekwerk snel volgen! Heel veel succes!
Tjebbe Galema en Marcel Geleijnse ben ik dank verschuldigd voor hun cardiologische 
advies over de opzet en uitvoering van de AVARIJN studie en voor hun visie op individuele 
patiënten en echo’s.
Verder wil ik voor het kostenloos mogelijk maken van de AVARIJN studie de Cardiolo-
gen, echolaboranten en andere medewerkers van de volgende deelnemende centra 
in de regio bedanken voor hun medewerking: Erasmus MC, St. franciscus Gasthuis, 
vlietland Ziekenhuis, Ijsselland Ziekenhuis, Albert Schweitzer Ziekenhuis, Maas-
stad Ziekenhuis en het haven Ziekenhuis.
yusuf karamermer wil ik bedanken voor zijn inzet veel van de AVARIJN echo’s mede 
te beoordelen en mee op jacht te gaan naar nieuwe patiënten. Je was teleurgesteld in je 
baan destijds, ik hoop dat je nu op een meer comfortabele plek zit en wens je alle succes 
in je carrière! 
liz van der velden, zoveel patiënten waren enthousiast over alle aandacht en tijd 
die je hen schonk. Ze kennen je nu nog precies! Mede namens hen bedankt voor al je 
goede zorgen! Verder dank ik Marijke Rozema, Angelique venema, Els berenschot en 
liesbeth duininck voor de ondersteuning van de diverse studies en voor de vragen die 
jullie steeds weer bereid waren te beantwoorden. Natuurlijk ben ik ook Annet damhuis 
veel dank verschuldigd voor het regelen van diverse afspraken in de drukke agenda’s van 
de hoge heren en dame.
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loes klieverik en Menno van Gameren, collega onderzoekers destijds, bedankt voor 
de broodnodige afwisseling tijdens lange dagen onderzoek. Jullie hebben het toch wat 
sneller klaar gespeeld. Menno dank ik daarnaast voor het onderhouden van de monteurs- 
en plaatwerkers vaardigheden: rijdt de Mini eigenlijk nog? Loes, het weekendje New York 
was gezellig, wanneer delen we nog eens een kamertje?
Mijn opleider dr. berreklouw, mede-opleiders bart van Straten, joost ter Woorst, 
Erwin Tan, Ted Elenbaas en Ibrahim Özdemir. Het moeten werken met assistenten valt 
natuurlijk niet mee, zeker niet als ze ook nog eens bijdehand zijn. Ik geniet van de vele 
zaken die ik van jullie leer, vooral in de operatiekamer, maar ook daarbuiten. Dank voor 
het beantwoorden van de vragen die ik jullie stel, het geduld dat jullie betrachten en het 
vertrouwen dat er in mij gesteld wordt. 
Mede-assistenten niels verberkmoes, Martin de jonge en Astrid van boxtel, oud 
assistenten Sander bramer, bart koene, Mohamed Soliman en Suzanne kats en 
verder alle AnIOS en nurse practitioners die het dagelijkse werk veraangenamen bedank 
ik voor de gezelligheid, voor de collegialiteit en voor het uitwisselen van de vele ervaringen. 
dr. G.A.P. nieuwenhuijzen dank ik voor een zeer goede start van de opleiding door 
een gedegen introductie in de algemene chirurgie. Grard, je bent een zeer betrokken, 
correcte en enthousiaste opleider die assistenten mogelijkheden en tijd biedt voor andere 
zaken dan alleen het assistentschap: voor wetenschap kon ik tijd inruimen, mits dat niet 
ten koste ging van de sociale interactie met de groep. Een betere opleider kon die groep 
zich niet wensen denk ik. Hartelijk bedankt!
dr. l.k.j. de hondt dank ik voor de persoonlijke begeleiding in de laatste maanden.
Heren van de jaarclub, Mark van nijnatten, Ewoudt van de Garde, Ton bosshardt, 
haye Strikwerda, Mark van der lubbe, boudewijn Wilmink en frido Oei, de bijna-
men laat ik hier maar even achterwege.. Jaartje ’96 blijft toch het mooiste jaar: peren 
en presteren moeten hand in hand... Die balans wil ik weer herstellen, bovendien heeft 
de Utregse horeca het zwaar zonder ons. Ook een clubweekend in een stad als Madrid 
overslaan zal me niet snel meer gebeuren. Dank voor de onsterfelijke vriendschap! 
Een aantal andere vrienden wil ik nog expliciet noemen: Wouter Eikelboom, Wout, 
van al m’n vrienden ken ik jou het langst, we hebben nog samen in de box gelegen. De 
vriendschap is me dierbaar en ik ben dankbaar dat dit al die jaren heeft stand gehouden 
ondanks onze verschillende levens. Michiel Toxopeus, Tox, op jou kan ik terugvallen 
wanneer dat nodig is en dat is een fijne gedachte. Mijn dank hiervoor is groot. Michael 
dijkstra, Mich, ook jij bent een trouwe vriend op wie ik kan bouwen, en het komt goed uit 
dat je veel meer gastronomisch ingesteld bent dan ik. Dank voor de vele mooie avondjes 
thuis en in de diverse Utrechtse etablissementen.
Pap en mam, zonder jullie had ik het al meer dan eens niet gered en zonder jullie was 
dit promotie-onderzoek een paar jaar geleden gestrand. Dank voor het zitvlees dat jullie 
me al vroeg hebben laten kweken, ik heb het nodig gehad. Nog veel belangrijker is jullie 
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onvoorwaardelijke steun op velerlei vlakken, jullie niet-aflatende liefde en altijd aanwezige 
gastvrijheid. Dank voor de uitdagingen en de mogelijkheden die ik altijd van jullie heb 
gekregen, daarom zijn jullie ook op financieel vlak eigenlijk de hoofdsponsor van deze 
productie (en toch sta je dan onderaan het sponsorlijstje..). Pap, dank je voor het kritisch 
beoordelen van de eerdere papers, voor de inhoudelijke discussies en het uitwisselen van 
ervaringen. Dat je je taak om dit boekwerk nog eens kritisch na te lopen zo serieus nam, 
gaf me veel rust. Dankjewel!
Zusjes Irene en Marie-Sophie, Miep en Ietje. Tja Ietje, was ik toch nog eerder paranimf 
bij jou dan jij bij mij. Dat had ik eigenlijk op de middelbare school al moeten weten. Ik 
vind het prachtig om te zien hoe je je sindsdien hebt ontwikkeld, zowel in je werkzame 
bestaan als in je persoonlijke leven. Je hebt genoten van je jaar in Frankrijk en ik hoop van 
harte dat je die levensstijl blijft nastreven! Miepie, je bent een kanjer en een lief zusje. Hard 
wanneer dat moet, zacht wanneer het kan. Binnen enkele jaren run jij je eigen bedrijf of 
heb je er al een paar overgenomen, dat weet ik zeker. Dank je voor je genegenheid, voor 
je enthousiasme en natuurlijk voor al je kledingadviezen. 
Lieve Ingrid, je hebt al je principes aan de kant gezet en vervolgens heb ik hart gebro-
ken. Dat, en de manier waarop, spijt me zeer. Ik hoop m’n leven inmiddels beter op orde te 
hebben en in de toekomst niet meer gevangen te zitten in tweestrijd. Ik heb het te weinig 
laten blijken, maar je hebt met je vrolijkheid en genegenheid veel meer voor me betekend 
dan je denkt. Dankjewel.
Lieve Annebeth, ons zeilbootje is uiteindelijk toch vast komen te zitten en helaas niet 
vanwege het rietzeilen; dat hebben we te weinig gedaan. Ik realiseer me dat mijn werk, 
dit proefschrift en mijn karakter een grote wissel hebben getrokken op ons bestaan. Wat 
heb jij het zwaar gehad met mij. Ik hoop van harte dat we beiden ons geluk weer kunnen 
hervinden, in elk geval verdien je dat want je bent een mooi mens, een lieve vriendin en 
een geweldige moeder!
Lieve dries, jij bent het mooiste ventje dat ik me kan voorstellen, een leuker zoontje 
had ik me niet kunnen wensen! Bijna altijd ben je vrolijk, uitdagend en leergierig. Als er al 
wat nukkigheid naar boven komt blijkt steevast dat er onvoldoende is voldaan aan basale 
levensbehoeften als tijdige slaap en voeding. Je bent een pienter, lief en zachtaardig man-
netje. Verder ben je ontzettend gezellig met andere ‘kleuters’ van uiteenlopende leeftijden, 
hoewel je ook een eigen willetje hebt dat je altijd krachtig zult verdedigen. Je hebt humor 
blijkend uit de grappen die je maakt en je kletst de hele dag door, “Oh, waarom?” blijven 
hierbij de kernwoorden. Met je grote opmerkzaamheid en onstilbare nieuwsgierigheid wil 
je werkelijk alles tot in detail weten. In jou herken ik veel van mezelf en gelukkig veel ook 
niet. Je bent een verrijking van mijn leven, dankjewel!
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Curriculum Vitae
The author was born in Utrecht, the Netherlands, on June 25th 1978. In 1996 he graduated 
from high school, ‘Stedelijk Gymnasium Bredanum’ and started his medical training at 
the State University Utrecht. The senior internship was done at the department of cardio-
thoracic surgery of the Antonius Hospital Nieuwegein (prof.dr.ir. H.A. van Swieten) where 
he started working as a resident -not in training- after his graduation in April 2004. Here 
he obtained his first clinical experience and basic operative skills. The first serious scientific 
contributions were made during his Ph.D. training which was started in October 2005 
under supervision of prof.dr. A.J.J.C. Bogers, prof.dr. J.J.M. Takkenberg and prof.dr. A.P. 
Kappetein of the department of cardio-thoracic surgery of the Erasmus University Medical 
Center. Designing and running the AVARIJN study as well as work on micro-simulation 
in collaboration with Dr. Jamieson (University of British Columbia, Vancouver, Canada) 
formed the basis of this thesis. In the summer of 2008 a master in Clinical Epidemiology 
was obtained at the Netherlands Institute for Health Sciences (NIHES, prof.dr. A. Hofman). 
In October 2008 he started as a resident at the department of cardio-thoracic surgery of 
the Catharina Hospital in Eindhoven, and from March 2009 he is in training to become 
a cardio-thoracic surgeon. The first two years consisted of training in general surgery (dr. 
G.A.P. Nieuwenhuijzen), the remaining years of training in cardio-thoracic surgery are 
supervised by dr. E. Berreklouw.
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PhD Portfolio
Name PhD student:
Erasmus MC Department:
Research School:
PhD period:
Promotores:
M.W.A. van Geldorp
Cardio-thoracic Surgery
COEUR
2005-2012
Prof.dr. J.J.M. Takkenberg
Prof.dr. A.P. Kappetein
PhD Training Year Workload
Education
·  Master ‘Clinical Epidemiology’ at the Netherlands Institute for Health Sciences 
(NIHES)
· Erasmus Winter Programme (NIHES)
2007-2008
2006
70
4.5
Oral presentations
·  Patient outcome after AVR with mechanical or bioprostheses: weighing lifetime 
anticoagulant related event risk against reoperation risk (SHVD, New-York)
·  Symptomatic severe aortic stenosis-Therapeutic decisions and consequences in 179 
patients (1st prize NVT, Utrecht)
·  Symptomatic severe aortic stenosis-Therapeutic decisions and consequences in 179 
patients (EACTS, Lisbon)
·  Quality of life of patients with symptomatic severe aortic stenosis (NVT, Utrecht) 
·  Exercise testing in severe aortic stenosis reveals symptoms in one-third of 
previously presumed ‘asymptomatic’ patients (NVT, Leiden)
·  Exercise testing in severe aortic stenosis reveals symptoms in one-third of 
previously presumed ‘asymptomatic’ patients (SHVD, Berlin)
·  Clinical course of patients diagnosed with severe aortic stenosis: insights from the 
AVARIJN study (SHVD, Barcelona)
·  Quality of life of patients with severe aortic stenosis (SHVD, Barcelona)
·  Paraprosthetic regurgitation after surgical aortic valve replacement (NVT, Utrecht)
2007
2008
2007
2008
2008
2009
2011
2011
2011
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
Poster presentations
·  Patient outcome after AVR with mechanical or bioprostheses: weighing lifetime 
anticoagulant related event risk against reoperation risk (1st prize poster NVT, 
Amsterdam)
·  AVR improves quality of life in selected symptomatic patients  
with severe aortic stenosis (SHVD, Barcelona)
2007
2011
0.6
0.6
Coeur courses
· Cardiovascular imaging and diagnostics
· Congenital heart disease
· Vascular medicine
· Arrhythmia-research methodology
· Peripheral and intracranial aneurysmal diseases
2006
2006
2007
2007
2008
1.5
1.5
2
1.5
1.5
Coeur seminars and workshops
· Electrophysiology
· Pulmonary circulation
· Tetralogy of Fallot
· Percutaneous aortic valve implantation
2006
2007
2008
2009
0.4
0.4
0.4
0.4
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International conferences
· European Association of Cardio Thoracic Surgery annual meeting (Stockholm)
· ´At the heart of evolution, evolving scenarios in aortic valve surgery´ (Amsterdam)
· Society for Heart Valve Disease biennial meeting (New-York)
· European Association of Cardio Thoracic Surgery annual meeting (Lisbon)
· Society for Heart Valve Disease 5th biennial meeting (Berlin)
· Society for Heart Valve Disease 6th biennial meeting (Barcelona)
2006
2007
2007
2008
2009
2011
1.5
0.3
1.5
1.5
1.5
1.5
National and local conferences
· Meetings of the Dutch Association for Thoracic Surgery
· Meetings of the ‘Cardiologen Club Rijnmond’
· Cardiology and Vascular Medicine, update and perspective (Rotterdam)
· Local conferences
2004-2012
2005-2008
2006
2004-2012
3.5
0.5
1
4.5
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PAPERS
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Abbreviation Explanation Website
ACC American College of Cardiology www.acc.org
ACE Angiotensin Converting Enzyme
AHA American Heart Association www.heart.org
AS Aortic Stenosis
AV Aortic Valve
AVA Aortic Valve Area
AVR Aortic Valve Replacement
BNP Brain Natriuretic Peptide
BP Bioprosthesis
CABG Coronary Artery Bypass Grafting
CAD Coronary Artery Disease
CE-SAV Carpentier Edwards Supra-Annular Valve
CI Confidence Interval
CT Computed Tomography
EF Ejection Fraction
EFLE Event-Free Life Expectancy
EOA Effective Orifice Area
EuroQol European Quality of life group www.euroqol.org
ESC European Society of Cardiology www.escardio.org
EuroSCORE European System for Cardiac Operative Risk Evaluation www.euroscore.org
HR Hazard Ratio
KM Kaplan Meier
LAD Left Anterior Descending artery
lCL Lower Confidence Limit
LE Life Expectancy
LVEF Left Ventricular Ejection Fraction
LVOT Left Ventricular Outflow Tract
MAG Mean Aortic Gradient
MP Mechanical Prosthesis
MR Mitral Regurgitation
MS Micro-Simulation www.cardiothoracicresearch.nl 
MS-CT Multi-Slice Computed Tomography
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Nt-proBNP N-terminal prohormone Brain Natriuretic Peptide
NYHA New-York Heart Association
PAG Peak Aortic Gradient
PCI Percutaneous Coronary Intervention
PET Positron Emission Tomography
QALY Quality Adjusted Life Year
QOL Quality Of Life
RCT Randomized Clinical Trial
RFLE Reoperation-Free Life Expectancy
SAVR Surgical Aortic Valve Replacement
SD Standard Deviation
SF-36v2 Short-Form 36 version 2 www.sf-36.org
STS Society of Thoracic Surgery www.sts.org
SVD Structural Valve Deterioration
TAVI Transcatheter Aortic Valve Implantation
uCL Upper Confidence Limit
Vmax Maximum trans aortic jet velocity
VRE Valve Related Event
VTI Velocity Time Integral
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Acronym Explanation Website
ASTRONOMER Aortic STenosis pRogressiON Observation  
Measuring the Effects of Rosuvastatin
www.clinicaltrials.gov/ct2/show/NCT00800800
AVARIJN Aortic VAlve RIJNmond
PARTNER Placement of AoRtic TraNscathetER valve trial www.clinicaltrials.gov/ct2/show/NCT00530894
RAAVE Rosuvastatin Affecting Aortic Valve Endothelium www.clinicaltrials.gov/ct2/show/NCT00114491
SALTIRE Scottish Aortic stenosis and Lipid lowering Trial, 
Impact on REgression
SEAS Simvastatin and Ezetimibe in Aortic Stenosis
SOURCE SAPIEN XT™ Aortic Bioprosthesis Multi-region 
Outcome Registry
www.clinicaltrials.gov/ct2/show/NCT01238497
SURTAVI Safety and Efficacy Study of the Medtronic 
CoreValve® System in the Treatment of Severe, 
Symptomatic Aortic Stenosis in Intermediate Risk 
Subjects Who Need Aortic Valve Replacement
www.clinicaltrials.gov/ct2/show/NCT01586910 
TASS Tyrolean Aortic Stenosis Study
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Websites 
Aortaklep stenose www.aortaklep.nl 
American Association for Thoracic Surgery www.aats.org
American College of Cardiology www.acc.org
American Heart Association www.heart.org
American Thoracic Society www.thoracic.org
AVR Microsimulatie model www.cardiothoracicresearch.nl 
Cardio-thoracic Surgery Network www.ctsnet.org
Centers for Disease Control and Prevention www.cdc.gov
Centraal Bureau voor Statistiek www.cbs.nl
Clinical trials www.clinicaltrials.gov 
Erasmus MC www.erasmusmc.nl 
European Society of Cardiology www.escardio.org
European Society of Cardio-Thoracic Surgery www.eacts.org
European System for Cardiac Operative Risk Evaluation www.euroscore.org
EuroQol www.euroqol.org
International Society for Heart & Lung Transplantation www.ishlt.org
International Society for Minimally Invasive Cardiothoracic Surgery www.ismics.org
Ministerie van Volksgezondheid, Welzijn en Sport www.rijksoverheid.nl/ministeries/
vws#ref-minvws
Nederlandse Vereniging voor Cardiologie www.nvvc.nl 
Nederlandse Vereniging voor Thoraxchirurgie www.nvtnet.nl
Short-Form 36TM Health Survey www.sf-36.org en www.qualitymetric.
com
Society for Heart Valve Disease www.shvd.org
Society of Thoracic Surgery www.sts.org
Statistics Canada www.statcan.gc.ca
United Kingdom National Statistics www.statistics.gov.uk
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